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FALCIPARUM FOR DRUG DISCOVERY AND SUPPRESSING 
RESISTANCE 
Abstract 
Malaria is a preventable and treatable disease caused by infection with 
Plasmodium parasites. Complex socioeconomic and political factors limit access to 
vector control and antimalarial drugs, and an estimated 600,000 people die from malaria 
every year. Rising drug resistance threatens to make malaria untreatable. As for all new 
traits, resistance is limited by fitness, and a small number of pathways are heavily 
favored by evolution. These pathways are targets for drug discovery. Pairing 
compounds active against the wild-type and the small emerging resistant population, a 
strategy we termed “targeting resistance,” could block the rise of competitively viable 
resistance.  
We characterized resistance pathways to dihydroorotate dehydrogenase 
(PfDHODH) inhibitors. PfDHODH is a novel target with several compounds in 
development for clinical use. In vitro resistance selections led to a variety of point 
mutations in the gene pfdhodh, which all lined the tunnel for electron transfer between 
cofactors: L172F, E182D, F188I/L, F227I, I263F, L527I, and L531F. We chose to focus 
on E182D, as it arose in response to two structurally unrelated inhibitors. Screening 
iv 
identified an E182D-selective inhibitor (IDI-6273). Selection of the E182D mutant 
parasites with IDI-6273 led to a novel mutation in pfdhodh, which resulted in a reversion 
to the wild-type protein sequence. Simultaneous rather than sequential selection of wild-
type parasites with a wild-type and mutant-type inhibitor failed to give resistance in 80 
days.  
The in vitro selection work was corroborated with biochemical assays of protein 
activity, which also allowed us to determine that the E182D mutation led to a reduced 
catalytic efficiency. In keeping with this, competitive growth assays showed that the 
E182D mutant and D182E revertant were less fit than the wild-type parent. 
Crystallography revealed that changes in aromatic stacking and helix packing were the 
likely mechanisms of resistance. 
We believe that evolutionary fitness constraints allow few pathways to resistance, 
and these pathways can be anticipated and preemptively blocked. The combination of 
well-chosen antimalarial agents active against sensitive and resistant parasites 
effectively kills parasites in the short-term, and in the long-term, can help shape parasite 
evolution away from the development of drug resistance.	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CHAPTER ONE: 
INTRODUCTION 
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1.1 MALARIA 
Malaria is an infectious disease transmitted by female Anopheles mosquitoes. Disease 
symptoms typically include severe fever and headache, but there are many possible 
manifestations including respiratory distress, coma, and death. Malaria is caused by 
infection with protozoan parasites of the genus Plasmodium. Plasmodium parasites are 
highly host-specific, and five out of several hundred species are known to infect humans: 
falciparum, vivax, malariae, ovale, and knowlesi. Plasmodium falciparum infection is the 
most deadly. Malaria is widespread in tropical and subtropical regions, including parts of 
the Americas, Asia, and Africa. Nearly half the world’s population is at risk of infection, 
and an estimated 200 million people are infected each year, resulting in approximately 
600,000 malaria-related deaths in 2012 1. The majority of malaria-related deaths occur in 
children under the age of five in Sub-Saharan Africa. Morbidity and mortality from 
malaria costs the African continent an estimated US$12 billion and 1.3% GDP growth 
per year 1, and as such, is a global public health and economic concern.  
1.2 PARASITE BIOLOGY 
The phylum Apicomplexa contains several unicellular protist parasites of medical and 
veterinary significance, including Plasmodium, Toxoplasma, Babesia, Eimeria, and 
Cryptosporidium. Apicomplexans are characterized by a three-membrane outer pellicle 
and an apical set of structures – often including rhoptries, micronemes, and dense 
granules – which are specialized for invasion of the host. Most, but not all, also contain a 
unique double-endosymbiotic organelle dubbed the apicoplast.  
The genus Plasmodium contains hundreds of species, each with a narrow range of 
hosts and vectors. Hosts include specific mammals, birds, and reptiles. Vectors are 
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typically specific mosquito species. Infection with a Plasmodium parasite leads to the 
disease malaria. Plasmodium has a complex life cycle (Figure 1.2.1), and human-
infecting parasites must cycle between an Anopheles mosquito vector and a human host. 
When an infected mosquito takes a blood meal from a human, 10-20 parasite 
sporozoites in the mosquito salivary glands enter the human bloodstream. Sporozoites 
migrate to the liver, where they pass through several hepatocytes before settling in a 
final host cell. In this final hepatocyte, the sporozoite replicates to 30-40 thousand cells 
over a period of days to weeks, depending on the species 2. Kinship sensing leads to 
manipulation of the host hormone hepcidin to reduce the risk of superinfection (and thus 
competition) with other lineages of malaria parasites 3. The infected liver cells burst, 
releasing tens of thousands of merozoites into the bloodstream. Merozoites rapidly 
invade red blood cells, establishing infection in this MHC class II-negative, 
immunologically sheltered, nutritionally-replete cell within 30-120 seconds 4. Rapid 
invasion limits exposure to the immune system, and parasites also directly and indirectly 
suppress the immune response through methods like antigenic variation, adherence of 
infected red blood cells to the vascular endothelium, tandem repeats in antigens that 
provide a smokescreen for formation of antibodies against “true” functional moieties, and 
induction of suppressive cytokines such as IL-10 and TGF-β 5. This intricate interplay 
with the human immune system reflects our long co-evolutionary history. 
All symptoms come from the blood stages. Typical symptoms include anemia, cycles of 
severe chills and fever, and headache. These symptoms are rather non-specific and 
better diagnostics to distinguish among bacterial, viral, and malaria infections would 
simplify treatment. More severe symptoms include respiratory distress, metabolic 
acidosis, coma, seizure, organ failure (lung, liver, and spleen being the most common), 
splenomegaly, and death. Cerebral malaria results when parasites overwhelm the 
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vasculature in the brain, and patients rapidly deteriorate into coma and seizures. The 
mortality rate of cerebral malaria is much higher than so-called “uncomplicated” malaria, 
and survivors often suffer from neurological sequelae	  6.  
In the blood stages, merozoites mature into ring stages, which rapidly build a plasma 
membrane parasitophorous vacuole and remodel the host cell. Ring stages mature into 
trophozoites, which are more metabolically active and begin DNA synthesis.  
Trophozoites mature into schizonts, which form daughter merozoites from the mass of 
free nuclei and burst out of the host cell to begin the cycle anew. Trophozoites and 
schizonts – so-called “late stages” – adhere to the vascular endothelium, and ring stages 
circulate freely in the bloodstream. In P. falciparum, 16-32 daughter nuclei are formed in 
a 48-hour life cycle.  
 
Figure 1.2.1: Plasmodium spp. life cycle (Suh et al 2004) 7 
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A small fraction of the blood stage cells will follow a different path, and commit to sexual 
development 8. This process produces male and female gametocytes. Forming 
gametocytes sequester in the bone marrow, and are released into the bloodstream when 
mature. Mature gametocytes can thus be taken up by a mosquito blood meal. Once in 
the mosquito, male and female gametocytes must rapidly find each other and fuse in the 
mosquito midgut to form the diploid ookinete. The ookinete burrows through the 
mosquito midgut and forms the oocyst. After development, the oocyst ruptures and free 
sporozoites migrate to the salivary glands. These sporozoites can then infect a person 
when the mosquito takes a blood meal. 
1.3 CONTROL AND ERADICATION 
Infectious disease control relies on a combination of reducing transmission and treating 
cases on an individual and population-wide level. Transmission is traditionally 
interrupted by eliminating the vector and/or population-wide vaccination or drug 
administration. Treating infected patients requires that the patients be identifiable and 
that there are effective and available treatments for those patients.  
The sexual forms of malaria (gametocytes) are transmitted by the bite of female 
Anopheles mosquitoes. Mosquitoes breed in standing water and tend to feed at dusk, 
but changing patterns of behavior are complicating efforts to deploy localized 
insecticides, bed nets, and larval control methods like draining standing water and the 
use of larvivorous fish. In addition, rising levels of resistance or “behavioral resilience” to 
a variety of insecticides greatly limits our ability to control mosquito populations 9.  
There is no effective vaccine for malaria, despite valiant and long-running efforts 10, 11.  
The vast majority of exposed people develop at most partial and short-lasting immunity 
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to malaria, and this requires several years of exposure to locally circulating parasite 
strains. This is part of the reason why young children are so susceptible to malaria – 
their immune systems are still developing, and they do not yet have partial immune 
protection from surviving repeated bouts of malaria. Malaria parasites also have 
sophisticated strategies for immune evasion, including residing in MHC class II-negative 
erythrocytes, general immune suppression of the host, and antigenic variation 5. 
Given the difficulties with vector control and vaccination, it is clear that antimalarial 
treatments will be key in controlling and eradicating malaria 12. Antimalarial agents tend 
to come from ethnobotany or war-time development efforts 13. The first widely-used 
antimalarial, quinine, came from the bark of the cinchona tree in the Peruvian Amazon 14. 
Quinine and its later derivative, chloroquine, are still effective antimalarials in the 
Americas, but are largely obsolete in Africa and Asia due to at least four chloroquine 
resistance founder events and strong directional selective sweeps 15. 
Malaria is an ancient foe, and descriptions of intermittent fevers and proposed 
treatments can be found in Chinese physician Ge Hong’s Si Ku Quan Shu (Emergency 
Prescriptions Kept Up One’s Sleeve), which was first published in 340 A.D. 16. One 
proposed treatment, qing hao (Artemisia annua) steeped in cold water, eventually led to 
what we now know as artemisinin 17, 18 - although it should be noted that the active 
natural product was not isolated until 1971 and Cold War politics prevented the 
widespread adoption of artemisinin for years afterward 13. Artemisinin-based therapies 
are the core of most modern antimalarial therapies, and reports of delayed patient 
clearance and potential resistance to artemisinin have raised serious alarms over the 
future of malaria control 19.  
In 1955, The World Health Organization (WHO) spearheaded the Global Malaria 
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Eradication Programme (GMEP). Culturally, the “golden age of antibiotics” led to a 
sense of invincibility against microbes, DDT (dichloro-diphenyl-trichloroethane) had been 
used with great success as an insecticide in World War II, and the antimalarial 
chloroquine was effective, easily available, and cheap. There was considerable optimism, 
but also considerable naivety regarding implementation and how quickly drug resistance 
could develop and spread. Fourteen years later, the GMEP was ended and worldwide 
malaria eradication was declared unachievable with the existing tools and resources. 
Despite this outcome, malaria was eradicated from many locales with mild to moderate 
transmission, including the United States of America (Figure 1.3.1). The WHO learned 
the hard way that applying a single strategy worldwide would not work, and that merely 
reducing transmission and case loads was not sufficient – total elimination with vigilant 
and long-term agile surveillance was required to prevent malaria resurgence 20. 
 
Figure 1.3.1: The risk of malaria infection over time (Sachs et al 2002) 21 
The last decade has seen a renewed commitment toward malaria control and 
eradication, and malaria deaths have fallen by 26% worldwide 1. Research into the 
biology of the malaria parasite and mosquito vector have led to improved methods and 
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programs, such as intermittent preventative treatment for pregnant women and indoor 
residual spraying, as well as a larger arsenal of antimalarial drugs. However, the 
progress achieved is fragile and complacency as transmission and perceived risk 
decrease is a major concern. Complex societal issues such as poor health infrastructure, 
war and forced displacement, counterfeit or substandard drugs, loss of political will, and 
loss of financial support threaten to erode or even reverse recent gains. Rising drug 
resistance in the mosquito vector and the malaria parasite are also grave threats. 
Sustained commitment to key interventions (such as proper use of insecticide-treated 
bednets and access to effective, affordable antimalarial drugs) will be crucial. 
1.4 DRUG RESISTANCE   
Resistance has emerged to nearly all antimalarial drugs. Plasmodium parasites have a 
remarkably agile stress response, and drug pressure is no exception (Figure 1.4.1).  
 
Figure 1.4.1: Useful lifetimes of antimalarial therapies 22 
1632 1940 1950 1960 1970 1980 1990 2000 2010 
1945-1957 
Chloroquine 
1951-1971 
Amodiaquine 
1994-2012? 
Artemisinin Combination 
Therapies (ACTs) 
1988-1990 
Halofantrine 
1996-2002 
Atovaquone/Proguanil 
1977-1982 
Mefloquine 
1967-1967 
Sulfadoxine/Pyrimethamine 
Quinine 
1632-1910 
Figure 2.2 Antimalarial drug resistance can emerge quickly 
Data from Ekland, E. H. et al. (2008). International Journal for Parasitology, 38(7), 743–747.  
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While some antimalarials, such as quinine, have had long effective lifetimes, other drugs 
have not – e.g., significant atovaquone resistance occurred during clinical trials, and 
30% of treated patients recrudesced (meaning that the infection was not eliminated and 
subsequently bounced back, in this case with resistant parasites) 23. No drugs with novel 
mechanisms of action will be ready for clinical use for at least five years 13, so research 
to protect new and old antimalarials from drug resistance will be critical. In vitro 
resistance selections can mirror in vivo patient isolate results, but are rarely identical. 
For example, chloroquine and mefloquine resistance are negatively correlated in vitro 
and in vivo 24. Chloroquine resistance in the field is largely due to the K76T mutation in 
pfcrt, and in vitro chloroquine selections gave K76I or K76N mutations in pfcrt	  25.  
1.5 EVOLUTION, FITNESS, AND STRESS RESISTANCE    
Malaria has co-evolved with humans, and each has shaped the other’s genome (Figure 
1.5.1). Human alleles that afford protection from malaria infection or severe disease 
largely match the distribution of malaria, even though several are highly deleterious 
when homozygous - e.g., heterozygous hemoglobin S protects from severe malaria, but 
homozygous hemoglobin S results in the disease sickle cell anemia (Figure 1.5.1 A). 
Conversely, alleles that allow parasites to escape selective pressures like the human 
immune system or antimalarial drugs (Figure 1.5.1 B) have emerged and spread 26. 
 Drug resistance is limited by trade-offs among growth, transmissibility, and resistance: 
fitness costs limit the diversity of escape pathways. For the P. falciparum dihydrofolate 
reductase inhibitor pyrimethamine, there is a single dominant resistance-fitness 
maximum accessible by a small number of mutational paths, and these paths are not 
equally accessible 27, 28. Resistance can leave organisms vulnerable to other stresses. 
For example, M184V/I mutations in HIV-1 reverse transcriptase confer resistance to 
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nucleoside reverse transcriptase inhibitors such as lamivudine. However, these mutants 
are hypersensitive to zidovudine, stavudine, and tenofovir-DF, and have a compromised 
ability to incorporate natural nucleotide substrates 29. Point mutations in the BCR-ABL 
kinase that drives chronic myeloid leukemia can give resistance to imatinib 30, but these 
mutated kinases differ in their transforming ability and second-generation inhibitors like 
nilotinib and dasatinib target many of the imatinib-resistant kinases 31. We propose that 
the universal balance between fitness costs and the development of new traits can be 
exploited to prevent the development and spread of drug resistance.  
 
Figure 1.5.1: Co-evolution has shaped the human and Plasmodium genomes 
(A). Malaria has shaped human evolution: the geographic distribution of alleles that give 
partial protection from malaria infection coincides with the distribution of malaria. Duffy 
negative erythrocytes, left, and hemoglobin S, right <http://www.map.ox.ac.uk/>  
(B). Humans have shaped malaria evolution: the use of antimalarial chemotherapy has 
led to selective sweeps for Plasmodium spp. Observed antimalarial drug resistance 
(1975-2013). <http://www.wwarn.org/>  
 
 
 
  
Figure 2.1 Co-evolution has shaped the human and malarial genomes 
A.  
B.  
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Evolutionary fitness impacts both the emergence of resistance in a single patient and its 
spread in a population. Conceptually, the strength of selective pressure will determine 
the relative fitness of wild-type (WT) and mutant-type (MT) parasites (Figure 1.5.2). A 
drug-resistant mutant is typically less fit than the WT at low concentrations of drug, and 
more fit at higher concentrations. The mutant selection window (MSW) defines the 
range of drug concentrations where a MT will outcompete the WT as long as it is 
reproducing above replacement levels (fitness = 1). The wild type growth window 
(WGW) is the range of drug concentrations where the WT will outcompete the MT – in 
this low drug range, treatment failures can occur without drug resistance. Treatment 
failure without resistance is often seen for protease inhibitor-based HIV-1 therapies, 
particularly with non-compliant patients 32. Treatment failure with or without resistance 
can occur in the WGW-MSW overlapping area. Drug concentrations above the MSW 
theoretically kill everything, but such concentrations may not be physically possible due 
to toxicity or drug stability. 
 
Figure 1.5.2: Selection windows that drive drug resistance and treatment failure 
(modified from Rosenbloom et al 2012) 32 
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1.6 METHODS TO SUPPRESS DRUG RESISTANCE 
The classic strategy for suppressing drug resistance is combination therapy, with the 
central idea being that it is difficult to become resistant to multiple compounds at the 
same time. Combination therapies may inhibit targets in different pathways, distinct 
nodes in the same pathway, or the same target in different ways 33. They may also be 
synergistic, additive, or antagonistic (Figure 1.6.1).  
In a synergistic combination, the effect of two compounds is greater than the additive 
sum of their individual effects. Synergistic combinations can be highly potent, but also 
provide strong selective pressure towards the development of resistance. In strongly 
antagonistic combinations, dubbed “suppressive” combinations, the effect of two 
compounds is less than the additive sum and even less than the individual effects – e.g., 
the compounds in some way mask the effect of each other.  
 
Figure 1.6.1: Fitness and resistance to combination therapies: synergy versus 
strong antagonism (“suppression”) (modified from Chait et al 2012 34) 
Synergy 
1+1=3 
Suppression 
1+1=0.75 
Fitness 
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In a suppressive combination, an organism is more fit if it remains sensitive to both 
compounds than if it gains resistance to one. Thus, resistant organisms are at a fitness 
disadvantage compared to the parental sensitive type, and will be outcompeted. Gaining 
stepwise resistance to both compounds is less likely in a suppressive combination than 
in a synergistic combination 35, 36, 37.  
We propose an alternative strategy for combination therapy which we call “targeting 
resistance” (Figure 1.6.2): simultaneously inhibiting the wild-type and the most fit mutant 
forms can suppress the emergence of competitively viable resistance. If an organism 
becomes resistant to the wild-type inhibitor, it will very likely be through one of few 
resistance pathways that maintain a competitive level of fitness. These pathways can be 
anticipated and pre-emptively blocked. Resistance to the wild-type compound would 
result in increased sensitivity to the mutant-type compound. With appropriate 
combinations, the risk of resistance is reduced as resistance to one compound 
decreases fitness more than remaining sensitive to both. 
We explore here the possibility of blocking the emergence of resistance with a 
population biology trap: by identifying situations where resistance to one compound 
confers hypersensitivity to another, we can design combination therapies that not only 
kill the parasite, but also guide its evolution away from resistance. This concept trades 
short-term potency for long-term protection from resistance. We tested the idea of 
“targeting resistance” with antimalarial agents not yet in clinical use in an effort to protect 
their efficacy once deployed. The antimalarial agents discussed block pyrimidine 
biosynthesis by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). 
14 
 
Figure 1.6.2: Targeting resistance: combining wild-type and mutant-type drugs 
suppresses resistance 
In “targeting resistance,” WT parasites are inhibited by WT inhibitors. The small 
population of emerging resistant mutants is inhibited by mutant inhibitors. Combining WT 
and mutant inhibitors should prevent the emergence of highly fit, and thus viable, 
resistant mutants. 
1.7 PYRIMIDINE BIOSYNTHESIS 
Pyrimidines  - including thiamine (vitamin B1) and the nucleobases thymine, cytosine, 
and uracil - are ubiquitous and essential in cells. There are two ways to obtain 
pyrimidines: de novo synthesis and salvage. Humans can do both, and salvage is 
sufficient for nearly all cell types. Exceptions include rapidly-proliferating lymphocytes, 
which was exploited for the treatment of rheumatoid arthritis with the HsDHODH inhibitor 
Leflunomide 38, and the fetal neural crest. Partial disruption of HsDHODH function during 
fetal development results in abnormal neural crest-derived tissues, resulting in postaxial 
acrofacial dysostosis (Miller syndrome) 39. Unlike humans, malaria parasites lack 
pyrimidine salvage pathways, and are completely reliant upon de novo synthesis 40. The 
enzyme dihydroorotate dehydrogenase (DHODH) is the rate-limiting step in pyrimidine 
biosynthesis. 
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DHODH enzymes are broadly categorized in two classes (Table 1.7.1), which differ in 
their final electron acceptor, subcellular localization, oligomerization state, and catalytic 
residue. Humans and Plasmodium parasites both have class II DHODH enzymes. 
Table 1.7.1: Classes of dihydroorotate dehydrogenase (DHODH) enzymes 
 
Crystal structures showed significant structural differences in the human and P. 
falciparum DHODH enzymes, which suggested the possibility of selective inhibitors 41, 42. 
PfDHODH is anchored in the inner mitochondrial membrane, where it couples the 
reduction of L-dihydroorotate to orotate with the oxidation of respiratory chain 
ubiquinone to dihydro-ubiquinone (Figure 1.7.1). The ping-pong redox reaction 
catalyzed by PfDHODH is the rate-limiting step in pyrimidine biosynthesis. Several 
groups have developed inhibitors specific for the human or malarial enzymes (Figure 
1.7.2) 43, 44, and PfDHODH is seen as a promising antimalarial drug target 45, 46.  
Parallel efforts at the University of Texas at Southwestern 47, GlaxoSmithKline 48, and 
Harvard 49 led to the development of several structural classes of PfDHODH inhibitors. 
Several of these compounds are active in rodent models of disease and are 
progressing in the drug development pipeline 44, 50. 
Class Electron acceptor Location Example Oligomerization 
Catalytic 
base 
IA Fumarate Cytosol Saccharomyces cerevisiae  Homodimer Cysteine 
IB NAD+ Cytosol Bacillus subtilis Heterotetramer Cysteine 
IS NAD+ Cytosol Sulfolobus solfataricus Heterotetramer Serine 
II Ubiquinone Membrane 
Plasmodium 
spp., Homo 
sapiens 
Monomer Serine 
16 
 
 
Figure 1.7.1: The Plasmodium mitochondrial electron transport chain 
 
 
 
 
Figure 1.7.2: PfDHODH inhibitors 
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Figure 3.2  Antimalarial target: dihydroorotate dehydrogenase 
Compound SMILES 
DSM74 FC(F)(F)C1=CC=C(NC2=CC(C)=NC3=NC=NN32)C=C1 
Genz-668419 O=C(NC1CC1)C2=CC=C(N3C(C)=C(C4=CC=C(F)C=C4)N=C3C)S2 
Genz-669178 O=C(NC1CC1)C2=CC=C(N3C(C=CC=C4C#N)=C4N=C3C)S2 
IDI-6253 CC1=NN=C2C3=C(C=CC=C3)C(N4CCC5=C(C=CC=C5)C4)=NN21 
IDI-6273 ClC1=CC=C(CN2C(C)=C3C(C=CC=C(OCC)C3=C2C)=O)C=C1 
GSK3 CCSC1=NN=C(N1CC)C2CCCN(C2)CC(NC3=C(Cl)C=CC(C(F)(F)F)=C3)=O 
GSK8 CC(C1=C(NC=C1CC2=CC=CC(C(F)(F)F)=C2)C)=O 
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Figure 2.4  Example PfDHODH inhibitors 
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1.8 STRUCTURE OF THE THESIS 
In this work, we sought to better understand drug resistance in Plasmodium falciparum, 
the causative agent of the most severe form of human malaria, and to design strategies 
to help suppress the emergence of resistance. We used in vitro drug resistance 
selections to identify optimal resistance pathways to PfDHODH inhibitors. Protein activity 
assays recapitulated the changes in drug sensitivity seen in selected parasite lines, 
suggesting that point mutations in the target gene pfdhodh explain the observed 
changes. We then used the concepts of evolutionary fitness and competitive advantage 
to set a trap: by pairing antimalarial drugs targeting the sensitive and resistant alleles of 
a target gene, we can prevent the spread of those resistant alleles. This strategy, coined 
“targeting resistance,” would maintain a sensitive population and thereby extend the 
useful lifetime for antimalarial drugs. 
	   
 
 
CHAPTER TWO: 
EVOLUTIONARY OSCILLATIONS FOR A HIGHLY FIT 
PFDHODH MUTANT 
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2.1 ATTRIBUTIONS  
Leila S. Ross1, Amanda K. Lukens2, Amar bir Singh Sidhu1, Richard Heidebrecht1,2, 
Francisco-Javier Gamo3, Maria Jose Lafuente-Monasterio3, Michael L. Booker4, Roger C. 
Wiegand2, Dyann F. Wirth1,2 
1. Department of Immunology and Infectious Diseases, Harvard School of Public Health, 
Boston, MA 
2. Infectious Disease Initiative, Broad Institute, Cambridge, MA  
3. Tres Cantos Medicine Development Campus, GlaxoSmithKline, Tres Cantos, Spain 
4. Genzyme Corporation, Waltham, MA 
 
Chemical synthesis was carried out by R.H., F-J.G, M.J.L-M. and M.L.B.  M.L.B 
performed a PfDHODH screen which led to the Genz-666136 series of compounds. F-
J.G. and M. J.L-M performed a PfDHODH screen which led to the GSK3 and GSK8 
compounds. A.B-S.S performed the selection that resulted in the PfDHODH E182D, 
PfDHODH F227I, and PfDHODH L531F mutants. A.K.L. performed initial 
characterization of A.B-S.S’s selected parasite lines. L.S.R. performed all parasite 
proliferation assays shown. L.S.R. performed the selection that resulted in the 
PfDHODH E182D: D182E parasite line. Cloning, purification, and biochemical assays 
with recombinant PfDHODH protein were performed by L.S.R. Competitive growth 
assays and allelic discrimination analysis were performed by L.S.R.   
Funding for this work was provided by grants from the Medicines for Malaria Venture, 
the Bill and Melinda Gates Foundation, the Broad Institute SPARC program, the 
Genzyme Humanitarian Assistance for Neglected Disease Program, and NIH grant R01 
AI093716-01A1. 
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2.2 INTRODUCTION   
The evolution of new traits requires diversity and selection. In Plasmodium parasites, 
population diversity is generated through sexual recombination in the mosquito, errors in 
DNA replication and repair, and random sampling of genomic amplifications 51. Selection 
occurs through parasite-host interactions such as immune responses as well as more 
modern forces such as antimalarial drugs.  
Malaria is currently preventable and treatable. This is threatened by rising levels of 
resistance of the mosquito vector to insecticides and of the parasite to antimalarial drugs. 
Drug resistance can develop quickly in malaria: in the case of atovaquone, resistance 
emerged during clinical trials and 30% of treated patients recrudesced with resistant 
parasites 23. The antimalarial pipeline contains few compounds with novel mechanisms 
of action 52, so cross-resistance with existing therapies is a major concern.  
The control and eradication of malaria requires a steady supply of cheap, stable, and 
effective antimalarial drugs that are safe for entire populations, including pregnant 
women and infants. Drug resistance complicates this already-lofty goal. Given that an 
infected person may on the order of 1010 - 1013 parasites in their bodies, and that there 
are an estimated 350-500 million cases of malaria per year, the potential for resistance 
is enormous 53. New therapies must take potential resistance into account, or we will 
forever be in a Red Queen’s race where each new drug only buys a short amount of 
time before becoming obsolete. 
Methods to limit resistance have largely relied on combination therapy, where the driving 
concept is that it is more difficult to become resistant to two compounds than one. This 
is logical, but the truth is more complicated. Synergistic combinations, often chosen 
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because of their greater-than-additive potency, actually accelerate the evolution of drug 
resistance when compared to single drugs or antagonistic combinations 54. This is 
thought to be because a mutant resistant to one of the two drugs has a selective 
advantage over the sensitive parent. Conversely, strongly antagonistic combinations, 
referred to as “suppressive” combinations, select away from resistance 36. Thus, it would 
be wise to trade in short-term potency for long-term resistance suppression. 
Evolutionary fitness constraints limit the diversity of resistance pathways in a population. 
In Plasmodium falciparum, pyrimethamine resistance is best accomplished with a 
quadruple mutant in dihydrofolate reductase (DHFR). Although there are twenty-four 
(i.e., 4!) possible orders of mutations to get these four residues, three pathways account 
for 90% of observed resistance, and all veer to the same outcome of four specific 
mutated residues. Similarly, a limited number of paths to resistance were followed with 
high probability for bacterial beta-lactamase inhibitors, indicating that this is a 
widespread phenomenon that applies to both prokaryotes and eukaryotes 27.  
Over time, compensatory mutations can restore fitness 55 – this expands the number of 
possible resistance pathways. Thus, acting early to prevent the initial emergence of 
resistance may restrict parasite options to those few heavily favored, highly fit pathways. 
These pathways can be predicted through in vitro selection experiments 22, and pre-
emptively blocked through the development of mutant-selective inhibitors. As a caveat, 
in vitro experiments do not replicate a key factor of human infection: the immune 
response. 
Identifying and combining antimalarial compounds that selectively target the bulk wild-
type (WT) population and the small, emerging resistant population (mutant type, MT) is 
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a novel approach to antimalarial combination therapy. We tested this idea, coined 
“targeting resistance,” with antimalarial agents targeting pyrimidine biosynthesis.  
We performed resistance selections with PfDHODH inhibitors against wild-type 
parasites (3D7 and Dd2). Characterization of the resulting resistant lines showed point 
mutations in the PfDHODH target: E182D, F227I, and L531F. Testing of a small set of 
PfDHODH inhibitors revealed an interesting pattern: while cross-resistance was 
observed, as expected, for structurally related compounds, different structural classes of 
inhibitors were often unaffected or even more potent against the mutant parasites than 
the parental wild-type. We performed further resistance selections with these mutant-
selective inhibitors. Selection of the 3D7 E182D parasite line with IDI-6273, a mutant-
selective inhibitor, led to a novel mutation in pfdhodh that resulted in a reversion to the 
wild-type protein sequence. Simultaneous selection of a Dd2 wild-type parasite with a 
combination of Genz-669178 (a wild-type inhibitor) and IDI-6273 (a mutant-selective 
inhibitor) did not yield resistance in 80 days. Activity assays with purified protein 
recapitulated the results seen in whole cells, and suggest that the PfDHODH E182D 
mutant has a lower catalytic efficiency than the wild-type protein. 
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2.3 MATERIALS AND METHODS 
PARASITE CULTURE: 
The erythrocytic stages of P. falciparum were grown at 37°C in solutions of 4% O+ 
hematocrit in RPMI 1640 medium supplemented with 28 mM NaHCO3, 25 mM HEPES, 
5% albumax II (w/v), and 20 µm gentamicin sulfate. Human blood was supplied from 
Research Blood Components or Interstate Blood Bank. Cultures were grown in a gas 
mixture of 5% O2, 5% CO2, and 90% N2. Cultures were maintained with media changes 
every other day and were sub-cultured to maintain parasitemia below 4%. At least 25% 
of the hematocrit was replaced weekly. Parasite growth was synchronized by treatment 
with sorbitol 56. Frozen stocks were prepared using a sterile solution composed of 28% 
glycerol, 3% sorbitol, and 0.65% sodium chloride. The Dd2 parasite used was MR4 
strain MRA-156. 
RESISTANCE SELECTION:  
Approximately 1 x 109 ring stage Dd2 or 3D7 parasites were treated with ten times the 
EC50 of a compound for 6-8 days in four independent flasks to eliminate all viable 
parasites visible by microscopy. Compound pressure was then removed and the 
cultures were fed on alternate days with compound-free complete RPMI media. Once 
healthy parasites reappeared in the culture flasks, compound exposure was repeated. 
These steps were executed for 30-60 days. Selected parasites were cloned by limiting 
dilution in a 96-well plate with an inoculum of 0.5 infected red blood cells per well. 
Parasite clones were detected after 2.5 weeks of growth by microscopy.  
GENOMIC DNA ANALYSIS:  
Genomic DNA was extracted from parasites using the QIAamp blood kit (Qiagen) for 
sequence analysis of the pfdhodh gene (PlasmoDB ID: Pf3D7_0603300). A 2.2 kb 
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fragment encompassing the complete pfdhodh ORF was PCR amplified from drug-
resistant clones and parental lines (primer sequences below). PCR-amplified fragments 
were fully sequenced using pfdhodh-specific primers. The pfmdr1 and pfcrt genetic 
determinants of Genz-666136-resistant clones were analyzed using previously 
published protocols, and comparison was performed with the parental lines 57.  
PfDHODH Forward 5’- GATCCCTAGGATGATCTCTAAATTGAAACCTCAATTTATG -3’  
PfDHODH Reverse 5’- GATACTCGAGTTAACTTTTGCTATGCTTTCGGCCAATG -3’ 
PfDHODH internal 5’- CATTATTTGGATTATATGGTTTTTTTGAATCTTATAATCCTG -3’ 
The pfdhodh gene was amplified with Pfu Ultra II Fusion DNA polymerase (Agilent) with 
the following conditions: 95°C 120 seconds, 55°C 20 seconds, 60°C 100 seconds, go to 
step two and repeat 30 times. PCR amplicons were purified with a PCR clean-up kit 
(Qiagen) and sequenced via Genewiz. 
WHOLE GENOME SEQUENCING AND ANALYSIS:  
Genomic DNA was sheared and made into a 200 bp fragment Illumina sequencing 
library, and sequenced with paired-end reads on an Illumina GAIIx machine at the Broad 
Institute. The sequenced reads were aligned against the P. falciparum 3D7 reference 
from PlasmoDB (version 7.1*) 58 using BWA version 0.5.7 59. Duplicate reads were 
marked using the Picard MarkDuplicates tool <http://picard.sourceforge.net/>. The 
consensus bases were called using the Genome Analysis Toolkit's (GATK) Unified 
Genotyper (version 1.0.5974) 60 and the SAMtools (version 0.1.16)61 mpileup command. 
Only bases that were called as homozygous for the reference or the alternate allele with 
a genotype quality of at least 30 were considered. The GATK Unified Genotyper called 
3685 SNPs in the Genz-66136-resistant strain relative to stock (2108 intergenic, 248 
intronic, 423 synonymous coding and 906 nonsynonymous coding). By contrast, only 47 
SNPs passed all the quality filters when using the SAMtools genotyper (25 intergenic, 2 
intronic, 3 synonymous, 17 nonsynonymous). Of these, only eight overlapped with the 
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GATK set (2 intergenic and 6 nonsynonymous). The nonsynonymous mutations fell in 
four genes: 1) F227I in PFF0160c (the dhodh gene), 2) I352T and E355D in PF07_0111, 
a highly polymorphic gene of unknown function, 3) adjacent mutations in the PfEMP 
PF08_0106, and 4) I1548M in PFI1280c, a putative protein kinase that is also highly 
polymorphic. Whole genome sequencing was also performed for the 3D7 E172D: 
D182E parasite line with similar procedures and results. 
IN VITRO DRUG SENSITIVITY AND EC50 DETERMINATIONS:  
Drug susceptibility was measured using the SYBR Green method 62. Twelve point 
curves based on 2-fold dilutions of the test compound were carried out in triplicate and 
replicated on three different days. EC50 values were calculated using the log(inhibitor) vs. 
response – Variable slope equation in GraphPad Prism version 5.0d (described below):  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚1 + 10  !"# !"!"!! ×  !"##  !"#$% 
Where X = concentration of compound, and Y = normalized percent viability.  
Note that the fold-change values are the EC50 of the described parasite line divided by 
that of the parent for a single, paired assay – so the fold changes may not exactly match 
the EC50 values given if different cultures were assayed on different days (and are thus 
normalized to different parental values than what is shown). The trends are very similar 
even if the exact numbers do not match.  
SYNTHESIS OF DSM74:  
The compound DSM74 was prepared following the literature procedure 63 and was 
recrystallized from ethanol.  1H NMR spectra matched reported results 43 and HPLC 
analysis indicated > 95% purity. 
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SYNTHESIS OF GSK8:  
 
 
Pentane-
2,4-dione (0.206 mL, 2.00 mmol) was added to a solution of 2-propyn-1-amine (0.274 
mL, 4.00 mmol) in water (5 mL) and the resulting mixture was stirred at room 
temperature for 16 hr. The reaction was extracted with dichloromethane and the organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure to give 275 mg of (Z)-4-(prop-2-yn-1-ylamino)pent-3-en-2-one (275 mg, 2.005 
mmol, 100 % yield) as a yellow oil: 1H-NMR (CDCl3, 400 MHz) d 2.02 (s, 3H), 2.28 (t, J = 
2.4 Hz, 1H), 3.99 (dd, J = 6.2, 2.4 Hz, 2H), 5.06 (s, 1H), 10.76 (br. s, 1H). MS: m/e 138 
(M+H+). Purity was determined as >95 % by HPLC (308 nm), Rt: 0.95 (Acquity UPLC 
BEH C18 1.7u 3x50mm, CH3CO2NH4 25mM + 10%ACN at pH 6.6 / ACN). 
To a solution of  (Z)-4-(prop-2-yn-1-ylamino)pent-3-en-2-one (260 mg, 1.895 mmol), CuI 
(7.22 mg, 0.038 mmol), PdCl2(Ph3P)2 (26.6 mg, 0.038 mmol) and DIPEA (3.89 mL, 22.74 
mmol) in N,N-Dimethylformamide (DMF) (1 mL) under argon atmosphere, 3-
iodobenzotrifluoride (0.410 mL, 2.84 mmol) was added and the resultant mixture was 
stirred at room temperature for 1 h 45 min, the reaction was partitioned between water 
and EtOAc. The layers were separated and the aqueous was extracted with EtOAc. The 
combination of the organic layers was washed with aq. 0.5 N HCl and brine. After drying 
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over anhydrous Na2SO4, the organic layer was filtered and concentrated under reduced 
pressure. The resulting crude was purified by column chromatography (10g, Merck, 
CyHex:EtOAc gradients from 100:0 to 90:10 to 50:50) to give 365 mg of (Z)-4-((3-(3-
(trifluoromethyl)phenyl)prop-2-yn-1-yl)amino)pent-3-en-2-one (365 mg, 1.298 mmol, 
68.5 % yield) as a yellow solid: 1H-NMR (CDCl3, 400 MHz) d 2.04 (s, 3H), 2.07 (s, 3H), 
4.23 (d, J = 6.1 Hz, 2H), 5.09 (s, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.58 (m, 2H), 7.67 (s, 1H), 
10.87 (br. s, 1H). MS: m/e 282 (M+H+). Purity was determined as > 95 % by HPLC (309 
nm), Rt: 1.28 (Acquity UPLC BEH C18 1.7u 3x50mm, CH3CO2NH4 25mM + 10% ACN at 
pH 6.6 / ACN).  
  
To a solution of 3-iodobenzotrifluoride (100 mg, 0.368 mmol) in anhydrous Dimethyl 
Sulfoxide (DMSO) (5 mL) under argon atmosphere, cesium carbonate (240 mg, 0.735 
mmol) was added and the resultant mixture was stirred at room temperature for 1 h. The 
reaction was then diluted with EtOAc and 0.5 N aq. HCl. The layers were separated and 
the aqueous was extracted with EtOAc. The combination of the organic layers was 
washed with water, then brine, and then dried over anhydrous Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting crude was purified by column 
chromatography (dry head, 2g, Isolute, CyHex:EtOAc gradients from 100:0 to 80:20 to 
0:100) to give 83 mg of 1-(2-methyl-4-(3-(trifluoromethyl)benzyl)-1H-pyrrol-3-yl)ethanone 
as a pale brown solid: 1H-NMR (DMSO-D6, 400 MHz) d 2.24 (s, 3H), 2.42 (s, 3H), 4.03 
(s, 2H), 6.36, (d, J = 3 Hz, 1H), 7.46 (m, 4H), 11.05 (s, 1H). 13C-NMR (DMSO-D6, 100 
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MHz) d 15.4, 31.2, 32.9, 120.1, 122.7 (t, J = 3.7 Hz), 123.3, 125.0 (q, J = 272 Hz), 125.3 
(q, J = 3.7 Hz), 129.2 (q, J = 31.5 Hz), 129.5,133,2, 135.9, 144.2, 193.9. 19F-NMR 
(DMSO-D6, 376 MHz) d -60.8 (s, 3F). MS: m/e 282 (M+H+). Purity was > 95 % by HPLC 
(249 nm), Rt: 1.20 (Acquity UPLC BEH C18 1.7u 3x50 mm, CH3CO2NH4 25mM + 10% 
ACN at pH 6.6 / ACN). 
PFDHODH PLASMID CONSTRUCTION AND MUTAGENESIS: 
A synthetic codon-optimized gene encoding residues 159-565 of PfDHODH 41 (Genbank 
accession No. AY685129) was cloned into a pET28b plasmid with an amino-terminal 
6xHistidine tag followed by an rTEV cleavage site as described by Deng et al 64, 
resulting in pET28b-6xHistidine-rTEV-PfDHODH (codon optimized) del 1-158. The 
PfDHODH E182D mutation was created with the following primers, then cloned into the 
tagged pET28b construct described above: 
E182D Forward 5’-GTACATCGATGGTGACATTTGCCATGACCTG-3’  
E182D Reverse 5’-CAGGTCATGGCAAATGTCACCATCGATGTAC-3’ 
PFDHODH PROTEIN EXPRESSION AND PURIFICATION: 
BL21(DE3)Star Escherichia coli (Invitrogen) were transformed with WT and E182D 
PfDHODH expression constructs. Transformed cells were grown in Terrific Broth with 
100 µg/mL kanamycin at 37°C and 180 rpm, then dropped to 20°C and induced with 200 
µm isopropyl-D-thiogalactoside. Cultures were grown 12-16 hours post-induction, then 
pelleted by centrifµation at 10,000x g and frozen at -80°C for later use. For purification, 
conical tubes of frozen cell pellets were thawed in 25°C water. Thawed pellets were then 
resuspended in buffer A (100 mM HEPES pH 8.0, 150 mM NaCl, 10% glycerol, 0.05% 
Thesit). The cells were lysed by sonication on ice (Branson digital sonifer 450, 5 minutes 
at 40% amplitude with a pattern of 5 seconds on and 10 seconds off). The cell lysate 
was clarified by centrifugation at 40,000 x g for 45 minutes at 4°C, then filtered through a 
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0.45 µm filter. The clarified and filtered lysate was applied to a HisPrep FF 16/10 column 
(GE Healthcare) pre-equilibrated with buffer A on an AKTA Purifier FPLC. The column 
was washed with 30 cV of buffer A, then eluted with stepwise increments of buffer B 
(100 mM HEPES pH 8.0, 150 mM NaCl, 10 glycerol, 0.05% Thesit, 400 mM imidazole). 
The eluted protein was concentrated by centrifugation in concentrator spin columns 
(Pierce), then injected into a HiLoad 16/60 Superdex 200 size exclusion column pre-
equilibrated with running buffer (10 mM HEPES pH 7.8, 100 mM NaCl, 5% glycerol, 1 
mM N,N-dimethyldodecylamine N-oxide, 10 mM DTT). Fractions containing PfDHODH 
were pooled and concentrated. Protein concentration was assessed by Bradford assay 
(Pierce). Catalytically active protein concentration was assessed by boiling 50 µLof 
protein, clarifying by centrifugation for 10 minutes at 13,200x g, and then measuring 
absorbance of the cleared supernatant at 445 nm to determine the flavin 
mononucleotide concentration (ε445 = 12.5 mM-1 cm-1). Aliquots of protein were flash-
frozen in liquid nitrogen, then stored at -80°C. 
PFDHODH BIOCHEMICAL ASSAYS: 
Substrate-dependent inhibition of recombinant PfDHODH protein was assessed in an in 
vitro assay in 60 µLvolumes in 384-well clear plates (Corning 3702). A 16-point dilution 
series of inhibitor concentrations were assayed against 2-10 nM protein with 500 µm µm 
L-dihydroorotate substrate (L-DHO, excess), 18 mM dodecylubiquinone electron 
acceptor (CoQD, ~ Km), and 100 µm 2,6-dichloro-indophenol indicator dye in DHODH 
assay buffer (100 mM HEPES pH 8.0, 150 mM NaCl, 5% glycerol, 0.5% Triton X-100). 
Assays were incubated at 25°C for twenty minutes, then assessed by measuring the 
absorbance at 600 nM in a SpectraMax M5 plate reader. Molecular oxygen, which can 
act as an electron acceptor in this reaction, was depleted through the addition of 0.1 
mg/mL of glucose oxidase, 0.02 mg/mL of catalase, and 50 mM glucose, followed by 
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incubation at 25° for five minutes prior to assay assembly. Data were normalized to 1% 
DMSO and excess inhibitor (500 nM Genz-669178 unless another compound was 
appropriate). Steady-state kinetic parameters were determined by directly assessing the 
production of orotic acid (ε296 = 4.3 mM-1 cm-1) in UV-transparent 384-well plates 
(Corning 3672). For enzyme oxidase activity, 100 nM of enzyme was assayed against a 
range of L-DHO concentrations (5-500 uM). For oxidant affinity, 5-50 nM of enzyme was 
assayed against a range of CoQd (1-150 uM) or dissolved molecular oxygen (~300 uM) 
with excess substrate (500 µm L-DHO). Unless otherwise specified, oxygen was 
depleted from the reactions using the glucose oxidase-catalase system described above. 
Data were fitted to the Michaelis-Menten equation in GraphPad Prism 5 to determine the 
steady-state parameters (kcat and Km). 
𝑌 = (𝐸𝑡  ×  𝑋)(𝐾𝑚 + 𝑋) 
Y = enzyme velocity, Et = total enzyme concentration, and X = substrate concentration. 
COMPARATIVE FITNESS ASSAYS: 
Parasite lines to be used were synchronized with sorbitol 56 for two consecutive life 
cycles. 2 mL cultures were seeded in triplicate with a mixture of two synchronized 
parasite lines. Initial parasitemia was 1% total in 4% hematocrit. Cultures were grown at 
37°C in complete RPMI with 40 rpm gentle shaking. 80-90% of the cultures were taken 
every other day (one life cycle) to isolate genomic DNA. This DNA was then analyzed by 
allelic discrimination qPCR to determine the relative ratios of the two parasite lines in 
question (primers and reporters listed on page 31, polymorphism site bolded and 
underlined). Note that at this parasitemia and hematocrit, there is no competition for red 
blood cells, so this assay measures comparative growth and not competitive growth. 
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Parasite lines Forward 
primer 
Reverse 
primer 
Reporter 1 
(VIC), Wild-type 
Reporter 2 
(FAM), Mutant 
3D7 versus 
3D7: E182D 
TGGTTTTT
TTGAATCT
TATAATCC
TGAATTTT
TTT 
 
CTATCATT
ACTAGTAT
CATATGGT
AATATATT
ATATTTTC 
 
ATTGATGGTG
AAATATGTC 
 
ATTGATGGTG
ATATATGTC 
 
3D7 versus 
3D7: D182E 
TGGTTTTT
TTGAATCT
TATAATCC
TGAATTTT
TTT 
 
CTATCATT
ACTAGTAT
CATATGGT
AATATATT
ATATTTTC 
 
ATTGATGGTG
AAATATGT 
 
TTGATGGTGA
GATATGT 
 
Competitive growth assays were carried out for six generations. Allelic discrimination 
assays were performed with TaqMan Universal PCR Master Mix with no AmpErase 
UNG (Applied Biosystems) on a 7900 HT real-time PCR machine (Applied Biosystems). 
Cycling conditions were 95°C for 10 minutes, followed by 45 cycles of 95°C for 15 
seconds and 56°C for 1 minute. 
STATISTICAL ANALYSES: 
 EC50 data are shown as mean ± standard deviation and were analyzed by one-way 
ANOVA with Dunnett’s multiple comparison post hoc test (for three or more groups) or a 
two-tailed t-test (for two groups) via Graph Pad Prism 5.0d Software. Differences were 
considered significant for P < 0.05. 
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2.4 RESULTS 
PRIMARY PFDHODH INHIBITOR SELECTIONS: WILD-TYPE PARASITES 
Two classes of PfDHODH inhibitors are the alkylthiophenes	  44 and the 
triazolopyrimidines 43 (Figure 2.4.1). 
 
Figure 2.4.1: Two classes of PfDHODH inhibitors 
Alkylthiophenes (left) and triazolopyrimidines (right) 
 
We did in vitro resistance selections on a lead candidate from each inhibitor class: Genz-
666136 and DSM74. Genz-66136 is closely related to the derivatives Genz-668419 and 
Genz-669178, both of which are discussed later. We carried out selections with these 
two compounds against two well-characterized parasite lines, 3D7 and Dd2 (Table 2.4.1).  
 
Table 2.4.1: Initial PfDHODH inhibitor resistance selections 
  
S O
HN
N
N
Genz-666136 
F
F
F
NH
N
N
N
N
DSM74 
Selection Information PfDHODH allele 
Parasite 
Line Drug Resistance Residue Nucleotide Copy # 
Dd2 Genz-666136 Y F227I  T687A 1 DSM74 Y L531F G1593T 1 
3D7 Genz-666136 Y E182D A516T 1 DSM74 Y E182D  A516T 1 
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These selections resulted in three point mutations in pfdhodh: E182D, F227I, and L531F. 
Note that E182D appeared for both compounds, even though they are from different 
structural classes. This suggests that E182D is a common route to resistance for 
PfDHODH inhibitors, and may thus be a fitness maximum for resistance. Whole-genome 
sequencing was performed on the F227I mutant to identify other potential resistance 
mechanisms, but no known or logical polymorphisms were detected. This does not rule 
out resistance by copy number variation, which whole genome sequencing is 
notoriously ineffective at detecting, or non-genetic changes such as epigenetic changes, 
signal transduction, and generalized stress responses. The known efflux pumps 
PfMDR1 and PfCRT1 were not amplified. PfDHODH was not amplified (see Chapter 3). 
We then screened these three resistant lines against a small panel of structurally 
diverse PfDHODH inhibitors, and made an interesting observation: while cross-
resistance was observed for some PfDHODH inhibitors, other inhibitors were much 
more potent against the mutant lines than the wild-type (WT) (Figure 2.4.2 and Table 
2.4.2). We termed these potentiated agents “PfDHODH mutant-type (MT) inhibitors.” For 
example, when compared to the parental 3D7 parasite line, the 3D7: E182D line was 
8.7-fold less sensitive to Genz-669178, a “WT inhibitor,” but 12.5-fold more sensitive to 
IDI-6273, which was deemed a “MT inhibitor.” IDI-6273 is a relatively poor inhibitor of 
WT parasites, with whole cell EC50 values of 181.4 nM. The IDI-6273 EC50 improves to 
13.5 nM in the 3D7: E182D mutant line. This induced hypersensitivity implied that the 
resistant form of the target can be a target itself.  
Given that resistance emerges in an ecological context where fitness costs limit the 
diversity of escape pathways, we proposed that we could anticipate resistance pathways 
and preemptively block them with mutant-specific inhibitors. In theory, this idea of 
“targeting resistance” would prevent the emergence of competitively viable resistance.  
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Figure 2.4.2: Resistance and induced sensitivity 
(A). Parasite lines resistant to WT PfDHODH inhibitors show cross-resistance to some 
PfDHODH inhibitors, but are hypersensitive to others, which were deemed “mutant 
PfDHODH inhibitors.” 
(B). The unrelated antimalarial chloroquine shows no difference in the parasite lines 
tested. Note that 3D7-based lines are much more sensitive to chloroquine than Dd2. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of triplicate measurements.   
“Targeting resistance” could be accomplished with a combination therapy where one 
compound targeted WT parasites (the bulk population), and a partner drug targeted the 
emerging resistant population (a much smaller population, and much less likely to have 
the diversity necessary to develop resistance). This paired treatment could occur 
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concurrently or sequentially. To minimize selective pressure towards resistance to the 
partner drug, the partner would ideally have negligible activity against the WT, and only 
become an active drug with a target(s) after resistance to the primary drug arose. As the 
compounds tested here were initially identified as WT PfDHODH inhibitors, we have no 
completely specific compounds. Identifying or designing mutant-specific inhibitors would 
be an interesting area of future work. 
Table 2.4.2: PfDHODH inhibitor resistant line data 
 
(A). EC50 fold shifts relative to the parental parasite line demonstrate both increased and 
decreased sensitivity to different classes of PfDHODH inhibitors. 
(B). EC50 values demonstrate both increased and decreased sensitivity to different 
classes of PfDHODH inhibitors. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.   
 
Although these resistance selections gave three point mutations in PfDHODH, we chose 
to focus on the E182D mutation as it appeared in response to both an alkylthiophene 
EC50 (nM) ± s.d. 
Dd2 Dd2: F227I Dd2: L531F 3D7 3D7: E182D 
PfDHODH allele WT F227I L531F WT E182D 
PfDHODH  
WT  
Inhibitors 
Genz-669178 6.88 ± 0.14 25.02 ± 6.51 3.87 ± 1.65 5.66 ± 3.30 38.4 ± 8.75 
Genz-668419 5.71 ± 3.62 44.4 ± 14.68 5.98 ± 0.93 6.8 ± 3.78 35.68 ± 19.88 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1049.33 ± 267.1 62.8 ± 87.64 3750 ± 494.97 778.93 ± 159.96 1295 ± 373.73 
IDI-6273 209.17 ± 72.76 24.82 ± 10.41 1170 ± 177.48 181.4 ± 53.25 13.48 ± 5.25 
GSK3 182.43 ± 71.7 49.27 ± 36.26 249.35 ± 11.46 145 ± 49.76 1872.17 ± 1063.0 
Standard 
Antimalarials Chloroquine 58.03 ± 10.35 66 ± 34.58 284.6 ± 6.51 6.95 ± 4.74 6.74 ± 4.0 
EC50 fold shift over parent ± s.d. 
Parent E182D F227I L531F 
PfDHODH allele WT E182D F227I L531F 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 8.73 ± 5.03 4.06 ± 0.95 0.31 ± 0.07 
Genz-668419 1 6.65 ± 4.36 9.19 ± 3.75 0.36 ± 0.04 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 1.64 ± 0.13 0.02 ± 0.01 1.52 ± 0.71 
IDI-6273 1 0.08 ± 0.03 0.12 ± 0.01 2.23 ± 1.05 
GSK-3 1 15.14 ± 10.15 0.26 ± 0.12 0.41 ± 0.06 
Standard 
Antimalarials Chloroquine 1 1.20 ± 0.56 0.82 ± 0.10 0.76 ± 0.04 
A.  
B. 
Table 2.2 PfDHODH inhibitor resistant line data 
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inhibitor (Genz-666136) and a triazolopyrimidine inhibitor (DSM74), and may therefore 
be an evolutionarily favored pathway to resistance.  
Analysis of a crystal structure of PfDHODH (Figure 2.4.3) showed that E182 forms a 
strong salt bridge with R262, and that this bond is one of surprisingly few interactions 
holding the membrane-adjacent α1-α2 helix lid in place. This two-helix lid defines the 
“species-selective inhibitor site” 65, and is the presumed tunnel for electron transfer 
between respiratory chain ubiquinone and the flavin mononucleotide (FMN) cofactor.  
Figure 2.4.3: PfDHODH E182D mutation 
(A). Selection of 3D7 parasites with either of the structurally unrelated PfDHODH 
inhibitors Genz-666136 and DSM74 led to the same resistance mutation, E182D. This 
implies that E182D is a fitness maximum for resistance. 
(B). Close-up structure of PfDHODH showing the position of residue E182. Note the 
hydrogen bonding to R262 and location near the drug-binding site.  
(C). Overall structure of PfDHODH for orientation. 
All images shown are of PDB ID: 3o8a and were created with CCP4mg 66.  
Figure 2.6  PfDHODH E182D mutation 
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A glutamate to aspartate (E to D) mutation is quite conservative, with only one carbon in 
a chain removed, but this may weaken the hydrogen bond to R262, which could then 
weaken the overall interactions holding the lid in place. The triazolopyrimidine class of 
inhibitors is thought to work by blocking electron flow between ubiquinone and flavin 
mononucleotide64-65, so altering the shape of this tunnel could lead to resistance by 
preventing drug binding and/or allowing electron flow to occur even when drug is bound.  
To test the idea of “targeting resistance,” we carried out two selection strategies: 
sequential and simultaneous (Figure 2.4.4). In the sequential selection, we took the 
3D7: E182D parasites and selected them with IDI-6273 (a MT inhibitor). In the 
simultaneous selection, we took 3D7 WT parasites and selected with a combination of 
Genz-669178 (a WT inhibitor) and IDI-6273 (a MT inhibitor). 
 
Figure 2.4.4: “Targeting resistance” treatment strategy 
SEQUENTIAL PFDHODH INHIBITOR SELECTIONS: MUTANT-TYPE PARASITES 
In the sequential selection, drug-resistant parasites emerged in one of four flasks in 41 
days (Figure 2.4.4, Table 2.4.3). The three remaining flasks never recovered, indicating 
that this was not a resistant parasite genome present in the founding population. As 
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WT 
 inhibitors 
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 inhibitors 
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inhibitors 
+ = 
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expected, selection with IDI-6273 decreased sensitivity to the selection agent. The 
sequentially selected parasites showed a 52.8-fold increase in the EC50 for IDI-6273, 
shifting from 48.5 nM to 2.3 uM. Curiously, the sequentially selected line was 4-fold 
more sensitive to Genz-669178, a WT inhibitor, with EC50 values dropping from 31.9 nM 
to 8.8 nM. This value is similar to the 3D7 parental 3.5 nM. Chloroquine, 
dihydroartemisinin, and atovaquone - control compounds that are presumably unrelated 
to pyrimidine synthesis or metabolism - showed small but significant differences, e.g., a 
23% increase in sensitivity to chloroquine. Taken together, these results implied that 
physiological changes affecting multiple pathways had occurred.  
PCR sequencing of the pfdhodh gene in the sequentially selected line uncovered a 
novel mutation in codon 182. Surprisingly, codon 182 was now the alternate codon for 
glutamate, the original WT residue (Figure 2.4.5 C). We called this WT “reversion” line 
3D7 E182D: D182E. There are likely to be changes outside of pfdhodh as sensitivity to 
unrelated compounds like chloroquine was also altered, and not all PfDHODH inhibitors 
returned to WT ranges of sensitivity. Whole-genome sequencing of the 3D7 E182D: 
D182E line showed a non-synonymous polymorphism of I772V in cytochrome c oxidase 
(PlasmoDB ID: mal_mito_1), which could affect the mitochondrial electrochemical 
gradient and thus PfDHODH activity or stability. However, this mutation was also 
present in the 3D7: E182D parent, and so cannot explain the observed differences.    
The evolutionary oscillation between glutamate and aspartate at codon 182 suggests 
that these are two optimal solutions to the fitness-resistance compromise. Nevertheless, 
there are other solutions, even if they are less easy to reach or provide lower benefit, so 
sequential cycling between Genz-669178 and IDI-6273 is unlikely to remain effective as 
other mutants arise and spread or compensatory mutations increase fitness.   
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Figure 2.4.5: 3D7 E182D: IDI-6273 selection gave reversion to WT protein. 
(A). EC50 fold shifts relative to the parental selection line show a return to WT-like 
sensitivity for some PfDHODH inhibitors but not others (e.g., IDI-6273). 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show significant 
differences among the three lines tested, indicating that there are physiological changes 
beyond PfDHODH point mutations. 
(C). PCR sequencing of the PfDHODH gene revealed a novel nucleotide mutation in 
codon 182, which led to a reversion to the WT protein sequence. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements. 
Significance relative to parental EC50 was determined by one-way ANOVA with 
Dunnett’s multiple comparison test. n.s., not significant. *, p<0.05. **, p<0.005, ***, 
p<0.0005. 
A.  
Figure 2.7 
3D7   
 AAATATATTGATGGTGAAATATGTCATGACCTTTT 
3D7 E182D  
 AAATATATTGATGGTGATATATGTCATGACCTTTT 
3D7 E182D: D182E  AAATATATTGATGGTGAGATATGTCATGACCTTTT  
   ***************** 
*****************  
C.  
3D7 E182D: IDI-6273 selection 
gave reversion to wild type protein 
B.  
3D7   AAATATATTGATGGTGAAATATGTCATGACCTTTT 
3D7 E182D  AAATATATTGATGGTGATATATGTCATGACCTTTT 
3D7 E182D: D182E  AAATATATTGATGGTGAGATATGT A GACCTTTT  
   ***************** *****************  
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Table 2.4.3: 3D7 E182D: IDI-6273 selection data 
(A). EC50 fold shifts relative to the parental parasite line demonstrate both increased and 
decreased sensitivity to different classes of PfDHODH inhibitors. 
(B). EC50 values demonstrate both increased and decreased sensitivity to different 
classes of PfDHODH inhibitors. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.   
EC50 (nM) ± s.d. 
3D7 Parent Flask #2 
PfDHODH allele WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 3.50 ± 0.23 31. 86 ± 6.09 8.75 ± 0.33 
Genz-668419 7.16  ± 2.11 67.59 ± 23.33 19.03 ± 6.92 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 5679.9 ±  6760.08 6495.45 ± 7699.76 12134.11 ± 14405 
IDI-6273 450.43 ± 227.67 48.50 ± 28.43 2315.43 ± 516.20 
GSK-3 68.11 ± 11.45 880.47 ± 140.59 198.60 ± 22.03 
Standard 
Antimalarials 
Chloroquine 3.05 ± 0.40 3.59 ± 1.05 3.22 ± 0.73 
Dihydroartemisinin 3.18 ± 1.15 2.18 ± 0.49 2.12 ± 0.63 
Atovaquone 0.15 ± 0.07 0.21 ± 0.07 0.24 ± 0.10 
EC50 fold shift over parent ± s.d. 
3D7 Parent Flask #2 
PfDHODH allele WT E182D E182D: D182E 
PfDHODH  
WT  
Inhibitors 
Genz-669178 0.10 ± 0.01 1 0.24 ± 0.05 
Genz-668419 0.010 ± 0.01 1 0.25 ± 0.02 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 0.87 ± 0.01 1 1.86 ± 0.01 
IDI-6273 8.51 ± 0.53 1 52.85 ± 12.62 
GSK-3 0.07 ± 0.07 1 0.20 ± 0.06 
Standard 
Antimalarials 
Chloroquine 0.83 ± 0.08 1 0.77 ± 0.08 
Dihydroartemisinin 1.39 ± 0.12 1 0.87 ± 0.04 
Atovaquone 0.72 ± 0.19 1 1.11 ± 0.06 
A.  
B.  
Table 2.3 3D7-E182D: IDI-6273 selection results 
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 While the sequential selections were proceeding, we also performed concurrent WT 
plus MT inhibitor selections – a test of the “targeting resistance” combination therapy 
idea. In theory, this combination should suppress the emergence of the targeted alleles, 
which in this case were WT and E182D.  
SIMULTANEOUS PFDHODH INHIBITOR SELECTIONS: “TARGETING RESISTANCE” 
We simultaneously selected WT 3D7 parasites with Genz-669178 and IDI-6273. Genz-
669178 is a WT inhibitor and IDI-6273 selectively inhibits the PfDHODH E182D (and 
F227I) mutant. This selection tested the concept of “targeting resistance” – could we 
force parasites to remain sensitive to the WT PfDHODH inhibitor by blocking their most 
fit, most favored escape pathway? 
We allowed the selection to proceed for 80 days - twice the length necessary for the 
sequential selection. In keeping with our hypothesis, no resistance was observed (Figure 
2.4.6, Table 2.4.4). All recovered parasites remained WT in terms of drug sensitivity to 
PfDHODH inhibitors and control compounds, and the pfdhodh allele remained wild-type.  
This selection took one billion parasites through at least 40 generations. Given a nuclear 
genome of 23.3 megabases, two small organellar genomes in the mitochondria and the 
apicoplast, and a DNA replication error rate of 1 to 9.7 x10-9 per nucleotide per 
generation 67, this is ample time for every position in the genome to be mutated at least 
once. Of course, some positions are more susceptible to genomic alterations than others, 
but 80 days is also in vast excess of the 3 days that most patients take antimalarial 
therapies. 40 generations is also ample time for the development of resistance through 
mechanisms other than mutation, e.g., copy number variation and compensatory 
physiological changes. 
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Figure 2.4.6: Dd2: Genz-669178 + IDI-6273 selection gave no resistance 
(A). EC50 fold shifts relative to the parental selection line show no significant 
development of resistance. 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
This combination selection proceeded for 80 days (40 generations). EC50 values were 
calculated using a whole-cell SYBR Green assay. Error bars indicate the standard 
deviation of three biological replicates, each with triplicate measurements. Significance 
relative to parental EC50 was determined by one-way ANOVA with Dunnett’s multiple 
comparison test. n.s., not significant. *, p<0.05. **, p<0.005, ***, p<0.0005.  
A.  
Dd2: Genz-669178 + IDI-6273 
selection gave no resistance 
Figure 2.8 
B.  
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Table 2.4.4: Dd2: Genz-669178 + IDI-6273 selection results 
 
(A). EC50 fold shifts relative to the parental parasite line show no significant difference. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.   
 
The promising results from the sequential and simultaneous selections led us to better 
characterize the E182D mutant line. We wanted to determine if the PfDHODH E182D 
mutation was sufficient to explain the observed drug sensitivity phenotypes, or if other 
factors contributed to the phenotype. To address this question, we took two approaches: 
protein biochemistry and evolutionary competitive growth assays. These strategies 
allowed us to analyze the PfDHODH protein alone as well as the entire physiological 
context of the parent and daughter cell lines. Ideally, this would be extended to include 
allelic replacements of the mutant pfdhodh E182D gene in whole parasites. 
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT WT WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 3.53 ± 0.36 3.80 ± 1.58 3.60 ± 1.43 3.79 ± 0.65 3.39 ± 0.85 
Genz-668419 5.79 ± 1.50 5.71 ± 1.42 5.38 ± 1.95 6.33 ± 2.14 6.84 ± 1.31 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 18927.67 ± 13046.72 
26476.67 ± 
13479.50 
22652.00 ± 
12847.45 
26893.33 ± 
9707.35 
22290.00 ± 
13178.312 
IDI-6273 1189.50 ± 153.44 1665.30 ± 1082.86 1275.85 ± 510.74 1121.15 ± 426.88 1262.100 ± 446.75 
GSK-3 69.81 ± 22.16 66.73 ± 14.83 59.017 ± 11.52 72.28 ± 26.45 73.37 ± 36.28 
Standard 
Antimalarials 
Chloroquine 54.33 ± 21.53 81.94 ± 43.02 79.23 ± 40.81 49.20 ± 12.59 52.29 ± 10.41 
Dihydroartemisinin 3.82 ± 1.06 3.395 ± 0.43 3.13 ± 0.05 3.85 ± 1.91 4.29 ± 1.52 
Atovaquone 0.16 ± 0.16 0.093 ± 0.05 0.12 ± 0.06 0.18 ± 0.12 0.18 ± 0.19 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT WT WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 1.05 ± 0.32 1.00 ± 0.30 1.07 ± 0.09 0.96 ± 0.20 
Genz-668419 1 1.00 ± 0.19 0.94 ± 0.28 1.08 ± 0.12 1.20 ± 0.11 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 1.62 ± 0.50 1.31 ± 0.25 2.07 ± 1.41 1.27 ± 0.19 
IDI-6273 1 1.35 ± 0.74 1.05 ± 0.29 0.93 ± 0.24 1.05 ± 0.24 
GSK-3 1 1.00 ± 0.26 0.91 ± 0.35 1.05 ± 0.24 1.04 ± 0.30 
Standard 
Antimalarials 
Chloroquine 1 1.82 ± 1.52 1.72 ± 1.42 0.94 ± 0.12 1.02 ± 0.23 
Dihydroartemisinin 1 0.95 ± 0.35 0.87 ± 0.26 0.98 ± 0.23 1.12 ± 0.17 
Atovaquone 1 0.83 ± 0.39 1.10 ± 0.71 1.51 ± 0.81 1.06 ± 0.08 
A.  
B.  
Table 2.4  Dd2: Genz-669178 + IDI-6273 selection results 
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PURIFIED PFDHODH PROTEIN ACTIVITY AND COMPARISON WITH CELLULAR DATA 
We cloned and purified WT and E182D PfDHODH protein, and performed in vitro activity 
assays 65,	  49 to determine steady-state kinetic parameters and sensitivity to PfDHODH 
inhibitors via measurement of orotic acid or a coupled dye, respectively (Figure 2.4.7).   
We measured steady-state kinetic parameters for the PfDHODH oxidase reaction, where 
L-DHO is oxidized to orotic acid by flavin mononucleotide (FMN), and for the ping-pong 
redox reaction where the reduced FMN is oxidized by respiratory chain ubiquinone 
(Figure 2.4.7). The steady-state parameters for the PfDHODH WT and E182D proteins 
(Table 2.4.5) show a 1.8-fold decrease in kcat and a 4.7-fold increase in Km for the L-
DHO substrate in the E182D mutant. This would dramatically reduce the catalytic 
efficiency of the enzyme’s oxidase activity. Similarly, the E182D mutant protein had a 6-
fold decrease in kcat and a 6.2-fold increase in Km for CoQD.  
 
Figure 2.4.7: In vitro PfDHODH enzyme activity assays. 
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The observed decreases in catalytic efficiency for the PfDHODH E182D mutant 
presumably reduce whole-organism fitness, but the scale of these differences may be 
insignificant or masked by compensatory mechanisms inside cells.  
Table 2.4.5: Steady-state kinetic parameters for WT and E182D PfDHODH protein 
 
Steady-state kinetic measurements were performed at 25°C. Errors represent the 
standard deviation of the fit for three determinations. 
We carried out further analysis by measuring the effect of a panel of PfDHODH inhibitors 
on enzyme activity. In vitro protein activity assays recapitulated the results seen in 
whole-cell assays (Figure 2.4.8, Table 2.4.6): if a compound was more potent against 
WT than PfDHODH: E182D parasites in whole cell assays, then it was also more potent 
against the WT than the E182D mutant in protein assays. For example, E182D is 
resistant to Genz-669178 (Figure 2.4.8 A, rightward shift relative to WT) but sensitized to 
IDI-6273 (Figure 2.4.8 A, leftward shift relative to WT).  
EC50 fold changes (Figure 2.4.8 B) show highly significant changes between E182D 
(bars) and WT (represented by the dotted line at 100, one-fold). Note that these changes 
reflect the trends seen in whole cells, but are often more extreme (Figure 2.4.8 C). This 
is unsurprising, as in vitro protein assays are far simpler than living cells, and do not 
have the same extent of confounding factors such as plasma membranes, transporters 
or efflux pumps, off-target protein binding, and so on. The fact that the protein and cell 
results are largely commensurate indicates that sensitivity or resistance to PfDHODH 
PfDHODH allele WT E182D 
L-DHO 
kcat (s-1) 1.95 ± 0.32 1.08 ± 0.10 
Km (uM) 19.93 ± 2.71 93.1 ± 31.77 
CoQD 
kcat (s-1) 6.99 ± 0.59 1.16 ± 0.004 
Km (uM) 6.29 ± 1.95 38.86 ± 21.53 
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inhibitors is principally due to alterations in the pfdhodh gene itself. As protein 
expression in E.coli is currently much faster than allelic replacement in P. falciparum, 
protein activity is an ideal method for quickly determining the effect of PfDHODH 
mutations on drug sensitivity and kinetic parameters. 
 
Figure 2.4.8: Recombinant protein in vitro activity assays mirror cellular data. 
(A). Example EC50 curves reflects trends seen in whole-cell assays. Error bars indicate 
triplicate measurements. 
(B). EC50 fold changes show significant changes in sensitivity to a panel of PfDHODH 
inhibitors. Error bars indicate the standard deviation of three biological replicates, each 
with triplicate measurements.  
(C). Protein data mirrors cell data, although the fold changes are more extreme for the in 
vitro protein assays. Error bars indicate the standard deviation of three biological 
replicates, each with triplicate measurements.  
EC50 values were calculated using an indirect DCIP-coupled assay. Significance relative 
to parental EC50 was determined by one-way ANOVA with Dunnett’s multiple 
comparison test. n.s., not significant. *, p<0.05. **, p<0.005, ***, p<0.0005.  
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Table 2.4.6: Inhibition of PfDHODH WT and E182D protein activity 
 
(A). EC50 fold shifts relative to PfDHODH WT shows significant differences. 
(B). EC50 values for the same data set. 
EC50 values were calculated using an indirect DCIP-coupled assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.   
COMPETITIVE GROWTH ASSAYS:  POPULATION DYNAMICS AND EVOLUTIONARY FITNESS 
After focusing on molecular details of resistance, we panned out to a population level 
with competitive growth assays. These assays allow for a quantitative assessment of 
evolutionary fitness. We performed pairwise assays between the WT 3D7 parental 
EC50 (nM) ± s.d. 
Parent Resistant line 
PfDHODH allele WT E182D 
PfDHODH  
WT  
Inhibitors 
Genz-669178 79.50 ± 6.04  3483.33 ± 1290.96 !
Genz-668419 144.60 ± 5.54 ! 6722.33 ± 2564.01 !
DMS74 381.43 ± 93.07 ! 18783.3 ± 2915.62 !
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 3527.67 ± 215.93 !14216.67 ± 323.31 !
IDI-6273 13493.3 ± 3163.9 ! 2153.00 ± 133.37 !
GSK-3 1686.67 ± 459.57 !17263.33 ± 5432.9 !
EC50 fold shift over parent ± s.d. 
Parent Resistant line 
PfDHODH allele WT E182D 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 43.19 ± 12.41 !
Genz-668419 1 46.09 ± 15.62 !
DSM74 1 49.89 ± 3.97 !
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 4.04 ± 0.15 !
IDI-6273 1 0.17 ± 0.05 !
GSK-3 1 10.14 ± 0.54 !
A.  
B.  
Table 2.5 In vitro protein activity results 
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parasites and two PfDHODH mutants: E182D and the D182E WT revertant, and then 
analyzed the results with allelic discrimination assays (Figure 2.4.9). In all cases, the WT 
3D7 line outcompeted the mutant regardless of the starting inoculum.  
Over the course of six generations, the E182D mutant dropped by two-fold Figure 2.4.9 
A). In contrast, the D182E revertant decreased by five-fold (Figure 2.4.9 B). This implies 
that WT is more fit than the E182D mutant, and the E182D mutant is more fit than the 
D182E revertant. These assays were done without the presence of any drugs. The 
mutants would presumably have a fitness advantage when WT PfDHODH inhibitors are 
present, and a disadvantage when mutant PfDHODH inhibitors are present.  
 
Figure 2.4.9: Pairwise competitions show a mutant fitness defect 
(A). The wild-type 3D7 parasite is more fit than the mutant 3D7 E182D. 
(B). The wild-type 3D7 parasite is more fit than the wild-type revertant parasite 3D7 
E182D: D182E. Thus, the revertant line has changes outside of the pfdhodh gene that 
reduce its fitness, or the alternate glutamate codon compromises PfDHODH function. 
Results shown are of competitions done in triplicate, with triplicate allelic discrimination 
assays performed for each sample. Error bars represent the standard deviation. 
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It is interesting that the D182E revertant mutant is less fit than the WT. Earlier drug 
sensitivity data showed that although the protein sequence of the pfdhodh gene was the 
same in these parasite lines, there were significant differences in sensitivity to PfDHODH 
inhibitors and unrelated antimalarial drugs. There must be changes outside of the 
pfdhodh nucleotide mutation to account for these differences in drug sensitivity and 
overall competitive fitness. All three lines discussed have a single copy of pfdhodh (see 
Chapter 3). These mutations could potentially lead to different protein levels due to 
transcriptional or translational control, rare codons, or protein stability. Protein levels 
could be assessed with a PfDHODH antibody, which we recently obtained as a kind gift 
from Professor Margaret Phillips. Translational control could be assessed by ribosome 
footprinting	  65.  
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2.5 DISCUSSION AND FUTURE DIRECTIONS   
Drug resistance is an enormous issue for malaria, and we are relying on an increasingly 
narrow range of artemisinin-based therapies for treatment. Recent reports of potential 
artemisinin resistance at the Thai-Cambodian border 19 are a serious threat, as 
resistance from Southeast Asia has spread worldwide for both chloroquine and 
pyrimethamine 68. Drug resistance can rapidly compromise the effective useful lifetime 
of antimalarial agents, and cross-resistance with existing therapies is a major concern 
as few compounds with novel mechanisms of action are being developed. However, 
drug resistance emerges in the context of a population and is limited by evolutionary 
fitness costs. If a parasite is drug-resistant, but pays a heavy fitness price, it is unlikely 
to be competitively viable. These limitations result in a very small number of mutational 
escape pathways being heavily favored in Plasmodium 27, and likely in many other 
organisms as well. These escape pathways can be anticipated and blocked.	   
PfDHODH is a promising novel antimalarial drug target. In this study, we sought to 
characterize mechanisms of resistance to PfDHODH inhibitors and develop strategies to 
suppress the emergence and spread of resistance. To do so, we tested resistant 
parasite lines against a panel of antimalarial agents and identified compounds that were 
more potent against the mutants than the WT parent. These compounds could be said 
to have mutually incompatible resistance mechanisms as resistance to one leads to 
hypersensitivity to the other. The identification of mutant-selective compounds allows us 
to set a trap: if resistance to one compound results in hypersensitivity to another, then a 
parasite will be more fit if it retains WT sensitivity.  We call this concept “targeting 
resistance,” and it is an extension of the strong antagonism known as suppression 36.  
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We demonstrated the efficacy of “targeting resistance” with two selections: in the first, 
mutant-type 3D7 parasites with a PfDHODH E182D mutation were selected with the 
mutant-selective compound IDI-6273. The only resistant line to emerge had a novel 
mutation in pfdhodh, and this resulted in a reversion to the WT protein sequence. In the 
second, WT Dd2 parasites were selected with a combination of Genz-669178 (a WT 
inhibitor) and IDI-6273 (a mutant inhibitor). No resistance emerged in 80 days. The 
evolutionary loop between WT and E182D implies that these are both fitness maximums, 
and thus likely outcomes. 
“Targeting resistance” relies on stepwise acquisition of resistance. If the parasite is able 
to become resistant to both compounds in a single step, targeting resistance would be 
much more likely to fail. The PfDHODH inhibitors shown all bind the same pocket, 
although in different ways (see crystallography in Chapter 3). However, this may not be 
sufficient. An improved combination set would target binding sites that do not influence 
each other. A distant site on the same target or another target entirely would be ideal.  
Identifying compounds that target mutant PfDHODH parasites without necessarily 
inhibiting mutant PfDHODH directly is part of an ongoing effort from Dr. Amanda Lukens. 
It will be interesting to see what targets and pathways are represented in the mutant-
selective inhibitors. Suppressive combinations would likely include other mitochondrial 
targets, ubiquinone biosynthesis, or the folate pathway, as these all affect flux through 
the pyrimidine biosynthetic pathway. General translation is also a possibility, as DHODH 
inhibition kills cells by arresting translational elongation in the zebrafish neural crest 69. 
Another approach to identify suppressive partners would be to screen for compounds 
that rescue parasites from death due to DHODH inhibition 70. 
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There is only one known drug-binding site in PfDHODH, but it is a large tunnel and 
inhibitors that bind sufficiently distinct portions of this site may be less susceptible to 
cross-resistance. The assays used to identify PfDHODH inhibitors measure activity, not 
binding to a specific site, so it is possible that a screen will identify compounds with 
different binding sites.  
Another area for improvement would be to identify mutant-specific (rather than mutant-
selective) compounds. These efforts are being carried out by Leila Saxby Ross and Dr. 
Tomoyo Kato. The mutant-selective compounds have relatively little activity against the 
WT, but it is not negligible. This selective force can lead to resistance developing in the 
WT population, which would compromise the effectiveness of the mutant-selective 
compound when needed. The WT population is large and thus has a large potential for 
diversity. The emerging resistant population is small and thus has relatively little 
diversity. The less time the minority resistant population is allowed to exist, the less time 
it has to accumulate diversity (and thus become competitively viable resistant parasites). 
The goal, therefore, is to neutralize emerging threats as soon as possible, before they 
have a chance to spread or become more fit through compensatory mutations. 
Identifying mutant-specific inhibitors would eliminate selective pressure for resistance in 
the WT population.  
The observation of cross-resistance to some PfDHODH inhibitors and hypersensitivity to 
others implies that the drug-binding site has a limited mutational flexibility, likely limited 
by fitness constraints. The combination of well-chosen anti-malarial agents active 
against sensitive and resistant parasites effectively kills parasites in the short-term, and 
in the long-term, can help shape parasite evolution away from the development of drug 
resistance. 
  
 
 
CHAPTER THREE: 
ASSESSING RESISTANCE POTENTIAL OF 
ANTIMALARIALS IN DEVELOPMENT 
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3.1 ATTRIBUTIONS  
Leila S. Ross1, Amar bir Singh Sidhu1, Richard Heidebrecht1,2, Onkar M. P. Singh3, Paul 
Rowland3, Francisco-Javier Gamo4, Maria Jose Lafuente-Monasterio4, Michael L. 
Booker5, Piotrek Sliz6, Roger C. Wiegand2, Dyann F. Wirth1,2 
1. Department of Immunology and Infectious Diseases, Harvard School of Public Health, 
Boston, MA 
2. Infectious Disease Initiative, Broad Institute, Cambridge, MA  
3. GlaxoSmithKline, Stevenage, United Kingdom 
4. Tres Cantos Medicine Development Campus, GlaxoSmithKline, Tres Cantos, Spain 
5. Genzyme Corporation, Waltham, MA 
6. Children’s Hospital of Boston, Boston, MA 
 
 
Chemical synthesis was carried out by R.H., F-J.G, M.J.L-M. and M.L.B.  M.L.B 
performed a PfDHODH screen which led to the Genz-666136 series of compounds. F-
J.G. and M. J.L-M performed a PfDHODH screen which led to the GSK3 and GSK8 
compounds. A.B-S.S performed the selection that resulted in the PfDHODH E182D, 
PfDHODH F227I, and PfDHODH mutants. L.S.R. performed all other selections shown. 
L.S.R. performed all parasite proliferation assays shown. L.S.R. performed molecular 
dynamics simulations in the laboratory of P.S. Cloning, purification, and biochemical 
assays with recombinant PfDHODH protein were performed by L.S.R. Protein 
crystallography was performed by O.M.P.S., and the data were collected and structures 
solved by P.R.  
Funding for this work was provided by grants from the Medicines for Malaria Venture, 
the Bill and Melinda Gates Foundation, the Broad Institute SPARC program, the 
Genzyme Humanitarian Assistance for Neglected Disease Program, and NIH grant R01 
AI093716-01A1. 
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3.2 INTRODUCTION  
Hard-earned lessons from the 1955 Global Malaria Eradication Programme (GMEP) 20 
taught us that the largest predictor of success lay in sustained commitment to fine-tuned 
control programs aimed at total eradication. Merely reducing transmission was not 
sufficient, and in many cases, a temporary reduction in malaria mortality was paid for 
dearly when the beaten-down but not eradicated parasites resurged against a now-
immunologically naïve population. Mustering the funding, infrastructure, and political will 
to maintain vigilant surveillance as malaria transmission decreases will be a challenge 71, 
especially when considering competing health concerns, e.g., HIV-1 and family planning. 
The island of Aneityum took five years of surveillance after malaria transmission had 
dropped below detectable levels before both P. falciparum and P. vivax malaria were 
declared eradicated and control measures were stopped 72.  
Control measures include managing both the mosquito vector and the Plasmodium 
parasite. Vector control is primarily accomplished through insecticide-treated bed nets 
and indoor residual spraying of insecticides 73. Many classes of insecticides have been 
abandoned due to concerns about off-target toxicity, as for DDT 20, or due to resistance 
in the mosquito, such as in the pyrethroids 71. Ivermectin is a promising new insecticide 
74. Any malaria control measure must include a robust vector control component. Control 
measures for the parasite largely consist of antimalarial drugs as no effective vaccine 
has been developed. Many antimalarial drugs also have issues of resistance and/or 
toxicity, e.g., primaquine toxicity for people with G6PD deficiency 75. 
The cessation of control measures, whether through lack of implementation or lack of 
effectiveness, is a complex topic. A study of 75 resurgence events between 1930-2000 
showed that these resurgences could be attributed to a loss of commitment to control 
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measures in 91% of cases, of which 57% were due to a lack of funding. Antimalarial 
drug resistance accounted for 32% of program failures 76. Money and malaria are 
inextricably linked, and issues of global poverty cycles, foreign aid dependency, and in-
country self-sufficiency are at the fore when discussing the massive scale and long 
timeframe needed to eradicate malaria.   
Part of this is a question of timing: we know that drug resistance can spread locally 
within a single transmission season, and globally in a few short years 75. With no 
effective vaccines, antimalarial drugs are a key intervention, and resistance would 
defang control efforts. This means that effective interventions must be deployed in a 
coordinated, saturating, full-scale effort in an attempt to eradicate malaria before 
resistance compromises the tools used.  
It is crucial that malaria control and eradication efforts place considerable effort on 
strategies to limit and contain resistance in both the parasite and the mosquito vector. 
This would extend the useful lifetime of antimalarial agents and give eradication 
programs more time to succeed. Fitness costs in maintaining resistance to the classic 
antimalarial chloroquine have resulted in sensitivity returning after years of disuse 77, but 
cycling through existing antimalarials will likely not be sufficient or apply worldwide. 
Characterizing resistance pathways for antimalarial agents in development will aid in 
understanding the potential for resistance and developing strategies to protect the 
efficacy of these drugs before clinical use.  
We identified resistance mechanisms of dihydroorotate dehydrogenase (PfDHODH) 
inhibitors via in vitro resistance selections. We then characterized the drug responses of 
these resistant mutant parasites to a panel of DHODH inhibitors (Figure 3.1.1) and 
seemingly unrelated control compounds. Most of the resistance appeared to be due to 
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point mutations in the PfDHODH target. This finding was corroborated by work with 
purified recombinant wild-type and mutant-type proteins, which showed the same trends 
in drug sensitivity and resistance. Crystallography of PfDHODH with a variety of 
inhibitors revealed potential molecular mechanisms of resistance. Several resistant lines 
had no mutations in the gene pfdhodh, and the mechanism(s) of resistance for these are 
unknown. Targeted sequencing of candidate loci revealed a likely involvement of the 
folate pathway in one case, but the rest will likely require whole-genome sequencing to 
generate testable hypotheses.  
 
Figure 3.1.1: PfDHODH inhibitors 
 
 
Compound SMILES 
DSM74 FC(F)(F)C1=CC=C(NC2=CC(C)=NC3=NC=NN32)C=C1 
Genz-668419 O=C(NC1CC1)C2=CC=C(N3C(C)=C(C4=CC=C(F)C=C4)N=C3C)S2 
Genz-669178 O=C(NC1CC1)C2=CC=C(N3C(C=CC=C4C#N)=C4N=C3C)S2 
IDI-6253 CC1=NN=C2C3=C(C=CC=C3)C(N4CCC5=C(C=CC=C5)C4)=NN21 
IDI-6273 ClC1=CC=C(CN2C(C)=C3C(C=CC=C(OCC)C3=C2C)=O)C=C1 
GSK3 CCSC1=NN=C(N1CC)C2CCCN(C2)CC(NC3=C(Cl)C=CC(C(F)(F)F)=C3)=O 
GSK8 CC(C1=C(NC=C1CC2=CC=CC(C(F)(F)F)=C2)C)=O 
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Figure 2.4  Example PfDHODH inhibitors 
A. Structures B. Formulas 
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3.3 MATERIALS AND METHODS 
PARASITE CULTURE: 
The erythrocytic stages of P. falciparum were grown at 37°C in solutions of 4% O+ 
hematocrit in RPMI 1640 medium (Invitrogen) supplemented with 28 mM NaHCO3, 25 
mM HEPES, 5% albumax II (w/v), and 20 µm gentamicin sulfate. Human blood was 
supplied by Research Blood Components or Interstate Blood Bank. Cultures were grown 
in a gas mixture of 5% O2, 5% CO2, and 90% N2. Cultures were maintained with media 
changes every other day and were sub-cultured to maintain parasitemia below 4%. At 
least 25% of the hematocrit was replaced weekly. Parasite growth was synchronized by 
treatment with sorbitol 56. Frozen stocks were prepared using a sterile solution 
composed of 28% glycerol, 3% sorbitol, and 0.65% sodium chloride. The Dd2 parasite 
used was MR4 strain MRA-156. 
RESISTANCE SELECTION:  
Approximately 1 x 109 ring stage parasites were treated with ten times the EC50 of a 
compound for two days in four independent flasks. Compound pressure was removed 
and the cultures were fed on alternate days with compound-free complete RPMI media. 
Once healthy parasites reappeared in the culture flasks and parasitemia reached 1%-
2%, compound exposure was repeated. Selected parasites were cloned by limiting 
dilution in a 96-well plate with an inoculum of 0.2 infected red blood cells per well. 
Parasite clones were detected after 2.5 weeks of growth by microscopy.  
GENOMIC DNA ANALYSIS:  
Genomic DNA was extracted from parasites using the QIAamp blood kit (Qiagen) for 
sequence analysis of the pfdhodh gene (PlasmoDB ID: Pf3D7_0603300). A 2.2 kb 
fragment encompassing the complete pfdhodh ORF was PCR amplified from drug-
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resistant clones and parental lines. PCR-amplified fragments were fully sequenced 
using pfdhodh-specific primers.  
PfDHODH Forward 5’- GATCCCTAGGATGATCTCTAAATTGAAACCTCAATTTATG -3’  
PfDHODH Reverse 5’- GATACTCGAGTTAACTTTTGCTATGCTTTCGGCCAATG -3’ 
PfDHODH internal 5’- CATTATTTGGATTATATGGTTTTTTTGAATCTTATAATCCTG -3’ 
The pfdhodh gene was amplified with Pfu Ultra II Fusion DNA polymerase (Agilent) with 
the following conditions: 95°C 120 seconds, 55°C 20 seconds, 60°C 100 seconds, go to 
step two and repeat 30 times. PCR amplicons were purified with a PCR clean-up kit 
(Qiagen) and sequenced via Genewiz 
IN VITRO DRUG SENSITIVITY AND EC50 DETERMINATIONS:  
Drug susceptibility was measured using the SYBR Green method 62. Twelve point 
curves based on 2-fold dilutions of the test compound were carried out in triplicate and 
replicated on three different days. EC50 values were calculated using the log(inhibitor) vs. 
response – Variable slope equation in GraphPad Prism (described below):  
𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 + 𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚1 + 10  !"# !"!"!! ×  !"##  !"#$% 
Where X = concentration of compound and Y = normalized parasite viability. 
MOLECULAR DYNAMICS SIMULATIONS: 
PDB ID: 3o8a was used as a scaffold for molecular dynamics simulations. Conformation 
A was chosen for the disulfide bonds, and conformation B was deleted from the PBD file. 
The coordinates were prepared with Desmond  (Desmond Molecular Dynamics System, 
versions 2.2 and 3.0, D. E. Shaw Research, New York, NY, 2008 78). One microsecond 
simulations were run on the Orchestra cluster supported by the Harvard Medical School 
Research Information Technology Group. The simulations used 132 cores in the 
infiniband-enabled Rehearsal subset of the Orchestra cluster. 
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SYNTHESIS OF DSM74:  
The compound DSM74 was prepared following the literature procedure 63 and was 
recrystallized from ethanol.  1H NMR spectra matched that reported 43 and HPLC 
analysis indicated > 95% purity. 
SYNTHESIS OF GSK8:  
 
 
 
Pentane-2,4-dione (0.206 mL, 2.00 mmol) was added to a solution of 2-propyn-1-amine 
(0.274 mL, 4.00 mmol) in water (5 mL) and the resulting mixture was stirred at room 
temperature for 16 hr. The reaction was extracted with dichloromethane and the organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced 
pressure to give 275 mg of (Z)-4-(prop-2-yn-1-ylamino)pent-3-en-2-one (275 mg, 2.005 
mmol, 100 % yield) as a yellow oil: 1H-NMR (CDCl3, 400 MHz) d 2.02 (s, 3H), 2.28 (t, J = 
2.4 Hz, 1H), 3.99 (dd, J = 6.2, 2.4 Hz, 2H), 5.06 (s, 1H), 10.76 (br. s, 1H). MS: m/e 138 
(M+H+). Purity was determined as >95 % by HPLC (308 nm), Rt: 0.95 (Acquity UPLC 
BEH C18 1.7u 3x50mm, CH3CO2NH4 25mM + 10%ACN at pH 6.6 / ACN). 
To a solution of  (Z)-4-(prop-2-yn-1-ylamino)pent-3-en-2-one (260 mg, 1.895 mmol), CuI 
(7.22 mg, 0.038 mmol), PdCl2 (Ph3P)2 (26.6 mg, 0.038 mmol) and DIPEA (3.89 mL, 
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22.74 mmol) in N,N-Dimethylformamide (DMF) (1 mL) under argon atmosphere, 3-
iodobenzotrifluoride (0.410 mL, 2.84 mmol) was added and the resultant mixture was 
stirred at room temperature for 1 h 45 min, the reaction was partitioned between water 
and EtOAc. The layers were separated and the aqueous was extracted with EtOAc. The 
combination of the organic layers was washed with aq. 0.5 N HCl and brine. After drying 
over anhydrous Na2SO4, the organic layer was filtered and concentrated under reduced 
pressure. The resulting crude was purified by column chromatography (10g, Merck, 
CyHex:EtOAc gradients from 100:0 to 90:10 to 50:50) to give 365 mg of (Z)-4-((3-(3-
(trifluoromethyl)phenyl)prop-2-yn-1-yl)amino)pent-3-en-2-one (365 mg, 1.298 mmol, 
68.5 % yield) as a yellow solid: 1H-NMR (CDCl3, 400 MHz) d 2.04 (s, 3H), 2.07 (s, 3H), 
4.23 (d, J = 6.1 Hz, 2H), 5.09 (s, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.58 (m, 2H), 7.67 (s, 1H), 
10.87 (br. s, 1H). MS: m/e 282 (M+H+). Purity was determined as > 95 % by HPLC (309 
nm), Rt: 1.28 (Acquity UPLC BEH C18 1.7u 3x50mm, CH3CO2NH4 25mM + 10% ACN at 
pH 6.6 / ACN).  
  
To a solution of 3-iodobenzotrifluoride (100 mg, 0.368 mmol) in anhydrous Dimethyl 
Sulfoxide (DMSO) (5 mL) under argon atmosphere, cesium carbonate (240 mg, 0.735 
mmol) was added and the resultant mixture was stirred at room temperature for 1 h. The 
reaction was then diluted with EtOAc and 0.5 N aq. HCl. The layers were separated and 
the aqueous was extracted with EtOAc. The combination of the organic layers was 
washed with water, then brine, and then dried over anhydrous Na2SO4, filtered, and 
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concentrated under reduced pressure. The resulting crude was purified by column 
chromatography (dry head, 2g, Isolute, CyHex:EtOAc gradients from 100:0 to 80:20 to 
0:100) to give 83 mg of 1-(2-methyl-4-(3-(trifluoromethyl)benzyl)-1H-pyrrol-3-yl)ethanone 
as a pale brown solid: 1H-NMR (DMSO-D6, 400 MHz) d 2.24 (s, 3H), 2.42 (s, 3H), 4.03 
(s, 2H), 6.36, (d, J = 3 Hz, 1H), 7.46 (m, 4H), 11.05 (s, 1H). 13C-NMR (DMSO-D6, 100 
MHz) d 15.4, 31.2, 32.9, 120.1, 122.7 (t, J = 3.7 Hz), 123.3, 125.0 (q, J = 272 Hz), 125.3 
(q, J = 3.7 Hz), 129.2 (q, J = 31.5 Hz), 129.5,133,2, 135.9, 144.2, 193.9. 19F-NMR 
(DMSO-D6, 376 MHz) d -60.8 (s, 3F). MS: m/e 282 (M+H+). Purity was > 95 % by HPLC 
(249 nm), Rt: 1.20 (Acquity UPLC BEH C18 1.7u 3x50 mm, CH3CO2NH4 25mM + 10% 
ACN at pH 6.6 / ACN). 
COPY NUMBER VARIATION QUANTITATIVE PCR: 
PfDHODH copy number was assessed using the quantitative PCR (qPCR) primers 
described in Guler 2013 51 (primers listed below). Two sets of primers were used to 
amplify regions of PfDHODH. DHODH front produced a 206 bp amplicon starting at 
nucleotide +656, and DHODH rear produced a 158 bp amplicon starting at nucleotide 
+1423. Seryl tRNA synthetase and 18s ribosomal RNA were used as reference genes. 
Power SYBR Green master mix with ROX (Applied Biosystems) was used on a 7900 HT 
qPCR machine (Applied Biosystems). The qPCR protocol was 95C for 10 minutes, 
followed by 40 rounds of 95C for 15 seconds and 60C for 1 minute. All experiments 
were followed by a dissociation curve (90C to 60C in 0.5C steps with 1 second hold at 
each step), and a 106 dilution curve of Dd2 genomic DNA was used to determine the 
amplification efficiency. Genomic DNA from Dd2 and 3D7 were used as one-copy 
controls. Selection clones served as the test, and the parent (Dd2 or 3D7) served as the 
control. Relative copy number was determined for 1 ng of genomic DNA using the ΔΔCT 
method 79. 
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Gene ID	   Function Primer Sequences Product 
PFF0160c 
DHODH 
Front 
 
DHODH 
Rear 
F-TCCATTCGGTGTTGCTGCAGGATTTGAT 
R-TCTGTAACTTTGTCACAACCCATATTA 
 
F-GTGTTAGCGGAGCAAAACTAAAAG 
R-ATAATTGACAAACTGAAGCACCTG 
206 bp  
 
 
158 bp  
PF07_0073 Seryl t-RNA Synthetase 
F-GGAACAATTCTGTATTGCTTTACC 
R-AAGCTGCGTTGTTTAAAGCTC 142 bp  
MAL13P1.435 18s Ribo-somal RNA 
F-ACAATTCATCATATCTTTCAATCGGTA 
R-GCTGACTACGTCCCTGCCC 69 bp  
 
PFDHODH PLASMID CONSTRUCTION AND MUTAGENESIS: 
A synthetic codon-optimized gene encoding residues 159-565 of PfDHODH 41 (Genbank 
accession No. AY685129) was cloned into a pET28b plasmid with an amino-terminal 
6xHistidine tag followed by an rTEV cleavage site as described by Deng et al 64, 
resulting in pET28b-6xHistidine-rTEV-PfDHODH (codon optimized) del 1-158. The listed 
mutations were created with the following primers, then cloned into the tagged pET28b 
construct described above: 
L172F Forward  5’-CCTGTACGATATTTTCTTCAAATTTTGTTTGAAGTA-3’ 
L172F Reverse 5’-GTACTTCAAACAAAATTTGAAGAAAATATCGTACA-3’ 
 
E182D Forward 5’-GTACATCGATGGTGACATTTGCCATGACCTG-3’  
E182D Reverse 5’-CAGGTCATGGCAAATGTCACCATCGATGTAC-3’ 
F188I Forward 5’-AGCCATGACCTGATTTTGCTGCTTGG-3’ 
F188I Reverse 5’-CCAAGCAGCAAAATCAGGTCATGGCT-3’ 
 
F188L Forward 5’- ATTTGCCATGACCTGCTGTTGCTGCTTGG-3’ 
F188L Reverse 5’- CCAAGCAGCAACAGCAGGTCATGGCAAAT-3’ 
 
F227I Forward 5’- GTTGCAGCTGGAATCGATAAAAACGGTG-3’ 
F227I Reverse 5’ CACCGTTTTTATCGATTCCAGCTGCAAC-3’ 
 
I263F Forward 5’- GAAACCGCGGTTCTTTCGTGACGTC-3’ 
I263F Reverse 5’-GACGTCACGAAAGAACCGCGGTTTC-3’ 
 
L527I Forward  5’-CTTCCGTGTGTCAGATCTATTCGTGCTT-3’ 
L527I Reverse 5’-AAGCACGAATAGATCTGACACACGGAAG-3’  
 
L531F Forward 5’- GCTCTATTCGTGCTTCGTTTTCAACGGTATG-3’ 
L531F Reverse 5’-	  CATACCGTTGAAAACGAAGCACGAATAGAGC-3’ 
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PFDHODH PROTEIN EXPRESSION AND PURIFICATION: 
BL21(DE3)Star Escherichia coli (Invitrogen) were transformed with WT and mutant 
PfDHODH expression constructs. Transformed cells were grown in Terrific Broth with 
100 µg/mL kanamycin at 37°C and 180 rpm, then dropped to 20°C and induced with 200 
µm isopropyl-D-thiogalactoside. Cultures were grown 12-16 hours post-induction, then 
pelleted by centrifugation at 10,000x g and frozen at -80°C for later use. For purification, 
conical tubes of frozen cell pellets were thawed in 25°C water. Thawed pellets were then 
resuspended in buffer A (100 mM HEPES pH 8.0, 150 mM NaCl, 10% glycerol, 0.05% 
Thesit). The cells were lysed by sonication on ice (Branson digital sonifer 450, 5 minutes 
at 40% amplitude with a pattern of 5 seconds on and 10 seconds off). The cell lysate 
was clarified by centrifugation at 40,000x g for 45 minutes at 4°C, then filtered through a 
0.45 µm filter. The clarified and filtered lysate was applied to a HisPrep FF 16/10 column 
(GE Healthcare) pre-equilibrated with buffer A on an AKTA Purifier FPLC. The column 
was washed with 30 cV of buffer A, then eluted with stepwise increments of buffer B 
(100 mM HEPES pH 8.0, 150 mM NaCl, 10 glycerol, 0.05% Thesit, 400 mM imidazole). 
The eluted protein was concentrated by centrifugation in concentrator spin columns 
(Pierce), then injected into a HiLoad 16/60 Superdex 200 size exclusion column pre-
equilibrated with running buffer (10 mM HEPES pH 7.8, 100 mM NaCl, 5% glycerol, 1 
mM N,N-dimethyldodecylamine N-oxide, 10 mM DTT). Fractions containing PfDHODH 
were pooled and concentrated. Protein concentration was assessed by Bradford assay 
(Pierce). Catalytically active protein concentration was assessed by boiling 50 µLof 
protein, clarifying by centrifugation for 10 minutes at 13,200x g, and then measuring 
absorbance of the cleared supernatant at 445 nm to determine the flavin 
mononucleotide concentration (ε445 = 12.5 mM-1 cm-1). Aliquots of protein were flash-
frozen in liquid nitrogen, then stored at -80°C. 
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PFDHODH BIOCHEMICAL ASSAYS: 
Substrate-dependent inhibition of recombinant PfDHODH protein was assessed in an in 
vitro assay in 60 µLvolumes in 384-well clear plates (Corning 3702). A 16-point dilution 
series of inhibitor concentrations were assayed against 2-10 nM protein with 500 µm L-
dihydroorotate substrate (L-DHO, excess), 18 mM dodecylubiquinone electron acceptor 
(CoQD, ~ Km), and 100 µm 2,6-dichloro-indophenol indicator dye in DHODH assay 
buffer (100 mM HEPES pH 8.0, 150 mM NaCl, 5% glycerol, 0.5% Triton X-100). Assays 
were incubated at 25°C for twenty minutes, then assessed by measuring the absorbance 
at 600 nM in a SpectraMax M5 plate reader. Molecular oxygen, which can act as an 
electron acceptor in this reaction, was depleted through the addition of 0.1 mg/mL of 
glucose oxidase, 0.02 mg/mL of catalase, and 50 mM glucose, followed by incubation at 
25°C for five minutes prior to assay assembly. Data were normalized to 1% DMSO and 
excess inhibitor (500 nM Genz-669178 unless another compound was appropriate).  
PFDHODH CRYSTALLOGRAPHY: 
Wild-type PfDHODH protein was produced as described above by GlaxoSmithKline 
(Stevenage, United Kingdom). Protein-compound complexes were formed by mixing 50 
µLof protein (in size exclusion buffer at ~10 mg/mL) with 1 µL of 500 mM N,N-
dimethyldodecylamine N-oxide (LDAO), 0.5 µLof 200 mM L-dihydroorotate, and 0.5 µLof 
200 mM compound. Complexes were allowed to form at room temperature for five 
minutes before being distributed into hanging drop or paraffin oil immersion microbatch 
trays by hand. 1 µLof protein-compound complex was mixed with 1 µLof precipitant in 
each drop. All trays were incubated at 20°C. Crystals were harvested from the following 
conditions for structure determination via synchrotron: 
WT PfDHODH, Genz-669178: 0.2M LiCl + 24% PEG 3350  
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WT PfDHODH, IDI-6253: 0.2M LiCl + 20% PEG 3350 
WT PfDHODH, IDI-6273: 0.1M MES pH 6.5 + 20% PEG 3350  
STATISTICAL ANALYSES: 
 EC50 data are shown as mean ± standard deviation and were analyzed by one-way 
ANOVA with Dunnett’s multiple comparison post hoc test (for three or more groups) or a 
two-tailed t-test (for two groups) via Graph Pad Prism 5.0d Software. Differences were 
considered significant for P < 0.05. 
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3.4 RESULTS 
PROPOSED RESISTANCE MECHANISMS TO PFDHODH INHIBITORS 
We sought to deeply sample resistance pathways to PfDHODH inhibitors, and did so 
through a comprehensive set of in vitro drug resistance selections. Earlier selections 
(described in Chapter 2) had shown that the PfDHODH mutations E182D, F227I, and 
L531F each gave resistance to PDHODH inhibitors. Examination of crystal structures 
(Figure 3.4.1) showed that these residues were all in or near the species-selective drug-
binding site, but did not appear to make direct contact with bound inhibitors. 
Figure 3.4.1: Lid dynamics and observed resistance mutations in PfDHODH 
(A). Overlay of molecular dynamics simulations at 1, 350, 750, and 1000 nanoseconds. 
The α1- α2 helix lid (in red) shows more mobility than the rest of the protein. 
(B). Observed resistance mutations: F188, L172, F227, L531, L527, E182, I263. All 
mutations observed in PfDHODH were near the α1- α2 helix lid or electron tunnel. 
All images shown are of PDB ID: 3o8a and were generated with CCP4mg 66. 
A.  B.  
Active site 
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All three resistance mutations appeared to be important in holding the α1- α2 helix lid to 
the main body of the protein. Crystal structures showed sparse contacts holding the lid 
to the body of the protein. Molecular dynamics simulations (Figure 3.4.1 A) corroborated 
the idea that the lid was loosely associated: the lid was by far the most mobile portion of 
the protein, and was held by a limited number of hydrogen bonds and hydrophobic 
interactions. The lid defines the PfDHODH inhibitor binding pocket and is the entrance 
to the presumed tunnel for electron flow between respiratory chain ubiquinone and the 
flavin mononucleotide cofactor. Given this, we proposed that mutations that weakened 
lid binding were potential drug resistance sites. Compromising lid binding would 
presumably affect the binding of ubiquinone in addition to that of PfDHODH inhibitors, 
so some theoretically possible mutations might result in non-viable parasites. PfDHODH 
amplification or a resistance pathway unrelated to the target gene were also logical 
resistance options. We chose to focus on single nucleotide polymorphisms (SNPs) and 
gene amplification in PfDHODH both for ease of detection and because in our hands, 
they were the most likely outcome.  
RESISTANCE SELECTIONS: AN OVERVIEW 
We carried out a variety of resistance selections. Intermittent pulse selections (Figure 
3.4.1 A) gave more consistently successful results than applying constant drug pressure. 
We used this intermittent pulse strategy in three ways (Figure 3.4.1 B, C): primary 
selection, where a wild-type (WT) parasite is treated with a WT PfDHODH inhibitor; 
sequential selection, where the resultant mutant parasites are treated with a mutant 
inhibitor; and simultaneous selection, where WT parasites are treated with a 
combination of WT and mutant inhibitors. The simultaneous selection is a test of the 
“targeting resistance” concept and should suppress the emergence of resistance. 
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Figure 3.4.2: Drug resistance selection strategies used and expectations 
(A). Repeated intermittent pulse selections: short-term stress and recovery cycles. 
(B). The selections used different parasite lines, inhibitors, and inhibitor combinations. 
(C). Expected results from different selection strategies. 
(D). Observed results were consistent with the hypotheses. 
Observed resistance mutations (Figure 3.4.2 D) were largely consistent with our 
hypothesis, but led to a refinement of the model: resistance mutations appear to line 
both lid-body interactions and the presumed ubiquinone-FMN electron transfer tunnel. 
This, coupled with the observation that triazolopyrimidine inhibitors appear to block 
electron flow from FMN to ubiquinone, but not from FMN to inorganic oxidants like 
Apply stress for  
one life cycle 
Allow full  
recovery 
WT 
cells 
WT 
 inhibitors 
Mutant 
cells 
Mutant 
 inhibitors 
WT 
cells 
WT + Mutant 
inhibitors 
A.  B.  
C.  
Type of 
selection Expected results 
Primary Resistance 
Sequential Return to wild-type or development of further resistance 
Simultaneous Suppression of resistance 
Type of 
selection Observed results 
Primary Resistance (F188I, Fi88L, E182D, F227I, L531F) 
Sequential Return to WT (D182E) or more mutations (L172F, L527I) 
Simultaneous Fewer cases of resistance (I263F) or none at all 
D.  
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atmospheric oxygen or ferricyanide 65,	  led to the following model: PfDHODH inhibitor 
resistance mutations disrupt electron flow between ubiquinone and FMN, and they may 
do so by either disrupting the lid-body interactions that create the electron tunnel, or by 
directly impeding electron flow in a normally-formed tunnel.  
Overall, we were able to raise resistant mutants to nearly every PfDHODH inhibitor 
tested (Table 3.4.1). In several cases, similar or even the same pfdhodh mutation 
occurred in independent cultures. This is further evidence that a small number of 
resistance pathways are heavily favored by evolution. For example, the selection of Dd2 
parasites (MR4 strain MRA-156) with Genz-669178 led to the highly similar pfdhodh 
mutations F188I and F188L in independent flasks. Selection of the Dd2-PfDHODH 
F227I mutant line with IDI-6253 gave an L527I mutation in all four flasks. Note that this 
mutation gave low-level resistance to PfDHODH inhibitors, but was not statistically 
significant. Perhaps L527I is a compensatory mutation that increases the fitness of the 
F227I mutant. Combination therapy led to fewer resistant populations (independent 
flasks) than monotherapy. The selection of 3D7 E182D with IDI-6273 and the selection 
of Dd2 with the combination of Genz-669178 and IDI-6273 were discussed in Chapter 2 
and will not be discussed in detail. 
Selections which gave resistance were subjected to copy number variation quantitative 
PCR for pfdhodh. No selections with mutations in pfdhodh had copy number variation, 
but several resistant lines with no mutations in pfdhodh had gene amplifications (Table 
3.4.1). These observations are consistent with the Guler 2013 study demonstrating that 
nonspecific gene amplification is the initial step in resistance to triazolopyrimidine 
PfDHODH inhibitors 51, and the amplifications are primed for mutation. Thus, selections 
with amplified pfdhodh should be continued to identify more mutational resistance. 
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Table 3.4.1: Summary of resistance selection results
 
The selections all took between six to ten weeks to yield stable resistance (Figure 3.4.3 
A), meaning that parasite lines maintained resistance after being frozen and revived in 
culture. The number of drug pulses required (Figure 3.4.3 B) ranged from a single pulse 
(3D7 E182D: IDI-6273) to eleven (3D7: Genz-669178). 
Selection Information PfDHODH locus 
Parasite 
Line Drug(s) Culture Resistance 
Candidate 
for WGS Residue Nucleotide Copy # 
3D7 Genz-669178 
1 Y Y WT  2 
2 Y Y WT  1 
3 Y Y WT  1 
4 N N WT  n.d. 
3D7 E182D IDI-6273 
1 N  N  WT  n.d. 
2 Y N  D182E T546G 1 
3 N  N  WT  n.d. 
4 N  N  WT  n.d. 
Dd2 Genz-669178 
1 N  N  WT  n.d. 
2 Y N  F188I T562A 1 
3 N Y WT  n.d. 
4 Y N  F188L T564A 1 
Dd2 F227I IDI-6253 
1 Y* N  L527I T1579A 1 
2 Y* N  L527I T1579A 1 
3 Y* N  L527I T1579A 1 
4 Y* N  L527I T1579A 1 
Dd2 F227I IDI-6273 
1 N Y F227I  1 
2 Y Y F227I  2 
3 Y Y F227I  2 
4 N Y F227I  1 
Dd2 F227I GSK3 
1 Y N  L172F A516T 1 
2 Y N  L172F A516T 1 
3 Y N  L172F A516T 1 
4 Y N  L172F A516T 1 
Dd2 Genz-669178 + IDI-6253 
1 N  N  WT  n.d. 
2 Y Y WT  4 
3 N  N  WT  n.d. 
4 N  N  WT  n.d. 
Dd2 Genz-669178 + IDI-6273 
1 N  N  WT  n.d. 
2 N  N  WT  n.d. 
3 N  N  WT  n.d. 
4 N  N  WT  n.d. 
Dd2 Genz-669178 + GSK3 
1 Y N  I263F A787T 1 
2 N  N  WT  n.d. 
3 N  N  WT  n.d. 
4 N  N  WT  n.d. 
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Figure 3.4.3: Parameters of successful resistance selections 
(A). Time to resistance varied from 6 to 10 weeks.  
(B). The number of stress pulse cycles until resistance developed ranged from 1 to 11. 
The Dd2: Genz-669178 + IDI-6273 selection did not develop resistance and is not 
shown on these charts. 
 
INDIVIDUAL DRUG RESISTANCE SELECTIONS 
The 3D7: Genz-669178 selection gave significant resistance to the selecting agent in 
two of four flasks (Figure 3.4.4 A). Curiously, it also gave resistance to structurally  
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Figure 3.4.4: The 3D7: Genz-669178 selection gave resistance to PfDHODH 
inhibitors of several structural classes 
(A). EC50 fold shifts relative to the parental selection line show significant development of 
resistance for four structural classes of PfDHODH inhibitors. 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements.  
Figure 3.8 3D7: Genz-669178 selection 
A.  
B.  
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unrelated PfDHODH inhibitors, but not to antimalarial agents with unrelated mechanisms 
of action (Figure 3.4.4 B). There were no mutations in pfdhodh. As sensitivity to 
unrelated antimalarial agents was decreased (though not significantly so), this may be a 
non-specific resistance due to efflux pumps. Culture #1 had two copies of the WT 
pfdhodh gene, but had similar drug sensitivities to cultures without gene amplification. 
Table 3.4.2: 3D7: Genz-669178 selection results 
 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors, although the pfdhodh allele was wild-type. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
  
A similar selection, using Dd2 as the WT selection line and again using Genz-669178 as 
the selection agent, gave starkly different results (Figure 3.4.5, Table 3.4.3).  
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT 2 copies of WT WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 6.29 ± 5.45 18.61 ± 21.35 15.89 ± 14.15 12.11 ± 11.43 11.67 ± 13.71 
Genz-668419 5.36 ± 3.48 10.93 ± 6.16 13.94 ± 2.82 10.94 ± 7.69 8.33 ± 7.45 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 16924.33 ± 6982.80 85876.66 ± 87359.51 88806.66 ± 80102.39 
35316.66 ± 
20068.73 30603.33 ± 13421.49 
IDI-6273 480.90 ± 68.57 1025.86 ± 181.84 1169.67 ± 90.72 901.13 ± 85.18 886.40 ± 159.79 
GSK-3 64.78 ± 21.47 111.89 ± 29.45 141.20 ± 66.97 107.12 ± 28.61 93.72 ± 25.72 
Standard 
Antimalarials 
Chloroquine 6.00 ± 1.62 9.92 ± 2.87 8.72 ± 2.87 7.72 ± 1.780 8.48 ± 1.04 
Dihydroartemisinin 2.39 ± 1.40 3.15 ± 1.62 3.56 ± 2.26 3.01 ± 1.52 3.89 ± 2.53 
Atovaquone 0.15 ± 0.06 0.19 ± 0.09 0.23 ± 0.10 0.19 ± 0.09 0.22 ± 0.17 
A. 
B.  
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT 2 copies of WT WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 2.49 ± 0.84 2.49 ± 0.09 1.85 ± 0.19 1.53 ± 0.58 
Genz-668419 1 2.22 ± 0.72 3.24 ± 1.65 2.06 ± 0.43 1.48 ± 0.54 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 4.71 ± 1.49 4.67 ± 0.74 2.10 ± 0.62 1.80 ± 0.07 
IDI-6273 1 2.13 ± 0.21 2.45 ± 0.23 1.89 ± 0.19 1.85 ± 0.33 
GSK-3 1 1.75 ± 0.11 2.12 ± 0.43 1.68 ± 0.11 1.47 ± 0.24 
Standard 
Antimalarials 
Chloroquine 1 1.79 ± 0.75 1.45 ± 0.27 1.30 ± 0.18 1.47 ± 0.31 
Dihydroartemisinin 1 1.41 ± 0.27 1.55 ± 0.37 1.35 ± 0.26 1.53 ± 0.29 
Atovaquone 1 1.24 ± 0.07 1.51 ± 0.14 1.24 ± 0.12 1.34 ± 0.50 
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Figure 3.4.5: The Dd2: Genz-669178 selection gave resistance to PfDHODH 
inhibitors of several structural classes 
(A). EC50 fold shifts relative to the parental selection line show highly significant 
resistance for the selecting agent in two of three flasks (flask #1 did not recover).  
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements.  
Figure 3.9 Dd2: Genz-669178 selection 
A.  
B.  
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The 3D7 selection gave low-level resistance with no discernable changes in pfdhodh. In 
contrast, the Dd2 selection gave two separate lines with highly significant resistance and 
one line with medium-level resistance (and one flask that never recovered). The two 
highly resistant lines developed strikingly similar mutations in pfdhodh, indicating a 
evolutionary fitness maximum for resistance.  
Table 3.4.3: Dd2: Genz-669178 selection results 
 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors. Note the two highly similar mutations in 
PfDHODH: F188I and F188L. These gave similar, but not the same, sensitivity changes. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
EC50 (nM) ± s.d. 
Parent Flask #2 Flask #3 Flask #4 
PfDHODH allele WT F188I WT F188L 
PfDHODH  
WT  
Inhibitors 
Genz-669178 2.50 ± 0.70 1556 ± 892 10.83 ± 3.88 700.43 ± 256.71 
Genz-668419 4.44 ± 0.70 708 ± 296 17.66 ± 4.55 169.37 ± 34.85 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 32753.67 ± 41203.66 16257 ± 6025 
54133.33 ± 
42312.46 
142925.0 ± 
128516.66 
IDI-6273 1197.67 ± 740.44 67316 ± 76212 3626.67 ± 2670.44 57043.67 ± 77167.70 
GSK-3 59.25 ± 27.21 1104 ± 490 108.23 ± 71.88 140.37 ± 49.62 
Standard 
Antimalarials 
Chloroquine 3.81 ± 0.57 5.5 ± 6.0 2.45 ± 0.95 3.34 ± 0.55 
Dihydroartemisinin 77.35 ± 53.36 83 ± 58 73.08 ± 47.74 71.70 ± 49.13 
Atovaquone 0.16 ± 0.06 0.24 ± 0.02 0.15 ± 0.03 0.13 ± 0.06 
EC50 fold shift over parent ± s.d. 
Parent Flask #2 Flask #3 Flask #4 
PfDHODH allele WT F188I WT F188L 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 210.59 ± 43.93  4.01 ± 0.39 276.22 ± 39.75 
Genz-668419 1 61.75 ± 10.44 3.34 ± 1.06 38.02 ± 4.60 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 16.77 ± 1.64 1.16 ± 0.63 3.40 ±  0.68 
IDI-6273 1 16.77 ± 0.97 1.84 ± 0.63 36.69 ± 35.37 
GSK-3 1 8.12 ± 1.73 1.98 ± 0.99 2.49 ± 0.42 
Standard 
Antimalarials 
Chloroquine 1 0.80 ± 0.17 0.90 ± 0.16 0.95 ± 0.07 
Dihydroartemisinin 1 0.63 ± 0.37 0.59 ± 0.15 0.89 ± 0.17 
Atovaquone 1 0.91 ± 0.20 0.92 ± 0.18 0.81 ± 0.09 
A.  
B. 
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Flask #2, which developed an F188I mutation in PfDHODH, became 210-fold resistant to 
Genz-669178, with EC50 values rising from 7.4 nM to 1556 nM. Flask #4, which gained 
an F188L mutation in PfDHODH, became 276-fold resistant to Genz-669178, with EC50 
values rising from 2.5 nM to 700 nM. Curiously, even though leucine and isoleucine are 
very similar residues, F188I was 3.3-fold more resistant to GSK3 than F188L (8.12 
versus 2.49-fold, respectively). Flask #3 gained a borderline significant 4-fold resistance 
to Genz-669178, rising from an EC50 of 2.5 nM to 10.8 nM. No mutations were found in 
pfdhodh, so this is a whole-genome sequencing candidate. No significant changes in 
sensitivity were observed for the unrelated antimalarial drugs chloroquine, atovaquone, 
or dihydroartemisinin. (Note: parental Dd2 data is shown for a paired assay with flasks 
#3 and #4, but Dd2 and flask #2 were run in a separate set of assays. Thus, the fold 
changes and EC50 values shown will not match for flask #2).  
After selecting two WT parasite lines (3D7 and Dd2) with WT PfDHODH inhibitors, we 
selected mutant parasite lines (PfDHODH E182D or F227I) with mutant-selective 
inhibitors. No mutant-selective inhibitors were found for PfDHODH L531F in the small 
set tested, so no selections were done with this mutant line. The selection of parasite 
line 3D7 E182D with compound IDI-6273 was discussed in Chapter 2.  
The first mutant parasite-mutant inhibitor selection was parasite Dd2 F227I with 
compound GSK3 (Figure 3.4.6, Table 3.4.4). Each of the four independent selections 
gave rise to the same PfDHODH mutation: L172F. This indicates a fitness maximum. 
Note that all selections were started from early freezes of the same clonal parasite line, 
so it is unlikely that L172F arising in all four flasks is a founder effect. This mutation was 
not seen in other Dd2 F227I selections. All of the selected flasks gave similar, though 
not identical, results. This may be due to other physiological changes in the lines. 
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Figure 3.4.6: The Dd2 F227I: GSK3 selection gave resistance to PfDHODH 
inhibitors of several structural classes  
(A). EC50 fold shifts relative to the parental selection line show highly significant 
resistance in all four selection flasks. These did not revert to WT-like sensitivity (Dd2). 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements.  
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Figure 3.10 Dd2 F227I: GSK3 selection 
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As expected, this selection led to resistance to the selecting agent, with GSK3 EC50 
values increasing at least 50-fold for all four flasks. Sensitivity to unrelated PfDHODH 
inhibitors was also affected: Genz-669178 became 4-fold less effective, IDI-6273 
became ~15-fold less effective, and IDI-6253 became 5-to-6-fold more effective. 
Unrelated control compounds showed no significant changes, although all four flasks 
gained a borderline significant two-fold sensitivity to atovaquone. 
Table 3.4.4: Dd2 F227I: GSK3 selection results 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors. All four flasks gained a PfDHODH L172F 
mutation, and had similar, but not identical, drug sensitivity profiles. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
 
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I L172F + F227I L172F + F227I L172F + F227I L172F + F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 889.57 ± 1422.39 168.81 ± 136.04 182.79 ± 80.58 317.53 ± 108.45 308.77 ± 125.90 
Genz-668419 469.50 ± 436.47 209.99 ± 161.40 392.97 ± 269.84 331.43 ± 51.21 367.70 ± 34.2 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 7747 ± 12596 4585.0 ± 3650.51 6181.1 ± 6529.28 7519.67 ± 3643.4 6466.33 ± 1866.32 
IDI-6273 3207 ±  684.48 455.75 ± 192.97 1415.23 ± 1639.20 533.07 ± 192.54 580.10 ± 159.87 
GSK-3 610.53 ± 916.66 2663.90 ± 2128.88 2676.68 ± 2273.74 3724.33 ± 575.48 3824.33 ± 1048.05 
Standard 
Antimalarials 
Chloroquine 155.44 ± 87.39 174.41 ± 83.39 173.05 ± 80.63 200.27 ± 45.30 171.27 ± 72.99 
Dihydroartemisinin 13.78 ± 3.71 10.68 ± 0.81 10.88 ± 1.72 10.36 ± 1.50 11.51 ± 0.52 
Atovaquone 0.44 ± 0.12 0.24 ± 0.098 0.24 ± 0.08 0.21 ± 0.02 0.22 ± 0.03 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I L172F + F227I L172F + F227I L172F + F227I L172F + F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 4.06 ± 0.77 3.9 ± 0.95 4.33 ± 1.04 4.43 ± 1.7 
Genz-668419 1 1.52 ± 0.29 2.17 ± 1.09 1.62 ± 0.38 2.0 ± 0.67 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 0.16 ± 0.04 0.16 ± 0.03 0.16 ± 0.04 0.2 ± 0.05 
IDI-6273 1 13.76 ± 1.03 16.6 ± 3.58 16.77 ± 1.31 16.32 ± 2.54 
GSK-3 1 50.81 ± 5.07 49.28 ± 1.22 54.63 ± 8.24 79.9 ± 45.05 
Standard 
Antimalarials 
Chloroquine 1 1.32 ± 0.38 1.31 ± 0.39 1.34 ± 0.38 0.97 ± 0.27 
Dihydroartemisinin 1 0.75 ± 0.18 0.75 ± 0.16 0.82 ± 0.16 1.26 ± 0.77 
Atovaquone 1 0.51 ± 0.15 0.54 ± 0.20 0.57 ± 0.20 0.64 ± 0.15 
A.  
B. 
Table 3.5 Dd2 F227I: GSK3 selection results 
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Selection of the Dd2 F227I parasite line with the mutant-selective compound IDI-6253 
also led to one mutation arising and dominating in all four independent flasks. In this 
case, the mutation was PfDHODH L527I. Although this mutation is in the presumed 
ubiquinone binding pocket, no statistically significant resistance was observed for 
PfDHODH inhibitors or for unrelated antimalarial compounds, and this mutation did not 
restore “WT” Dd2 levels of sensitivity (Figure 3.4.7, Table 3.4.5). However, it should be 
noted that this selection gained borderline significant 3 to 4-fold resistance to the 
selecting agent, IDI-6253. It is difficult to reach significance with small-scale resistance 
due to the inherent variability between assays that use human blood from different 
donors. This data would likely reach significance with further biological replicates.  
These results imply that the F227I + L527I combination has a benefit over the F227I 
parent that is unrelated to PfDHODH inhibitor resistance – or that the 3 to 4-fold 
resistance seen is actually significant in a biological sense. L527I may be a 
compensatory mutation that increases the fitness of the parent line. It is highly unlikely 
that the same mutation occurred in all four flasks and outcompeted all other potential 
alleles without a clear benefit. Competitive growth assays of F227I versus F227I + L527I 
(with and without drug present) would help clarify the role of this mutation. One 
possibility is that the double-mutant parasites grow better when there is no drug 
pressure – faster cycle times, larger burst size, and so on. Residues F227 and L527 and 
quite close to each other (see Figure 3.4.2 B). It is plausible that the original F227I 
mutation reduced a favorable, stabilizing hydrophobic interaction with spatial neighbor 
L527. This may have been alleviated when both residues were mutated to isoleucines, 
as “isoleucine zipper”-type hydrophobic interactions are likely stronger than isoleucine-
leucine interactions.  
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Figure 3.4.7: The Dd2 F227I: IDI-6253 selection did not give significant resistance  
(A). EC50 fold shifts relative to the parental selection line show low-level, non-significant 
resistance. All four flasks gained an L527I mutation in PfDHODH.  
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements.  
Figure 3.11 Dd2 F227I: IDI-6253 selection 
A. 
B. 
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Table 3.4.5: Dd2-F227: IDI-6253 selection results 
 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors. All four flasks gained a PfDHODH L527I 
mutation, and had similar, but not identical, drug sensitivity profiles. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
 
For the last single-drug selection, the Dd2 F227I line was selected with the mutant-
selective compound IDI-6273. This did not result in resistance to the selective agent, but 
curiously gave resistance to the structurally unrelated WT PfDHODH inhibitor Genz-
669178 (Figure 3.4.8, Table 3.4.6). In flasks #2 and #3, the EC50 for Genz-669178 
increased 3.6-fold, rising from 3.4 µm to ~10 uM. Although these changes are small, the 
error was small enough to declare this highly significant.  
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I F227I + L527I F227I + L527I F227I + L527I F227I + L527I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 40.52 ± 20.52 32.54 ± 19.85 34.78 ± 28.78 38.77 ± 29.50 36.73 ± 15.31 
Genz-668419 108.30 ± 11.83 74.40 ± 19.92 77.29 ± 28.34 84.81 ± 19.07 97.12 ± 30.63 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 199.94 ± 147.57 237.42 ± 187.78 287.30 ± 271.22 273.33 ± 217.49 255.30 ± 139.12 
IDI-6273 1062.27 ± 721.25 3463.67 ± 2823.82 3869.67 ± 3172.65 3922.67 ± 2923.38 4378.00 ± 2770.89 
GSK-3 32.36 ± 31.17 29.00 ± 27.56 33.15 ± 33.71 29.00 ± 29.47 26.95 ± 26.29 
Standard 
Antimalarials 
Chloroquine 83.35 ± 86.94 62.45 ± 52.54 90.88 ± 82.22 98.36 ± 83.14 103.10 ± 122.37 
Dihydroartemisinin 6.22 ± 6.06 6.40 ± 6.06 6.12 ± 5.16 6.92 ± 6.37 7.50 ± 5.71 
Atovaquone 0.26 ± 0.20 0.25 ± 0.23 0.21 ± 0.16 0.23 ± 0.13 0.32 ± 0.21 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I F227I + L527I F227I + L527I F227I + L527I F227I + L527I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 0.78 ± 0.08 0.78 ± 0.25 0.89 ± 0.22 0.95 ± 0.26 
Genz-668419 1 0.68 ± 0.13 0.71 ± 0.20 0.78 ± 0.09 0.89 ± 0.27 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 3.13 ± 0.52 3.51 ± 0.64 3.48 ± 0.66 4.18 ± 1.96 
IDI-6273 1 1.14 ± 0.23 1.27 ± 0.39 1.33 ± 0.08 1.42 ± 0.38 
GSK-3 1 0.89 ± 0.09 0.97 ± 0.11 0.83 ± 0.16 0.81 ± 0.10 
Standard 
Antimalarials 
Chloroquine 1 0.97 ± 0.14 0.98 ± 0.04 1.09 ± 0.17 1.38 ± 0.51 
Dihydroartemisinin 1 0.87 ± 0.21 1.24 ± 0.55 1.43 ± 0.85 1.10 ± 0.21 
Atovaquone 1 0.90 ± 0.17 0.81 ± 0.12 0.96 ± 0.20 1.36 ± 0.46 
A.  
B. 
Table 3.6 Dd2 F227I: IDI-6253 selection results 
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Figure 3.4.8: The Dd2 F227I: IDI-6273 selection gave highly significant resistance 
not to the selecting agent, but to the unrelated Genz-669178 
(A). EC50 fold shifts relative to the parental selection line show highly significant 
resistance to Genz-669178 in flasks #2 and #3, and non-significant resistance to other 
PfDHODH inhibitors. 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements.  
Figure 3.12 Dd2 F227I: IDI-6273 selection 
A.  
B.  
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Table 3.4.6: Dd2 F227I: IDI-6273 selection results 
 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors. All four flasks gained a PfDHODH L527I 
mutation, and had similar, but not identical, drug sensitivity profiles. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
No significant changes in sensitivity were observed for other PfDHODH inhibitors or 
unrelated control compounds. However, the same 3 to 4-fold decreases in sensitivity are 
seen for all PfDHODH inhibitors tested in flasks #2 and #3. Flasks #2 and #3 both had a 
two-fold amplification of pfdhodh F227I, which would explain their low-level resistance to 
PfDHODH inhibitors but not unrelated antimalarial drugs such as chloroquine.   
Combination selection of the WT Dd2 parasite line with Genz-669178 and GSK3 (Figure 
3.4.9, Table 3.4.7) led to significant resistance in one of four independent selections. 
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I F227I 2 copies of F227I 2 copies of F227I F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 3388.17 ± 5765.55 2175.97 ± 3620.64 9675.98 ± 16382.01 
10651.11 ± 
18038.40 4187.34 ± 7081.33 
Genz-668419 2853.54 ± 4839.72 2014.08 ± 3320.25 8802.49 ± 14967.7 9712.78 ± 16484.7 4518.03 ± 7694.92 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 357.29 ± 279.31 1701.65 ± 1454.72 970.83 ± 1010.02 1120.44 ± 919.23 1373.73 ± 1665.02 
IDI-6273 103.67 ± 39.91 172.79 ± 117.64 333.35 ± 156.53 338.86 ± 75.73 146.77 ± 26.62 
GSK-3 43.55 ± 54.03 80.94 ± 109.23 159.41 ± 211.43 172.60 ± 232.55 54.86 ± 72.41 
Standard 
Antimalarials 
Chloroquine 1442.44 ± 2303.53 143.89 ± 664.27 198.12 ± 632.37 208.97 ± 535.37 229.11 ± 568.62 
Dihydroartemisinin 143.89 ± 245.04 198.12 ± 337.92 208.97 ± 357.26 229.11 ± 392.09 277.26 ± 474.74 
Atovaquone 224.96 ± 389.51 255.35 ± 442.03 376.21 ± 651.41 341.64 ± 591.54 257.08 ± 445.10 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele F227I F227I 2 copies of F227I 2 copies of F227I F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 0.99 ± 0.33 3.67 ± 0.72 3.64 ± 0.46 1.43 ± 0.26 
Genz-668419 1 0.87 ± 0.21 3.16 ± 0.88 3.28 ± 0.67 1.41 ± 0.35 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 1.26 ± 1.89 3.95 ± 0.68 3.41 ± 0.69 1.54 ± 0.18 
IDI-6273 1 4.87 ± 0.42 3.64 ± 1.38 3.15 ± 0.57 1.47 ± 0.32 
GSK-3 1 1.21 ± 0.77 3.31 ± 1.35 3.44 ± 0.64 1.23 ± 0.33 
Standard 
Antimalarials 
Chloroquine 1 0.92 ± 0.56 0.72 ± 0.37 0.80 ± 0.53 0.95 ± 0.59 
Dihydroartemisinin 1 1.79 ± 0.08 0.95 ± 0.37 1.30 ± 0.70 1.49 ± 0.42 
Atovaquone 1 1.48 ± 0.47 1.08 ± 0.27 1.39 ± 0.64 1.84 ± 0.42 
A.  
B. 
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Figure 3.4.9: The Dd2: Genz-669178 + GSK3 combination selection gave highly 
significant resistance to both selection agents in one of four selections 
(A). EC50 fold shifts relative to the parental selection line show highly significant 
resistance to both selection agents in flask #1, which gained a PfDHODH I263F mutation. 
(B). The unrelated antimalarial compounds chloroquine and atovaquone show no 
significant differences among the lines tested. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements. 
Figure 3.13 Dd2: Genz-669178 + GSK3 
A.  
B.  
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Table 3.4.7: Dd2: Genz-669178 + GSK3 combination selection results 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors in one of four flasks. 
(B). EC50 values for the same data set. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
This selection treated a WT parasite with both WT and mutant-type PfDHODH inhibitors 
– a test of the “targeting resistance” concept discussed in Chapter 2. None of the four 
selection flasks showed resistance at 50 days. Extension of the selections to 80 days, 
however, led to substantial resistance to both selecting compounds in one of four flasks. 
While this finding certainly weakens the argument for targeting resistance, the lengthy 
treatment required and the fact that only one of four flasks gained resistance suggests 
that it is more difficult for the parasite to become resistant to this combination than either 
drug alone.   
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT I263F WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 3.53 ± 0.36 50.98 ± 14.27 3.78 ± 1.60 4.37 ± 2.14 5.50 ± 4.25 
Genz-668419 5.79 ± 1.5 110.23 ± 36.83 5.28 ± 1.25 5.81 ± 1.31 6.60 ± 3.88 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 18927.67 ± 13046.72 1189.50 ± 1418.32 
22091.67 ± 
12599.00 
28728.33 ± 
19614.32 26994.33 ± 61.01 
IDI-6273 1189.50 ± 153.44 18927.67 ± 228.40 1159.50 ±  118.90 1514.00 ± 197.99 1789.00 ± 284.26 
GSK-3 69.81 ± 22.16 9787.67 ± 5.86 59.70 ± 13.87 69.52 ± 19.70 86.39 ± 61.01 
Standard 
Antimalarials 
Chloroquine 54.33 ± 22.16 54.33 ± 61.20 86.83 ± 45.69 113.51 ± 65.95 96.24 ± 61.73 
Dihydroartemisinin 3.82 ± 1.06 3.50 ± 0.88 3.04 ±  0.67 3.73 ± 0.88 3.67 ± 2.00 
Atovaquone 0.16 ± 0.16 0.05 ± 0.03 0.093 ± 0.05 0.15 ± 0.10 0.17 ± 0.14 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT I263F WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 14.32 ± 0.32 0.96 ± 0.30 1.10 ± 0.09 1.33 ± 0.20 
Genz-668419 1 18.94 ± 0.19 0.87 ± 0.28 0.98 ± 0.12 1.01 ± 0.11 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 0.17 ± 0.50 1.27 ± 0.25 1.58 ± 1.41 1.42 ± 0.19 
IDI-6273 1 1.17 ± 0.74 0.98 ± 0.29 1.27 ± 0.24 1.50 ± 0.24 
GSK-3 1 119.64 ± 9.88 0.90 ± 0.35 1.07 ± 0.24 1.21 ± 0.30 
Standard 
Antimalarials 
Chloroquine 1 2.29 ± 1.52 1.89 ± 1.42 2.43 ± 0.12 2.18 ± 0.23 
Dihydroartemisinin 1 0.97 ± 0.61 0.97 ± 0.30 1.18 ± 0.35 1.07 ± 0.50 
Atovaquone 1 0.95 ± 0.35 0.81 ± 0.26 0.99 ± 0.23 0.95 ± 0.17 
A.  
B.  
Table 3.8 Dd2: Genz-669178 + GSK3 selection results 
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Flask #1 gained an I263F mutation in PfDHODH. This selected line gained 14.3-fold 
resistance to Genz-669178, with an EC50 rising from 3.5 nM to 51 nM. A 19-fold 
resistance was observed for the structurally similar compound Genz-668419. A striking 
120-fold increase in EC50 was seen for GSK3, rising from 68.91 nM to 9789.87 nM. This 
selected line gained a borderline significant 5-fold sensitivity to IDI-6253. No changes 
were seen in sensitivity to unrelated antimalarial compounds.  
The combination selection of Dd2 parasites with Genz-669178 and IDI-6253 gave similar 
results: in 80 days, one of four independent selections gave rise to resistance (Figure 
3.4.10, Table 3.4.8). In this case, there was a four-fold amplification of pfdhodh with no 
mutations in the gene. The resistance observed was small – only 2 to 3-fold – but 
applied to a variety of PfDHODH inhibitor structural classes. Curiously, these resistant 
parasites became hypersensitive to a variety of “unrelated” compounds. For instance, 
the EC50 for chloroquine dropped 10-fold, going from 46.59 nM to 2.6 nM. This 
resembles the change between parasite lines Dd2 (chloroquine resistant) and 3D7 
(chloroquine sensitive). It is unlikely that this flask is a 3D7 contaminant as we have no 
3D7-based lines with the same drug sensitivity profile. Analysis of an extended set of 
unrelated antimalarials showed a folate pathway alteration (Table 3.4.8 C), although it is 
unclear if these changes are related to resistance or are merely coincidental.   
The folate pathway is required for pyrimidine biosynthesis as a source of one-carbon 
units. Testing sensitivity to folate pathway inhibitors suggested that the resistant line has 
wild-type dihydropterate synthase (DHS, targeted by sulfadoxine), but mutant 
bifunctional dihydrofolate reductase-thymidylate synthase (DHFR-TS, targeted by 
pyrimethamine and cycloguanil). The sensitivity to sulfadoxine was unchanged. 
Pyrimethamine sensitivity increased 100-fold, and cycloguanil sensitivity increased a 
staggering 588-fold.  
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Figure 3.4.10: The Dd2: Genz-669178 + IDI-6253 combination selection gave 
significant resistance to multiple PfDHODH inhibitors in one of four selections 
(A). EC50 fold shifts relative to the parental selection line show highly significant 
resistance to both selection agents in flask #2, which had no mutations in pfdhodh. 
(B). The unrelated antimalarial compounds atovaquone shows no significant differences 
among the lines tested, but flask #2 became hypersensitive to chloroquine. 
EC50 values were calculated using a whole-cell SYBR Green assay. Error bars indicate 
the standard deviation of three biological replicates, each with triplicate measurements. 
 
 
Figure 3.14 Dd2: Genz-669178 + IDI-6253 
A.  
B.  
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Table 3.4.8: Dd2: Genz-669178 + IDI-6253 selection results 
 
(A). EC50 fold shifts relative to the parental parasite line show significant differences in 
sensitivity to a variety of PfDHODH inhibitors in one of four flasks. 
(B). EC50 values for the same data set. 
(C). EC50 fold shifts for a set of unrelated antimalarials and folate pathway inhibitors. 
EC50 values were calculated using a whole-cell SYBR Green assay. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
Targeted DNA sequencing confirmed these inferences: DHS was wild-type, and DHFR-
TS was mutant. The mutant DHFR-TS residues involved in clinically observed 
pyrimethamine and cycloguanil sensitivity are well characterized 80. The typical DHFR-
EC50 (nM) ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT WT 4 copies of WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 3.13 ± 0.36 2.66 ± 0.95 6.75 ± 1.38 2.57 ± 0.93 2.73 ± 0.83 
Genz-668419 5.27 ± 0.95 5.00 ± 0.40 12.59 ± 3.30 5.11 ± 0.72 5.42 ± 1.36 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 21151.00 ± 13882.82 
16270.00 ± 
10629.67 
41983.33 ± 
28762.27 
26143.00 ± 
22082.52 
27352.00 ± 
19706.17 
IDI-6273 756.65 ± 765.59 762.75 ± 797.97 1896.45 ± 1430.55 1182.15 ± 1389.96 1630.80 ± 2015.54 
GSK-3 57.30 ± 17.66 44.95 ± 2.55 162.43 ± 13.08 48.97 ± 9.93 54.32 ± 14.13 
Standard 
Antimalarials 
Chloroquine 46.59 ± 32.40 46.94 ± 36.45 2.60 ± 0.76 42.64 ± 20.04 45.51 ± 31.51 
Dihydroartemisinin 3.09 ± 2.06 3.58 ± 1.82 5.73 ± 2.40 3.22 ± 2.85 3.13 ± 0.60 
Atovaquone 0.10 ± 0.06 0.10 ± 0.06 0.11 ± 0.07 0.087 ± 0.08 0.10 ± 0.04 
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT WT 4 copies of WT WT WT 
PfDHODH  
WT  
Inhibitors 
Genz-669178 1 0.84 ± 0.23 2.16 ± 0.34 0.81 ± 0.21 0.86 ± 0.18 
Genz-668419 1 0.96 ± 0.12 2.42 ± 0.61 0.98 ± 0.10 1.05 ± 0.31 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 1 0.80 ± 0.17 2.02 ± 0.50 1.11 ± 0.39 1.36 ± 0.36 
IDI-6273 1 0.97 ± 0.07 3.18 ± 1.32 1.30 ± 0.53 1.65 ± 1.00 
GSK-3 1 0.82 ± 0.18 3.03 ± 0.97 0.92 ± 0.38 1.02 ± 0.48 
Standard 
Antimalarials 
Chloroquine 1 1.00 ± 0.15 0.09 ± 0.08 1.08 ± 0.36 0.97 ± 0.05 
Dihydroartemisinin 1 1.19 ± 0.79 2.00 ± 1.88 1.08 ± 0.72 1.01 ± 0.32 
Atovaquone 1 1.06 ± 0.05 1.10 ± 0.17 0.83 ± 0.31 1.05 ± 0.16 
A.  
B.  
EC50 fold shift over parent ± s.d. 
Parent Flask #1 Flask #2 Flask #3 Flask #4 
PfDHODH allele WT WT 4 copies of WT WT WT 
Standard 
Antimalarials 
Chloroquine 1 1.00 ± 0.15 0.09 ± 0.08 1.08 ± 0.36 0.97 ± 0.05 
Pyrimethamine 1 0.58 ± 0.38 0.0098 ± 0.0005 0.47 ± 0.23 0.94 ± 0.46 
Cycloguanil 1 1.14 ± 0.30 0.0017 ± 0.0002 0.89 ± 0.13 0.89 ± 0.09 
Sulfadoxine 1 0.80 ± 0.49 0.72 ± 0.28 0.70 ± 0.26 0.74 ± 0.32 
C. 
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TS pattern of mutations in the resistant Dd2 line relative to the sensitive 3D7 line (N51I, 
C59S, S108N) was slightly altered to N51I, C59S, and S108R. This S108R mutation 
might increase the efficiency of the enzyme, which could increase the cellular supply of 
methyl-tetrahydrofolate. Methyl-tetrahydrofolate is an essential source of one-carbon 
units when converting dUMP to dCTP in pyrmidine biosynthesis. Thus, a more efficient 
folate pathway could at least theoretically alleviate low-level PfDHODH inhibition.  
It is less clear how chloroquine sensitivity might be related to PfDHODH inhibitors. 
Although nucleotides get the vast majority of attention, it is worth noting that vitamin B1 
(thiamine) is also a pyrimidine, and so also requires PfDHODH activity. Vitamin B1 is an 
essential cofactor in many cellular processes, including glucose and amino acid 
metabolism, and the genes necessary for both scavenge and biosynthesis are present in 
Plasmodium spp. 81. Importantly, scavenging is not sufficient, and depleting thiamine 
from parasite growth media is detrimental. It has not gone unnoticed that the thiamine 
biosynthetic pathway is essential in malaria parasites and not present in humans, and a 
recent effort showed that oxythiamine, a thiamine analog, was lethal to P. falciparum in 
culture 82. It is plausible that a reduced vitamin B1 pool affects chloroquine sensitivity – 
e.g., slowing down glucose metabolism would decrease both cellular ATP and the flux 
through the pentose phosphate shunt, which would alter the redox status of the parasite. 
One of the main armaments against oxidative damage is glutathione. Glutathione has 
also been shown to degrade non-polymerized ferriprotoporphyrin IX (“free heme”) – it is 
thought that chloroquine works mainly through interrupting the polymerization of the free-
radical producing free heme into the more inert form hemozoin 83. Thus, reducing sugar 
metabolism would decrease cellular NADPH, which would lead to an over-reliance on 
glutathione for preventing oxidative damage. If the glutathione pools were sufficiently 
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shunted towards fighting oxidative damage and away from detoxifying free heme, this 
could potentiate the efficacy of chloroquine.	   
ASSESSING TARGET RESPONSIBILITY VIA PURIFIED PROTEIN 
These drug resistance selections were characterized by looking for changes in drug 
sensitivity and/or the target pfdhodh. Drug resistance, of course, may be due to other 
factors than mutations or copy number variation in the presumed target. However, there 
is not yet a robust and cost-effective methodology for determining mechanisms of drug 
resistance in a large number of parasite lines. Classic population genetics strategies like 
linkage mapping are still in use, but making genetic crosses in malaria is experimentally 
arduous and requires the use and potential sacrifice of non-human primates 84. It is 
highly unlikely that existing crosses (from controlled primate infections of isolated from 
human patients) would have resistance to PfDHODH inhibitors, as these drugs are not 
yet in clinical use. 
Genome-wide tools such as whole genome sequencing and microarrays can generate a 
long list of candidate genomic regions, but following up on those candidates is difficult 
due to the relative genetic intractability of P. falciparum (never mind that of P. vivax, 
which has yet to be successfully cultured long-term in a lab setting). In-progress 
advances in transfection and recombination technology – zinc finger nucleases 85, 
TALENS 86, and the RNA-guided CRISPR/Cas9 system 87, 88 – may change this.  The 
gold standard and eventual goal is to do allelic replacements to determine if mutations in 
pfdhodh are responsible for the observed changes in drug sensitivity. As current 
techniques would take 6-12 months to generate PfDHODH allelic replacement parasites, 
we decided to focus on protein biochemistry. 
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We cloned, expressed, and purified a total of 11 DHODH proteins in Escherichia coli 
(Figure 3.4.11). These included WT and all observed mutant PfDHODH proteins as well 
as the WT proteins from P. vivax and H. sapiens. Class II DHODH proteins are inactive 
without the cognate FMN cofactor. Some of the mutants – particularly L531F and all 
F227I-containing mutants – had only ~5% catalytically competent protein. This may have 
relevance to their in vivo activity, with the caveat that expression of a truncated form of 
the enzyme in a recombinant host might not reflect native expression parameters.  
 
Figure 3.4.11: Production and use of recombinant DHODH proteins 
(A). Purification resulted in a clean, single band by Coomassie staining (shown: 
PfDHODH I263F, 45 kDa). 
(B). The yield of protein (and catalytically competent protein with a flavin mononucleotide 
cofactor) varied widely between different constructs. However, we were able to obtain 
sufficient active protein for all 11 constructs. 
(C). The in vitro reaction catalyzed by DHODH protein. This can either be measured 
through direct observation of orotic acid product or through a coupled DCIP dye. 
 
Protein activity assays showed large differences in sensitivity to PfDHODH inhibitors 
(Figure 3.4.12, Figure 3.4.13, Table 3.4.10). These differences are shown as fold 
changes over WT PfDHODH (represented by the dotted line at 100 = 1). 
A.  
DHODH protein [Protein], mg/mL 
[FMN],  
uM 
[Active 
protein],  
mg/mL 
% 
Catalytically 
Competent 
Protein 
Pf WT 3.04 2.80 1.27 42.03 
Pf E182D 4.25 1.81 0.82 19.47 
Pf F227I 28.21 0.80 0.36 1.29 
Pf L531F 7.73 0.61 0.27 3.62 
Pf F188I 1.48 1.20 0.54 37.0 
Pf F188L 5.57 4.90 2.23 40.19 
Pf I263F 2.78 3.46 1.58 56.90 
Pf L172F + F227I 4.76 1.17 0.53 11.24 
Pf L527I + F227I 7.37 0.85 0.38 5.28 
Pv WT 1.62 1.20 0.54 33.80 
Hs WT 1.47 2.85 1.30 88.57 
B.  
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Figure 3.4.12: Inhibition of recombinant DHODH proteins in vitro 
In general, the protein data showed dramatic changes in sensitivity (note the log10 scale 
and µm numbers, in contrast to the linear scale an nM numbers for cell data). In some 
Figure 3.17 DHODH proteins show large changes in drug sensitivity  
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cases, the proteins were not sufficiently inhibited by the maximum allowable 
concentration of drug in the assay (2 mM), and these were referred to as “out of range” 
of the assay. This was largely due to solubility and reaching concentrations of DMSO 
that would affect enzyme activity (~8% by volume). Note that of the compounds shown, 
only IDI-6253 inhibited human DHODH (data not shown), and it did so with a nearly 
identical EC50 to the P. falciparum enzyme. 
Some of the proteins were hypersensitive to PfDHODH inhibitors: E182D was 5.9-fold 
more sensitive than WT to IDI-6273. F227I was 7 and 8-fold more sensitive to IDI-6253 
and IDI-6273, respectively, and 2-fold more sensitive to GSK3. Hypersensitivity was not, 
however, the most common observation – that was resistance on a dramatic scale.  
E182D was 40 to 50-fold resistant to the WT PfDHODH inhibitors Genz-669178, Genz-
668419, and DSM74. F188I and F188L were also 50-fold resistant to triazolopyrimidines 
like DSM4, but were hundreds to thousands-fold more resistant to alkylthiophenes like 
Genz-669178. The addition of either L172F or L527I to F227I considerably increased 
resistance to a variety of inhibitors: e.g., F227I was 62.7-fold resistant to Genz-668419, 
but L527I + F227I was 273.9-fold resistant and L172F + F227I was immeasurably 
resistant (at least 5000-fold, with the assay limited by compound solubility). L531F, 
originally isolated as a triazolopyrimidine-resistant line (selected with compound DSM74), 
was more sensitive to alkylthiophene PfDHODH inhibitors like Genz-669178 and Genz-
668419. 
The purified protein and cell data largely show the same upward and downward trends in 
drug sensitivity (Figure 3.4.14). This mirroring indicates that mutations in pfdhodh are 
major factors, if not necessarily the only factor, in determining sensitivity to PfDHODH 
inhibitors. Confirming this concept with allelic replacements in cells would be ideal, but 
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for now, purifying protein is a much faster option for testing the effect of different 
mutations on protein stability, activity, and sensitivity to inhibitors. Efforts to utilize new 
allelic replacement strategies (such as the use of zinc finger nucleases) are in progress. 
The protein data was more extreme than the cell data, and the EC50 values did not 
match perfectly. For example, the EC50 of Genz-669178 was 17.9 nM in WT Dd2 cells, 
and 79.5 nM in WT protein. (Note that the observed values for the protein assays 
depend on the amount of protein used, much like how copy number variation can affect 
cellular data, and it is difficult to match the concentration of purified protein in a well with 
the concentration of protein in a cell in the same assay volume). The Genz-669178 EC50 
rose to 38.4 nM for E182D cells, and 3483 nM for E182D protein. Thus, E182D is 
resistant to Genz-669178, but the cells had an 8.7-fold increase and the purified protein 
had a more extreme 43.2-fold increase.  
It is not surprising that the in vitro protein activity assay showed larger changes than in 
cell-based assays. Cells have many complicating factors that are not present in in vitro 
protein assays – biological membranes, alternate targets or non-specific protein binding, 
efflux mechanisms, and drug metabolism. The PfDHODH in vitro protein activity assay 
distills the reaction to its bare components, but the buffer used is certainly different than 
Plasmodium cytosol, and the reactions are run at 25°C (rather than the 37C-42°C of a 
febrile infected person or the constant 37°C of blood-stage culture).  
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Figure 3.4.13: Inhibition of recombinant DHODH proteins, organized by residue 
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Table 3.4.9: DHODH protein inhibition values 
 
 
(A). EC50 fold shifts relative to the WT PfDHODH protein show significant differences in 
sensitivity to a variety of PfDHODH inhibitors. 
(B). EC50 values for the first set of selection mutants (selected by Amar bir Singh Sidhu). 
(C). EC50 values for the expanded set of selection mutants (selected by Leila Saxby 
Ross). 
EC50 values were calculated using an indirect DCIP-coupled reaction. The s.d. is the 
standard deviation of three biological replicates, each with triplicate measurements.  
In a few cases, the protein and cell data did not match up. The I263F and L172F + F227I 
mutant parasites were both more sensitive to the compound IDI-6253 than the WT 
parasites. Nevertheless, both proteins were highly resistant, and L172F + F227I was 
insensitive to even 2 mM of this compound. Given the concordance of the rest of the 
data, this may reflect actual biology and not be an artifact. If so, it is difficult to explain 
unless factors outside of the target PfDHODH are involved in resistance.  
EC50 fold shift over parent ± s.d. 
PfDHODH allele E182D F227I L531F F188I F188L I263F L172F + F227I L527I + F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 43.19 ± 12.41 !18.31 ± 2.63 0.36 ± 0.17 1041.13 ± 331.86 
261.22 ± 
56.29 
1677.15 ± 
266.08 
11244.65 ± 
7365.47 58.39 ± 25.19 
Genz-668419 46.09 ± 15.62 !62.72 ± 22.19 0.44 ± 0.24 3753.11 ± 1182.62 
873.17 ± 
284.61 
606.33 ± 
54.72 > 5000 
273.88 ± 
166.53 
DSM74 49.89 ± 3.97 !19.29 ± 10.40 14.62 ± 0.83 57.16 ± 2.09 46.78 ± 0.76 12.82 ± 1.76 149.58 ± 97.23 19.54 ± 8.10 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 4.04 ± 0.15 ! 0.14 ± 0.01 4.48 ± 0.95 > 550 > 550 > 550 > 550 2.11 ± 0.88 
IDI-6273 0.17 ± 0.05 ! 0.12 ± 0.06 1.80 ± 0.15  > 150 27.72 ± 4.04 > 150 > 150 0.77 ± 0.41 
GSK-3 10.14 ± 0.54 ! 0.51 ± 0.09 0.26 ± 0.05 0.61 ± 0.002 0.22 ± 0.02 50.25 ± 21.51 18.024 ± 3.91 18.67 ± 7.21 
Table 3.11 Recombinant PfDHODH protein activity assay inhibition values 
A.  
EC50 (uM) ± s.d. 
PfDHODH allele WT E182D F227I L531F 
PfDHODH  
WT  
Inhibitors 
Genz-669178 0.08 ± 0.006 3.48 ± 1.29 1.47 ± 0.33 0.029 ± 0.01 
Genz-668419 0.14 ± 0.006 6.72 ± 2.56  8.99 ± 2.93 0.06 ± 0.03 
DSM74 0.38 ± 0.09 18.78 ± 2.92 6.71 ± 2.73 5.58 ± 0.32 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 3.52 ± 0.22 14.22 ± 0.32 0.50 ± 0.019 15.81 ± 3.36 
IDI-6273 13.49 ± 31.64 2.15 ± 0.13 1.70 ± 1.02 24.26 ± 1.98 
GSK-3 1.69 ± 0.46 17.26 ± 5.43 0.89 ± 0.37  0.044 ± 0.06 
EC50 (uM) ± s.d. 
PfDHODH allele WT F188I F188L I263F L172F + F227I L527I + F227I 
PfDHODH  
WT  
Inhibitors 
Genz-669178 0.08 ± 0.006 82.77 ± 26.383 20.77 ± 4.48 133.33 ± 21.15 893.95 ± 585.56 4.64 ± 2.00 
Genz-668419 0.14 ± 0.006 542.7 ± 171.00 126.26 ± 41.15 87.68 ± 7.91 > 2000 39.60 ± 24.08 
DSM74 0.38 ± 0.09 21.80 ± 0.79 17.85 ± 0.29 4.89 ± 0.66 57.05 ± 37.09 7.45 ± 3.09 
PfDHODH 
Mutant 
Inhibitors 
IDI-6253 3.52 ± 0.22 > 2000 > 2000 > 2000 > 2000 7.45 ± 3.09 
IDI-6273 13.49 ± 31.64 > 2000 374.07 ± 54.54 > 2000 > 2000 10.41 ± 5.53 
GSK-3 1.69 ± 0.46 1.03 ± 0.003 0.36 ± 0.03 84.76 ±  36.28 30.4 ± 6.59 31.49 ± 12.17 
B.  
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Figure 3.4.14: Protein activity data mirrors cell data 
 
CRYSTALLOGRAPHY 
In an effort to further our understanding of the molecular details of drug resistance, we 
collaborated with Dr. Onkar M.P. Singh and Dr. Paul Rowland at GlaxoSmithKline 
(Stevenage, United Kingdom) to determine the high-resolution crystal structures of 
PfDHODH bound to different inhibitors (Table 3.4.10, Figure 3.4.15, Figure 3.4.16, 
Figure 3.4.17, Figure 3.4.18, Figure 3.4.19). Attempts to crystallize E182D and F227I 
mutant proteins failed, and no other mutants were tried. The failure of the mutant 
proteins may be due to several factors. First, the quality of the preparation may not have 
been sufficient for crystallography. The same procedure was followed for both WT and 
mutant protein preparation, but what sufficed for the WT will not necessarily suffice for 
the mutants. Addition of another purification step (weak anion exchange with DEAE resin, 
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pH 8.0) did not improve crystallography attempts. Second, the mutant proteins often had 
lower flavin mononucleotide (FMN) loads than the WT (see Figure 3.4.11 B). If the 
proteins with and without FMN bound have different conformations, having a larger 
minority population could disrupt orderly packing. Finally, this may reflect actual biology. 
The model for how these mutations lead to resistance is that they weaken the 
interactions holding the α1- α2 helix lid to the body of the protein, which disrupts electron 
transfer between FMN and ubiquinone either directly or by disrupting formation of the 
electron tunnel. The mutants are more floppy than the WT and less likely to crystallize. 
This may reflect overall stability – although these mutants all support viable parasites. 
 In contrast, the WT PfDHODH protein crystallized with a variety of DHODH inhibitors. 
The alkylthiophene Genz-669178 was co-crystallized with WT PfDHODH protein with a 
resolution of 2.0 Å and an R-free of 0.19. Once published, this would be the highest 
resolution PfDHODH structure available. Co-crystals of the mutant-selective inhibitors 
IDI-6253 and IDI-6273 were also solved. These had lower resolution – 2.7 Å and 2.8 Å, 
respectively – but due to the rigid rings, the orientation of the inhibitors in the drug-
binding pocket is unambiguous.  
Table 3.4.10: Crystallography parameters 
 
 
S O
HN
N
N
C
N
N
N
N
N
N
N
Cl
O
O
Compound Resolution R R-free Space group 
Number of 
molecules 
Genz-669178 2.0 0.170 0.190 C2 2 
IDI-6273 2.8 0.171 0.230 P21 2 
IDI-6253 2.7 0.194 0.268 P21 2 
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An overlay of the structures (Figure 3.4.15) showed that there is considerable plasticity 
in the binding pocket, as was observed by Deng et al 64. Structurally distinct PfDHODH 
inhibitors bound in the same pocket, but with quite disparate orientations. Some 
commonalities include a small, hydrophobic moiety positioned near the FMN cofactor 
and a hydrogen bond to R265. Note that these commonalities likely mimic how the 
native ubiquinone binds, but there is no ubiquinone co-crystal structure to confirm this. 
Surprisingly, most of the residues lining the binding pocket do not move as different 
ligands bind. Only two – H185 and F188 – had substantial movement. Note that 
mutation of F188 gave substantial resistance to a variety of PfDHODH inhibitors. H185 
mutants were not recovered in the resistance selections discussed here, but we believe 
that they would also lead to resistance. 
 
Figure 3.4.15: PfDHODH inhibitors bind in widely different modes  
The residues H185 and F188 move substantially to accommodate different ligands. 
Image provide by Dr. Paul Rowland. 
The co-crystal structure of PfDHODH with Genz-669178 (Figure 3.4.16, Figure 3.4.17) 
was similar to the alkylthiophene Genz-667348 (PDB ID: 3o8a 44), but had an increased 
Phe188 
His185 
Overlay of four of the ligands Wide variation in binding modes 
Glu182, Phe227, and Arg262 do not move much with different ligands. 
His185 and Phe188 can move considerably to accommodate different ligands. 
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resolution of 2.0 Å. At the protein level, E182D gives 43.19-fold resistance, F227I gives 
18.31-fold resistance, F188I gives 1041-fold resistance, F188L gives 261-fold resistance, 
I263F gives 1677-fold resistance, L172F + F227I gives 1244.65-fold resistance, and 
L527I + F227I gives 58.39-fold resistance. L531F gives 3-fold sensitivity.  
All of these residues are close to the Genz-669178 ligand and many are also involved in 
holding the lid to the body of the protein. Resistance could be explained by steric 
interruptions of ligand binding, or through a weakened lid-body interaction that reduces 
the amount of time the binding pocket exists. The sensitivity seen with the L531F 
mutation may be due to gaining a positive pi stacking or edge-to-face interaction 
between phenylalanine and the ligand. This could increase the binding affinity and thus 
reduce the inhibitor EC50.  
 
Figure 3.4.16: Co-crystal of PfDHODH with Genz-669178 
A). Ribbon diagram of the α1- α2 helix lid for orientation. 
(B). All resistance mutations observed for PfDHODH inhibitors. All mutations other than 
L531F give PfDHODH inhibitor resistance. Although L531F was isolated as a resistant 
mutant, it is three-fold more sensitive to wild-type PfDHODH inhibitors. 
Images made with CCP4mg 66 using coordinates 4dtjm. 
L172 
F188 
E182 
I263 
F227 
L531 L527 
FMN 
L-DHO 
Genz-669178 
A.  B.  
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Figure 3.4.17: Resistance residues line portions of the inhibitor binding site 
(A). Diagram of resistance mutations in relation to Genz-669178, an alkylthiophene. 
(B). Orthogonal view. Resistance mutations surround the inhibitor, and appear to form 
spatial groups, e.g., F227 and F188, E182 and I263, L527 and L531. 
Images made with CCP4mg 66 using coordinates 4dtjm (PfDHODH with Genz-669178). 
PfDHODH was crystallized with compound IDI-6253, which is a mutant-selective 
inhibitor (Figure 3.4.18). At the protein level, E182D, L531F, and the combination L527I 
+ F227I gave low-level resistance of 2 to 5-fold magnitude. In contrast, F227I gave 6-fold 
sensitivity, and high-level resistance (>550-fold) was observed for F188I, F188L, I263F, 
and the combination L172F + F227I.  
It is interesting to consider the F227I mutation: alone, it gives sensitivity. When paired 
with L172F, it gives high-level resistance. When paired with L527I, it gives low-level 
resistance. L172F is too distant to have a direct interaction with F227I – although it is 
possible that when no ligand is bound, the lid helices are packed more tightly against the 
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body of the protein. In either case, the bulkiness of the L172F exchange may alter helix 
packing and thus change the binding pocket in a way that leads to resistance.  
 
Figure 3.4.18: Co-crystal of PfDHODH with IDI-6253	  	  
(A). Ribbon diagram of the α1- α2 helix lid for orientation. 
(B). All resistance mutations observed for PfDHODH inhibitors. L527I gives resistance to 
IDI-6253. F227I gives sensitivity.  
Images made with CCP4mg 66 using coordinates 2ihho. 
IDI-6253 is quite close to F227, so the F227I mutation may lead to sensitivity by 
reducing steric clashes (rather than favorable pi-pi interactions) and allowing a better fit. 
L527 is spatially close to F227, and a direct interaction is plausible. The combination of 
L527I + F227I may lead to a stronger interaction between the two residues in an 
isoleucine zipper, and this may change the binding pocket in a way that favors 
resistance.  
Finally, PfDHODH was crystallized with IDI-6273, a mutant-selective inhibitor (Figure 
3.4.19). At the protein level, E182D and F227I both gave ~6-fold sensitivity. As for IDI-
6253, F227 is very close, so mutation to a smaller residue may reduce steric clashes. It 
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is less clear how E182D leads to sensitivity. L531F and the combination L527I + F227I 
had little effect.  
 
Figure 3.4.19: Co-crystal of PfDHODH with IDI-6273 
(A). Ribbon diagram of the α1- α2 helix lid for orientation. 
(B). All resistance mutations observed for PfDHODH inhibitors. L172F gives 15-fold 
resistance to IDI-6273. E182D and F227I give hypersensitivity.  
Images made with CCP4mg 66 using coordinates 2ihho. 
Curiously, F188L gave 27.7-fold resistance, whereas the sister mutation F188I gave 
>550 fold resistance. As these often had differing impact on the potency of different 
PfDHODH inhibitors, solving crystal structures of F188I and F188L would be informative 
for fine-tuned detail about the drug-binding site. I263F and the combination L172F + 
F227I both gave >550-fold resistance.   
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3.5 DISCUSSION AND FUTURE DIRECTIONS 
This study focused on cataloging potential mechanisms of resistance to a small panel of 
structurally unrelated PfDHODH inhibitors, with an eye on developing strategies to 
suppress and contain these mechanisms should these compounds ever be developed 
into drugs. This was accomplished through in vitro drug resistance selections. We used 
an intermittent pulse strategy, which allows for recovery between stresses. Continuous 
selection with PfDHODH inhibitors tends to give gene amplification rather than point 
mutations 51. Using this approach, we discovered several mutations in PfDHODH, the 
target gene: L172F, F188I, F188L, E182D, F227I, I263F, L527I, and L531F, as well as 
several instances of copy number variation in pfdhodh. Resistant cell lines with no 
discernable alterations to pfdhodh sequence or copy number will be subjected to whole-
genome sequencing. Overall, the simultaneous use of a wild-type and mutant-type 
inhibitor lead to much less resistance (16%) than the use of a single drug in a primary or 
sequential selection (60-75%) (Figure 3.5.1). 
 
Figure 3.5.1: Selection with two drugs simultaneously led to fewer instances of 
resistance than selection with a single drug 
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Although these selected cell lines undoubtedly have mutations in addition to those in 
pfdhodh, the observed changes in drug sensitivity were largely recapitulated by in vitro 
assays with purified recombinant protein. This mirroring indicates that the mutations in 
PfDHODH are the driving force behind resistance, and also implies that purified protein 
can be used to predict the effect of different mutations in parasites. Producing protein is 
substantially faster and cheaper than doing drug resistance selections or making allelic 
replacements in parasites. Two caveats are that not all proteins will be able to be 
expressed, and that successful expression does not guarantee that the protein is 
sufficiently functional in cells to support viability.  
Determining the steady state kinetic parameters for all of the mutant proteins (as in 
Chapter 2) would help gauge the consequences of different mutations – e.g., a mutation 
which dramatically changes the Km or kcat for the substrate or cofactors likely has larger 
fitness repercussions than a more mild mutation. Pre-steady state measurements and 
more detailed enzymology could help explain detailed points about the catalysis of 
oxidative and reductive half-reactions 65 and the mode of inhibitor action. Although 
crystallography of the E182D and F227I mutant proteins failed, it may be worth pursuing 
crystallography further with these and other mutants. A WT structure with ubiquinone 
bound, rather than a PfDHODH inhibitor, would also be useful. Computational modeling 
has been surprisingly predictive with PfDHODH, and would likely be continued to guide 
medicinal chemistry efforts for greater selectivity and potency. 
Protein can also be used as a proxy for determining compound susceptibility in 
Plasmodium species that do not have in vitro culture systems. In the case of P. vivax, 
PvDHODH was similarly sensitive to the six inhibitors shown, with all falling within 10-
fold of the PfDHODH values  (Figure 3.5.1).  
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Figure 3.5.2: P. vivax PvDHODH protein is sensitive to PfDHODH inhibitors 
We are also working on complementary approaches in whole cells. Allelic replacements 
of the mutant pfdhodh genes would give parasites with different pfdhodh alleles in 
isogenic backgrounds. These parasite lines would be ideal for both testing drug 
sensitivity and for doing competitive growth assays (with and without a variety of drugs). 
While the growth habits (cycle time, burst size) of individual parasite lines could be 
characterized by FACS, we believe that it is unlikely to find gross differences, and that 
pairwise competitive growth provides a more sensitive measure of evolutionary fitness. 
As many of the mutations of interest are close to the amino-terminus of pfdhodh, 
traditional allelic replacement techniques are unlikely to succeed, and alternate 
strategies such as zinc finger nucleases or a cas9-based system are being pursued.	   
As the P. falciparum mitochondria is thought to be mainly important for its role in 
supplying reduced ubiquinone to PfDHODH 89, it is quite possible that mutations in 
pfdhodh and other resistance mechanisms would alter mitochondrial physiology. 
Mitochondrial function could be assessed by measuring the consumption of oxygen, 
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production of pyrimidines, and level of reactive oxygen species. A more global 
metabolomics project could provide this information and more. 
 
 
 
 
  
  
 
 
CHAPTER FOUR: 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
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Malaria is both preventable and curable, and yet there are hundreds of millions of 
infections and an estimated 600,000 malaria-related deaths every year 1. Malaria control 
programs rely on a combination of vector control with insecticides and bednets and 
disease control with antimalarial drugs. No effective vaccine exists, and humans only 
build short-term, partial immunity through natural exposure. Our long co-evolution with 
malaria parasites has left traces in both genomes: in humans, alleles for potentially 
deleterious hemoglobinopathies such as sickle cell anemia and the alpha and beta 
thalessemias are more common in areas with malaria transmission, likely because these 
alleles offer some degree of protection from severe malaria. In Plasmodium, the use of 
antimalarial drugs has led to selective sweeps, leading to changes in population 
structure and the rise and spread of drug-resistant parasites 15.  
Malaria parasites are highly adaptable, and drug pressure can lead to resistance nearly 
simultaneous with introduction 23, 75. Resistance is reported for nearly every antimalarial 
in use, including worrisome reports of delayed clearance with artemisinin-based 
combination therapies (ACTs), which form the backbone of most modern control 
programs 19. The armament of antimalarial agents is limited, with a heavy reliance on a 
small number of chemical scaffolds and biological targets 13. Cross-resistance of 
antimalarials in development with therapeutics in clinical use is a major concern. 
Drug resistance, however, is not necessarily inevitable or permanent. As with any trait, 
the evolution and spread of resistance is shaped and restricted by fitness considerations. 
If a resistant parasite is not competitively viable, it will not spread or be maintained in a 
population. In 1993, faced with an efficacy of less than 50%, Malawi phased out 
chloroquine and started using sulfadoxine-pyrimethamine instead. Over the course of 
eight years, the molecular marker for chloroquine resistance – specific mutations in 
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pfcrt1 – dropped to undetectable levels. This suggests that the fitness cost of the mutant 
pfcrt1 was high enough to drive it out of the parasite population once the selecting force 
was removed. It also implies that chloroquine could potentially be used again 77. 
Evolutionary oscillations between sensitive and resistant parasites can also occur on 
much smaller timescales through the use of suppressive combination therapy. 
Synergistic combinations tend to be favored for their short-term potency. Synergy, 
however, heavily selects for drug resistance, as parasites resistant to one of the two 
compounds used have a tremendous fitness advantage over the sensitive parent 90.  In 
contrast, strong antagonism (“suppression”) rewards sensitivity rather than resistance: 
resistance to one compound results in a fitness disadvantage, and the resistant line will 
be outcompeted by the sensitive parent. Suppressive combinations thus select away 
from resistance. Conceptually, suppressive combinations often work by having two 
compounds which in some way mask each other’s effects: perhaps the pathways they 
affect can compensate for each other, or their targets are not available at the same time. 
When resistance to one compound develops, the resistant parasites are now subject to 
the full force of the second compound. If this disadvantage is sufficiently large, then the 
sensitive parasites are more fit than the resistant ones, and the resistant parasites will 
be outcompeted. 
For example, in Escherichia coli, inhibitors of protein and DNA synthesis have 
suppressive interactions: cells grow faster in this combination than with each drug alone. 
Molecularly, this is because ribosomal genes are not directly regulated by DNA stress. 
This leads to a non-optimal excessively high rate of protein synthesis relative to DNA 
replication, which takes resources away from other necessary cellular processes and is 
thus a fitness disadvantage 37.  
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In Chapter 2, we described “targeting resistance,” a type of suppressive combination 
therapy that pairs inhibitors for the sensitive and resistant forms of a single target. We 
demonstrated that both sequential and simultaneous use of these inhibitors maintained 
or directed evolution towards a WT, sensitive allele for the target. These results were 
promising, but the fact that the WT and mutant-type inhibitors target the same binding 
pocket (though not the exact same site in that pocket) is a weakness. This is being 
addressed by Dr. Amanda Lukens through screening for compounds that inhibit the 
mutant parasite lines from a large collection of malaria-active compounds (instead of the 
small, biased set of DHODH inhibitors this study was started with). Ideally, this screen 
would identify compounds in unrelated pathways such that the binding pockets are 
unrelated and thus less likely to fail in one swoop. Another weakness is that the mutant-
type inhibitors are selective, but not specific. Future work includes identifying and 
developing specific compounds with no residual activity against the WT.  
We would also like to further explore the evolutionary aspects of drug resistance: this 
could be accomplished retrospectively through sequencing saved selection time points 
to chart the rise and fall of different alleles. This could be done on a whole-genome scale 
or with quantitative PCR for select individual alleles. The most interesting time points 
would be before official resistance, as there are likely multiple resistant parasite types 
competing with each other until one dominates the culture. It would be interesting to 
identify the unsuccessful minor variants and speculate as to why they were marginalized.  
If allelic replacement is successful, competitive growth assays with sensitive and 
resistant parasites with isogenic backgrounds would allow a fine-tuned description of 
fitness costs and benefits. This could be extended to include conditions with a variety of 
drugs and other stresses, such as febrile temperatures, to model some of the stresses 
inside a human infection.  
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In Chapter 3, we used in vitro selection, protein activity assays, and crystallography for 
an in-depth characterization of potential resistance mechanisms for PfDHODH inhibitors. 
The goal is to identify the small number of fitness-resistance maximums that the parasite 
is likely to take in order to design strategies for resistance control. This could extend the 
useful lifetime of DHODH inhibitors. Future work includes identifying the most fit of the 
resistance mutants, which can be approximated in vitro through competitive growth 
assays under a variety of conditions, and identifying inhibitors specific for those mutants.  
The efforts of the United States’ Office of Malaria Control in War Areas, the precursor to 
the Center for Disease Control and Prevention, reduced malaria in the United States 
(Figure 4.1), and eventually led to eradication with the National Malaria Eradication 
Program campaign between 1947-1952 91.  
 
 
Figure 4.1: The distribution of malaria in the United States of America, 1882-1935 
(The Center for Disease Control and Prevention 91) 
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The success of the United States’ National Malaria Eradication Program, which relied 
heavily on vector control through the use of the insecticide DDT and draining or 
otherwise compromising mosquito breeding sites, led to the World Health Organization-
led 1955 Global Malaria Eradication Programme (GMEP). GMEP successfully 
eradicated malaria from many countries. However, GMEP was abandoned after 14 
years with the acknowledgement that the current tools – the insecticide DDT and the 
antimalarial drugs chloroquine and pyrimethamine – were no longer effective, and that 
political will and financial support were dwindling. In areas where eradication was not 
complete, GMEP may actually have been harmful as the parasite population rebounded 
against a now-immunologically naïve population, and malaria often returned in 
epidemics 20.  
Studies of parasite resurgences show that the number one factor is the cessation of 
control programs due to a lack of funding 76. If sufficient funds are later obtained, there is 
a large risk that the previously effective tools have reduced efficacy or are even obsolete 
due to drug resistance. Given that drug resistance rapidly compromises insecticides and 
antimalarial agents, new strategies are needed to both understand how resistance 
develops and how to counter it in the field. The studies presented here suggest that 
suppressive drug combinations, particularly in the form of “targeting resistance,” may 
extend the useful lifetime of antimalarials and thus give eradication a better chance of 
success. 
Studies of small-scale eradication, such as on the island of Aneityum, have shown that 
community partnership and education are essential, as extensive and long-term 
coordination and cooperation are required to eliminate malaria 72. Mass drug 
administration, particularly for vulnerable pregnant women and young children, was 
combined with vigorous vector control through the use of indoor residual spraying, bed 
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net use, and the drainage of standing water. P. falciparum was declared eliminated one 
year after no transmission was observed. P. vivax took five years.  
This extensive follow-up time will be a challenge – how do you convince people and 
governments to continue with malaria interventions when transmission is decreasing or 
even stopped for several years? There are many competing priorities, but a relaxation of 
control measures could lead to a resurgence in malaria cases – and having to restart the 
clock. Sustaining financial commitment and the communal responsibility to prevent, 
diagnose, and treat malaria infection will require much more than bench science. 
Eradication is still possible. We have the tools – for now. We need to make more tools, 
and to develop strategies to protect their effectiveness. We also need a massive and 
sustained intersection of control measures, and these will require funding, political and 
social will, and education of the public 92. These measures must be completed before 
resistance renders them useless, and must be unrelenting even as transmission and 
perceived risk decrease.  
 
 
 
 
 
	   
 
 
 
REFERENCES   
  
	   117	  
1. Organization, W. H., World Malaria Report 2012. 2012. 
2. Prudencio, M.; Rodriguez, A.; Mota, M. M., The silent path to thousands of 
merozoites: the Plasmodium liver stage. Nature reviews. Microbiology 2006, 4 (11), 849-
56. 
3. Portugal, S.; Carret, C.; Recker, M.; Armitage, A. E.; Goncalves, L. A.; Epiphanio, 
S.; Sullivan, D.; Roy, C.; Newbold, C. I.; Drakesmith, H.; Mota, M. M., Host-mediated 
regulation of superinfection in malaria. Nature medicine 2011, 17 (6), 732-7. 
4. Cowman, A. F.; Berry, D.; Baum, J., The cellular and molecular basis for malaria 
parasite invasion of the human red blood cell. The Journal of cell biology 2012, 198 (6), 
961-71. 
5. Hisaeda, H.; Yasutomo, K.; Himeno, K., Malaria: immune evasion by parasites. 
The international journal of biochemistry & cell biology 2005, 37 (4), 700-6. 
6. Shikani, H. J.; Freeman, B. D.; Lisanti, M. P.; Weiss, L. M.; Tanowitz, H. B.; 
Desruisseaux, M. S., Cerebral malaria: we have come a long way. The American journal 
of pathology 2012, 181 (5), 1484-92. 
7. Suh, K. N.; Kain, K. C.; Keystone, J. S., Malaria. CMAJ : Canadian Medical 
Association journal = journal de l'Association medicale canadienne 2004, 170 (11), 
1693-702. 
8. Liu, Z.; Miao, J.; Cui, L., Gametocytogenesis in malaria parasite: commitment, 
development and regulation. Future microbiology 2011, 6 (11), 1351-69. 
9. Killeen, G. F.; Seyoum, A.; Sikaala, C.; Zomboko, A. S.; Gimnig, J. E.; Govella, N. 
J.; White, M. T., Eliminating malaria vectors. Parasites & vectors 2013, 6, 172. 
10. Agnandji, S. T.; Lell, B.; Fernandes, J. F.; Abossolo, B. P.; Methogo, B. G.; 
Kabwende, A. L.; Adegnika, A. A.; Mordmuller, B.; Issifou, S.; Kremsner, P. G.; Sacarlal, 
J.; Aide, P.; Lanaspa, M.; Aponte, J. J.; Machevo, S.; Acacio, S.; Bulo, H.; Sigauque, B.; 
Macete, E.; Alonso, P.; Abdulla, S.; Salim, N.; Minja, R.; Mpina, M.; Ahmed, S.; Ali, A. 
M.; Mtoro, A. T.; Hamad, A. S.; Mutani, P.; Tanner, M.; Tinto, H.; D'Alessandro, U.; 
Sorgho, H.; Valea, I.; Bihoun, B.; Guiraud, I.; Kabore, B.; Sombie, O.; Guiguemde, R. T.; 
Ouedraogo, J. B.; Hamel, M. J.; Kariuki, S.; Oneko, M.; Odero, C.; Otieno, K.; Awino, N.; 
McMorrow, M.; Muturi-Kioi, V.; Laserson, K. F.; Slutsker, L.; Otieno, W.; Otieno, L.; 
Otsyula, N.; Gondi, S.; Otieno, A.; Owira, V.; Oguk, E.; Odongo, G.; Woods, J. B.; Ogutu, 
B.; Njuguna, P.; Chilengi, R.; Akoo, P.; Kerubo, C.; Maingi, C.; Lang, T.; Olotu, A.; Bejon, 
P.; Marsh, K.; Mwambingu, G.; Owusu-Agyei, S.; Asante, K. P.; Osei-Kwakye, K.; 
Boahen, O.; Dosoo, D.; Asante, I.; Adjei, G.; Kwara, E.; Chandramohan, D.; Greenwood, 
B.; Lusingu, J.; Gesase, S.; Malabeja, A.; Abdul, O.; Mahende, C.; Liheluka, E.; Malle, 
L.; Lemnge, M.; Theander, T. G.; Drakeley, C.; Ansong, D.; Agbenyega, T.; Adjei, S.; 
Boateng, H. O.; Rettig, T.; Bawa, J.; Sylverken, J.; Sambian, D.; Sarfo, A.; Agyekum, A.; 
Martinson, F.; Hoffman, I.; Mvalo, T.; Kamthunzi, P.; Nkomo, R.; Tembo, T.; Tegha, G.; 
Tsidya, M.; Kilembe, J.; Chawinga, C.; Ballou, W. R.; Cohen, J.; Guerra, Y.; Jongert, E.; 
Lapierre, D.; Leach, A.; Lievens, M.; Ofori-Anyinam, O.; Olivier, A.; Vekemans, J.; Carter, 
T.; Kaslow, D.; Leboulleux, D.; Loucq, C.; Radford, A.; Savarese, B.; Schellenberg, D.; 
	   118	  
Sillman, M.; Vansadia, P., A phase 3 trial of RTS,S/AS01 malaria vaccine in African 
infants. N Engl J Med 2012, 367 (24), 2284-95. 
11. Daubenberger, C. A., First clinical trial of purified, irradiated malaria sporozoites 
in humans. Expert review of vaccines 2012, 11 (1), 31-3. 
12. Gosling, R. D.; Okell, L.; Mosha, J.; Chandramohan, D., The role of antimalarial 
treatment in the elimination of malaria. Clinical microbiology and infection : the official 
publication of the European Society of Clinical Microbiology and Infectious Diseases 
2011, 17 (11), 1617-23. 
13. Schlitzer, M., Malaria chemotherapeutics part I: History of antimalarial drug 
development, currently used therapeutics, and drugs in clinical development. 
ChemMedChem 2007, 2 (7), 944-86. 
14. Rocco, F., The miraculous fever-tree : malaria, medicine and the cure that 
changed the world. HarperCollins: London, UK, 2003; p xix, 348 p, [16] p. of plates. 
15. Wootton, J. C.; Feng, X.; Ferdig, M. T.; Cooper, R. A.; Mu, J.; Baruch, D. I.; 
Magill, A. J.; Su, X. Z., Genetic diversity and chloroquine selective sweeps in 
Plasmodium falciparum. Nature 2002, 418 (6895), 320-3. 
16. Ge, H. Z. H. B. J. F., Jin., Si Ku Quan Shu (Emergency Prescriptions Kept Up 
One's Sleeve). 340 A.D. 
17. Tu, Y., The development of new antimalarial drugs: qinghaosu and dihydro-
qinghaosu. Chinese medical journal 1999, 112 (11), 976-7. 
18. Wright, C. W.; Linley, P. A.; Brun, R.; Wittlin, S.; Hsu, E., Ancient Chinese 
methods are remarkably effective for the preparation of artemisinin-rich extracts of Qing 
Hao with potent antimalarial activity. Molecules 2010, 15 (2), 804-12. 
19. Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; Lwin, K. M.; 
Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.; Silamut, K.; Imwong, M.; 
Chotivanich, K.; Lim, P.; Herdman, T.; An, S. S.; Yeung, S.; Singhasivanon, P.; Day, N. 
P.; Lindegardh, N.; Socheat, D.; White, N. J., Artemisinin resistance in Plasmodium 
falciparum malaria. N Engl J Med 2009, 361 (5), 455-67. 
20. Najera, J. A.; Gonzalez-Silva, M.; Alonso, P. L., Some Lessons for the Future 
from the Global Malaria Eradication Programme (1955-1969). PLoS medicine 2011, 8 
(1). 
21. Sachs, J.; Malaney, P., The economic and social burden of malaria. Nature 2002, 
415 (6872), 680-5. 
22. Ekland, E. H.; Fidock, D. A., In vitro evaluations of antimalarial drugs and their 
relevance to clinical outcomes. International journal for parasitology 2008, 38 (7), 743-7. 
23. Chiodini, P. L.; Conlon, C. P.; Hutchinson, D. B.; Farquhar, J. A.; Hall, A. P.; Peto, 
T. E.; Birley, H.; Warrell, D. A., Evaluation of atovaquone in the treatment of patients with 
	   119	  
uncomplicated Plasmodium falciparum malaria. The Journal of antimicrobial 
chemotherapy 1995, 36 (6), 1073-8. 
24. Nzila, A.; Mwai, L., In vitro selection of Plasmodium falciparum drug-resistant 
parasite lines. The Journal of antimicrobial chemotherapy 2010, 65 (3), 390-8. 
25. Witkowski, B.; Berry, A.; Benoit-Vical, F., Resistance to antimalarial compounds: 
methods and applications. Drug resistance updates : reviews and commentaries in 
antimicrobial and anticancer chemotherapy 2009, 12 (1-2), 42-50. 
26. Nygaard, S.; Braunstein, A.; Malsen, G.; Van Dongen, S.; Gardner, P. P.; Krogh, 
A.; Otto, T. D.; Pain, A.; Berriman, M.; McAuliffe, J.; Dermitzakis, E. T.; Jeffares, D. C., 
Long- and short-term selective forces on malaria parasite genomes. PLoS genetics 2010, 
6 (9). 
27. Costanzo, M. S.; Hartl, D. L., The evolutionary landscape of antifolate resistance 
in Plasmodium falciparum. Journal of genetics 2011, 90 (2), 187-90. 
28. Costanzo, M. S.; Brown, K. M.; Hartl, D. L., Fitness trade-offs in the evolution of 
dihydrofolate reductase and drug resistance in Plasmodium falciparum. PloS one 2011, 
6 (5), e19636. 
29. Sarafianos, S. G.; Das, K.; Hughes, S. H.; Arnold, E., Taking aim at a moving 
target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Current 
opinion in structural biology 2004, 14 (6), 716-30. 
30. Shah, N. P.; Nicoll, J. M.; Nagar, B.; Gorre, M. E.; Paquette, R. L.; Kuriyan, J.; 
Sawyers, C. L., Multiple BCR-ABL kinase domain mutations confer polyclonal resistance 
to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic 
myeloid leukemia. Cancer cell 2002, 2 (2), 117-25. 
31. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J., Flying under the radar: the new 
wave of BCR-ABL inhibitors. Nature reviews. Drug discovery 2007, 6 (10), 834-48. 
32. Rosenbloom, D. I.; Hill, A. L.; Rabi, S. A.; Siliciano, R. F.; Nowak, M. A., 
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nature 
medicine 2012. 
33. Fischbach, M. A., Combination therapies for combating antimicrobial resistance. 
Current opinion in microbiology 2011, 14 (5), 519-23. 
34. Chait, R.; Vetsigian, K.; Kishony, R., What counters antibiotic resistance in 
nature? Nat Chem Biol 2012, 8 (1), 2-5. 
35. Yeh, P. J.; Hegreness, M. J.; Aiden, A. P.; Kishony, R., Drug interactions and the 
evolution of antibiotic resistance. Nature reviews. Microbiology 2009, 7 (6), 460-6. 
36. Chait, R.; Craney, A.; Kishony, R., Antibiotic interactions that select against 
resistance. Nature 2007, 446 (7136), 668-71. 
	   120	  
37. Bollenbach, T.; Quan, S.; Chait, R.; Kishony, R., Nonoptimal microbial response 
to antibiotics underlies suppressive drug interactions. Cell 2009, 139 (4), 707-18. 
38. Pinto, P.; Dougados, M., Leflunomide in clinical practice. Acta Reumatol Port 
2006, 31 (3), 215-24. 
39. Ng, S. B.; Buckingham, K. J.; Lee, C.; Bigham, A. W.; Tabor, H. K.; Dent, K. M.; 
Huff, C. D.; Shannon, P. T.; Jabs, E. W.; Nickerson, D. A.; Shendure, J.; Bamshad, M. J., 
Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 2010, 42 (1), 
30-5. 
40. Aravind, L.; Iyer, L. M.; Wellems, T. E.; Miller, L. H., Plasmodium biology: 
genomic gleanings. Cell 2003, 115 (7), 771-85. 
41. Hurt, D. E.; Widom, J.; Clardy, J., Structure of Plasmodium falciparum 
dihydroorotate dehydrogenase with a bound inhibitor. Acta crystallographica. Section D, 
Biological crystallography 2006, 62 (Pt 3), 312-23. 
42. Fishwick, C. W.; Bedingfield, P.; Cowen, D.; Acklam, P. A.; Cunningham, F.; 
Parsons, M.; McConkey, G. A.; Johnson, A. P., Factors influencing the specificity of 
inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases. J 
Med Chem 2012. 
43. Gujjar, R.; Marwaha, A.; El Mazouni, F.; White, J.; White, K. L.; Creason, S.; 
Shackleford, D. M.; Baldwin, J.; Charman, W. N.; Buckner, F. S.; Charman, S.; Rathod, 
P. K.; Phillips, M. A., Identification of a metabolically stable triazolopyrimidine-based 
dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem 
2009, 52 (7), 1864-72. 
44. Booker, M. L.; Bastos, C. M.; Kramer, M. L.; Barker, R. H., Jr.; Skerlj, R.; Sidhu, 
A. B.; Deng, X.; Celatka, C.; Cortese, J. F.; Guerrero Bravo, J. E.; Crespo Llado, K. N.; 
Serrano, A. E.; Angulo-Barturen, I.; Jimenez-Diaz, M. B.; Viera, S.; Garuti, H.; Wittlin, S.; 
Papastogiannidis, P.; Lin, J. W.; Janse, C. J.; Khan, S. M.; Duraisingh, M.; Coleman, B.; 
Goldsmith, E. J.; Phillips, M. A.; Munoz, B.; Wirth, D. F.; Klinger, J. D.; Wiegand, R.; 
Sybertz, E., Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase 
with anti-malarial activity in the mouse model. J Biol Chem 2010, 285 (43), 33054-64. 
45. Phillips, M. A.; Rathod, P. K., Plasmodium dihydroorotate dehydrogenase: a 
promising target for novel anti-malarial chemotherapy. Infectious disorders drug targets 
2010, 10 (3), 226-39. 
46. Rodrigues, T.; Lopes, F.; Moreira, R., Inhibitors of the mitochondrial electron 
transport chain and de novo pyrimidine biosynthesis as antimalarials: The present status. 
Current medicinal chemistry 2010, 17 (10), 929-56. 
47. Baldwin, J.; Michnoff, C. H.; Malmquist, N. A.; White, J.; Roth, M. G.; Rathod, P. 
K.; Phillips, M. A., High-throughput screening for potent and selective inhibitors of 
Plasmodium falciparum dihydroorotate dehydrogenase. J Biol Chem 2005, 280 (23), 
21847-53. 
	   121	  
48. Gamo, F. J.; Sanz, L. M.; Vidal, J.; de Cozar, C.; Alvarez, E.; Lavandera, J. L.; 
Vanderwall, D. E.; Green, D. V.; Kumar, V.; Hasan, S.; Brown, J. R.; Peishoff, C. E.; 
Cardon, L. R.; Garcia-Bustos, J. F., Thousands of chemical starting points for 
antimalarial lead identification. Nature 2010, 465 (7296), 305-10. 
49. Patel, V.; Booker, M.; Kramer, M.; Ross, L.; Celatka, C. A.; Kennedy, L. M.; 
Dvorin, J. D.; Duraisingh, M. T.; Sliz, P.; Wirth, D. F.; Clardy, J., Identification and 
characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate 
dehydrogenase. J Biol Chem 2008, 283 (50), 35078-85. 
50. Coteron, J. M.; Marco, M.; Esquivias, J.; Deng, X.; White, K. L.; White, J.; Koltun, 
M.; El Mazouni, F.; Kokkonda, S.; Katneni, K.; Bhamidipati, R.; Shackleford, D. M.; 
Angulo-Barturen, I.; Ferrer, S. B.; Jimenez-Diaz, M. B.; Gamo, F. J.; Goldsmith, E. J.; 
Charman, W. N.; Bathurst, I.; Floyd, D.; Matthews, D.; Burrows, J. N.; Rathod, P. K.; 
Charman, S. A.; Phillips, M. A., Structure-guided lead optimization of triazolopyrimidine-
ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase 
inhibitors with clinical candidate potential. J Med Chem 2011, 54 (15), 5540-61. 
51. Guler, J. L.; Freeman, D. L.; Ahyong, V.; Patrapuvich, R.; White, J.; Gujjar, R.; 
Phillips, M. A.; Derisi, J.; Rathod, P. K., Asexual Populations of the Human Malaria 
Parasite, Plasmodium falciparum, Use a Two-Step Genomic Strategy to Acquire 
Accurate, Beneficial DNA Amplifications. PLoS pathogens 2013, 9 (5), e1003375. 
52. Schlitzer, M.; Ortmann, R., Feeding the antimalarial pipeline. ChemMedChem 
2010, 5 (11), 1837-40. 
53. Goldberg, D. E.; Siliciano, R. F.; Jacobs, W. R., Jr., Outwitting evolution: fighting 
drug-resistant TB, malaria, and HIV. Cell 2012, 148 (6), 1271-83. 
54. Hegreness, M.; Shoresh, N.; Damian, D.; Hartl, D.; Kishony, R., Accelerated 
evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 2008, 105 
(37), 13977-81. 
55. Brown, K. M.; Costanzo, M. S.; Xu, W.; Roy, S.; Lozovsky, E. R.; Hartl, D. L., 
Compensatory mutations restore fitness during the evolution of dihydrofolate reductase. 
Molecular biology and evolution 2010, 27 (12), 2682-90. 
56. Lambros, C.; Vanderberg, J. P., Synchronization of Plasmodium falciparum 
erythrocytic stages in culture. The Journal of parasitology 1979, 65 (3), 418-20. 
57. (a) Johnson, D. J.; Fidock, D. A.; Mungthin, M.; Lakshmanan, V.; Sidhu, A. B.; 
Bray, P. G.; Ward, S. A., Evidence for a central role for PfCRT in conferring Plasmodium 
falciparum resistance to diverse antimalarial agents. Mol Cell 2004, 15 (6), 867-77; (b) 
Sidhu, A. B.; Uhlemann, A. C.; Valderramos, S. G.; Valderramos, J. C.; Krishna, S.; 
Fidock, D. A., Decreasing pfmdr1 copy number in plasmodium falciparum malaria 
heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and 
artemisinin. J Infect Dis 2006, 194 (4), 528-35. 
58. Aurrecoechea, C.; Brestelli, J.; Brunk, B. P.; Dommer, J.; Fischer, S.; Gajria, B.; 
Gao, X.; Gingle, A.; Grant, G.; Harb, O. S.; Heiges, M.; Innamorato, F.; Iodice, J.; 
Kissinger, J. C.; Kraemer, E.; Li, W.; Miller, J. A.; Nayak, V.; Pennington, C.; Pinney, D. 
	   122	  
F.; Roos, D. S.; Ross, C.; Stoeckert, C. J., Jr.; Treatman, C.; Wang, H., PlasmoDB: a 
functional genomic database for malaria parasites. Nucleic Acids Res 2009, 37 
(Database issue), D539-43. 
59. Li, H.; Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 2009, 25 (14), 1754-60. 
60. DePristo, M. A.; Banks, E.; Poplin, R.; Garimella, K. V.; Maguire, J. R.; Hartl, C.; 
Philippakis, A. A.; del Angel, G.; Rivas, M. A.; Hanna, M.; McKenna, A.; Fennell, T. J.; 
Kernytsky, A. M.; Sivachenko, A. Y.; Cibulskis, K.; Gabriel, S. B.; Altshuler, D.; Daly, M. 
J., A framework for variation discovery and genotyping using next-generation DNA 
sequencing data. Nat Genet 2011, 43 (5), 491-8. 
61. Li, H.; Handsaker, B.; Wysoker, A.; Fennell, T.; Ruan, J.; Homer, N.; Marth, G.; 
Abecasis, G.; Durbin, R., The Sequence Alignment/Map format and SAMtools. 
Bioinformatics 2009, 25 (16), 2078-9. 
62. Johnson, J. D.; Dennull, R. A.; Gerena, L.; Lopez-Sanchez, M.; Roncal, N. E.; 
Waters, N. C., Assessment and continued validation of the malaria SYBR green I-based 
fluorescence assay for use in malaria drug screening. Antimicrobial agents and 
chemotherapy 2007, 51 (6), 1926-33. 
63. Phillips, M. A.; Gujjar, R.; Malmquist, N. A.; White, J.; El Mazouni, F.; Baldwin, J.; 
Rathod, P. K., Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with 
potent and selective activity against the malaria parasite Plasmodium falciparum. J Med 
Chem 2008, 51 (12), 3649-53. 
64. Deng, X.; Gujjar, R.; El Mazouni, F.; Kaminsky, W.; Malmquist, N. A.; Goldsmith, 
E. J.; Rathod, P. K.; Phillips, M. A., Structural plasticity of malaria dihydroorotate 
dehydrogenase allows selective binding of diverse chemical scaffolds. J Biol Chem 2009, 
284 (39), 26999-7009. 
65. Ingolia, N. T., Genome-wide translational profiling by ribosome footprinting. 
Methods in enzymology 2010, 470, 119-42. 
66. McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E., Presenting your 
structures: the CCP4mg molecular-graphics software. Acta crystallographica. Section D, 
Biological crystallography 2011, 67 (Pt 4), 386-94. 
67. Bopp, S. E.; Manary, M. J.; Bright, A. T.; Johnston, G. L.; Dharia, N. V.; Luna, F. 
L.; McCormack, S.; Plouffe, D.; McNamara, C. W.; Walker, J. R.; Fidock, D. A.; Denchi, 
E. L.; Winzeler, E. A., Mitotic evolution of Plasmodium falciparum shows a stable core 
genome but recombination in antigen families. PLoS genetics 2013, 9 (2), e1003293. 
68. Hayton, K.; Su, X. Z., Drug resistance and genetic mapping in Plasmodium 
falciparum. Current genetics 2008, 54 (5), 223-39. 
69. White, R. M.; Cech, J.; Ratanasirintrawoot, S.; Lin, C. Y.; Rahl, P. B.; Burke, C. 
J.; Langdon, E.; Tomlinson, M. L.; Mosher, J.; Kaufman, C.; Chen, F.; Long, H. K.; 
Kramer, M.; Datta, S.; Neuberg, D.; Granter, S.; Young, R. A.; Morrison, S.; Wheeler, G. 
	   123	  
N.; Zon, L. I., DHODH modulates transcriptional elongation in the neural crest and 
melanoma. Nature 2011, 471 (7339), 518-22. 
70. Chait, R.; Shrestha, S.; Shah, A. K.; Michel, J. B.; Kishony, R., A Differential Drug 
Screen for Compounds That Select Against Antibiotic Resistance. PloS one 2010, 5 (12). 
71. Robert, V.; Trape, J. F.; Rogier, C., Malaria parasites: elimination is not 
eradication. Clinical microbiology and infection : the official publication of the European 
Society of Clinical Microbiology and Infectious Diseases 2011, 17 (11), 1597-9. 
72. Kaneko, A., A community-directed strategy for sustainable malaria elimination on 
islands: short-term MDA integrated with ITNs and robust surveillance. Acta tropica 2010, 
114 (3), 177-83. 
73. Karunamoorthi, K., Vector control: a cornerstone in the malaria elimination 
campaign. Clinical microbiology and infection : the official publication of the European 
Society of Clinical Microbiology and Infectious Diseases 2011, 17 (11), 1608-16. 
74. Chaccour, C. J.; Kobylinski, K. C.; Bassat, Q.; Bousema, T.; Drakeley, C.; Alonso, 
P.; Foy, B. D., Ivermectin to reduce malaria transmission: a research agenda for a 
promising new tool for elimination. Malar J 2013, 12, 153. 
75. Ekland, E. H.; Fidock, D. A., Advances in understanding the genetic basis of 
antimalarial drug resistance. Current opinion in microbiology 2007, 10 (4), 363-70. 
76. Cohen, J. M.; Smith, D. L.; Cotter, C.; Ward, A.; Yamey, G.; Sabot, O. J.; 
Moonen, B., Malaria resurgence: a systematic review and assessment of its causes. 
Malar J 2012, 11, 122. 
77. Laufer, M. K.; Thesing, P. C.; Eddington, N. D.; Masonga, R.; Dzinjalamala, F. K.; 
Takala, S. L.; Taylor, T. E.; Plowe, C. V., Return of chloroquine antimalarial efficacy in 
Malawi. N Engl J Med 2006, 355 (19), 1959-66. 
78. Kevin J. Bowers, E. C., Huafeng Xu, Ron O. Dror,      Michael P. Eastwood, Brent 
A. Gregersen, John L. Klepeis, Istvan Kolossvary, Mark A. Moraes, Federico D. 
Sacerdoti,      John K. Salmon, Yibing Shan, David E. Shaw, Scalable Algorithms for 
Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM/IEEE 
Conference on Supercomputing 2006. 
79. Livak, K. J.; Schmittgen, T. D., Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 2001, 25 (4), 
402-408. 
80. Fidock, D. A.; Wellems, T. E., Transformation with human dihydrofolate 
reductase renders malaria parasites insensitive to WR99210 but does not affect the 
intrinsic activity of proguanil. Proc Natl Acad Sci U S A 1997, 94 (20), 10931-6. 
81. Muller, S.; Kappes, B., Vitamin and cofactor biosynthesis pathways in 
Plasmodium and other apicomplexan parasites. Trends in parasitology 2007, 23 (3), 
112-21. 
	   124	  
82. Chan, X. W.; Wrenger, C.; Stahl, K.; Bergmann, B.; Winterberg, M.; Muller, I. B.; 
Saliba, K. J., Chemical and genetic validation of thiamine utilization as an antimalarial 
drug target. Nature communications 2013, 4, 2060. 
83. Meierjohann, S.; Walter, R. D.; Muller, S., Regulation of intracellular glutathione 
levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant 
Plasmodium falciparum. The Biochemical journal 2002, 368 (Pt 3), 761-8. 
84. Anderson, T.; Nkhoma, S.; Ecker, A.; Fidock, D., How can we identify parasite 
genes that underlie antimalarial drug resistance? Pharmacogenomics 2011, 12 (1), 59-
85. 
85. Straimer, J.; Lee, M. C.; Lee, A. H.; Zeitler, B.; Williams, A. E.; Pearl, J. R.; 
Zhang, L.; Rebar, E. J.; Gregory, P. D.; Llinas, M.; Urnov, F. D.; Fidock, D. A., Site-
specific genome editing in Plasmodium falciparum using engineered zinc-finger 
nucleases. Nature methods 2012, 9 (10), 993-8. 
86. Beurdeley, M.; Bietz, F.; Li, J.; Thomas, S.; Stoddard, T.; Juillerat, A.; Zhang, F.; 
Voytas, D. F.; Duchateau, P.; Silva, G. H., Compact designer TALENs for efficient 
genome engineering. Nature communications 2013, 4, 1762. 
87. Cong, L.; Ran, F. A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P. D.; Wu, X.; 
Jiang, W.; Marraffini, L. A.; Zhang, F., Multiplex genome engineering using CRISPR/Cas 
systems. Science (New York, N.Y.) 2013, 339 (6121), 819-23. 
88. Mali, P.; Yang, L.; Esvelt, K. M.; Aach, J.; Guell, M.; DiCarlo, J. E.; Norville, J. E.; 
Church, G. M., RNA-guided human genome engineering via Cas9. Science (New York, 
N.Y.) 2013, 339 (6121), 823-6. 
89. Painter, H. J.; Morrisey, J. M.; Mather, M. W.; Vaidya, A. B., Specific role of 
mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 2007, 
446 (7131), 88-91. 
90. Michel, J. B.; Yeh, P. J.; Chait, R.; Moellering, R. C., Jr.; Kishony, R., Drug 
interactions modulate the potential for evolution of resistance. Proc Natl Acad Sci U S A 
2008, 105 (39), 14918-23. 
91. Prevention, C. f. D. C. a. Distribution of malaria in the United States, 1882-1935. 
http://www.cdc.gov/malaria/about/history/elimination_us.html (accessed 17 July 2013). 
92. Fidock, D. A., Microbiology. Eliminating malaria. Science (New York, N.Y.) 2013, 
340 (6140), 1531-3. 
 
 
 
 
	   
 
 
APPENDIX 
 
 
 
	   126	  
 
Asterogynins: Secondary Metabolites
from a Costa Rican Endophytic Fungus
Shugeng Cao,† Leila Ross,† Giselle Tamayo,‡ and Jon Clardy*,†
Department of Biological Chemistry and Molecular Pharmacology, HarVard Medical
School, 240 Longwood AVenue, Boston, Massachusetts 02115, and Unidad Estrategica
de Bioprospeccion, Instituto Nacional de BiodiVersidad (INBio),
Santo Domingo de Heredia, Costa Rica
jon_clardy@hms.harVard.edu
Received August 19, 2010
ABSTRACT
An endophytic fungus isolated from the small palm Asterogyne martiana produced two unusual steroid-like metabolites, asterogynin A (1) and
asterogynin B (2), along with the known compounds viridiol (3) and viridin (4). Asterogynins A and B were characterized by NMR and MS
spectroscopic analysis.
Fungi have made noteworthy contributions to our store of
naturally occurring small molecules as they have contributed
more than a quarter by most reckonings, and these contribu-
tions have come from only a tiny fraction of the world’s
estimated 1.5 million fungal species. Only∼5% of the fungal
species have been scientifically studied, and a minority of
these have been studied chemically.1-3 The endophytic fungi
that live inside of vascular plants constitute one of the richest
sources of poorly examined fungi. As part of a longstanding
collaborative research project with INBio (National Biodi-
versity Institute), we have begun characterizing some of the
chemical diversity of Costa Rican endophytes. Costa Rica’s
location on the slender land bridge between North and South
American organisms makes it a natural mixing bowl for the
organisms of both continents. As a result, the country’s many
different ecological niches contain over 9000 species of
vascular plants.
In one recent project, extracts from Costa Rican endo-
phytes were screened for their ability to bind PfHsp86, an
essential protein-folding chaperone from Plasmodium falci-
parum, the parasite responsible for the most deadly form of
human malaria. Plasmodium falciparum encodes three full-
length Hsp90 genes for the proteins PfHsp86, PfGRP94, and
PfTRAP1. PfHsp86 has 59% amino acid identity with human
Hsp90R2, and its highly conserved ATP-binding Bergerat
fold has 75% identity. PfHsp86 could be a drug target for
malaria as the Plasmodium parasites transition between cold-
blooded mosquito vectors and warm-blooded and often
febrile human hosts, a transition that should create a
substantial requirement for assisted protein folding.4 Some
known human Hsp90 inhibitors, like geldanamycin, inhibit
parasite growth through PfHsp86 inhibition.4
The dichloromethane extract of CR1488E, which was
isolated from the host plant Asterogyne martiana (Arecaceae)
and whose closest relative based on DNA sequencing is
Chalara alabamensis, was active with an EC50 value of ∼24
µg/mL. Here we report the isolation and structure elucidation
of asterogynins A (1) and B (2) from CR1488E.
† Harvard Medical School.
‡ Instituto Nacional de Biodiversidad (INBio).
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(3) Henkel, T.; Brunne, R. M.; Muller, H.; Reichel, F. Angew. Chem.,
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The dichloromethane extract of CR1488E was separated
by C-18 prep-HPLC to yield compounds 1, 2, 3, and 4.
Compounds 3 and 4 were identified as the known natural
products viridiol5 and viridin,6 respectively. The viridin class
of steroidal furans contains potent antifungal agents and
covalent inhibitors of phosphatidylinositol 3-kinase (PI3
kinase) and polo-like kinase.7 As viridin-like compounds
react with the ATP-binding site of kinases, it is likely that
they could also bind the ATP pocket of chaperone and other
proteins.
The 1H NMR spectrum of 18 in CD3OD showed two
aromatic protons and one olefinic proton, one methoxy, three
methylenes, and one methyl group. The 13C NMR spectrum
exhibited 18 signals, including three carbonyls, six aromatic
carbons, one double bond, two quaternary and three second-
ary carbons, one methoxy, and one methyl group. These
assignments were further confirmed by the HSQC spectrum.
The HRMS (positive-ion mode) had an ion peak at m/z
295.0969, consistent with a molecular composition of
C18H15O4 ([M - H2O + H], calcd 295.0970), a molecular
formula that required 11 double-bond equivalents. Besides
three carbonyls, one double bond, and an aromatic ring, there
must be three more rings in the molecule. In the COSY
spectrum of 1, two cross-peaks from two coupling systems
[CHdCH (aromatic: δH 7.78, d, J ) 8.0 Hz, H-11; 8.01, d,
J ) 8.0 Hz, H-12) and CH2-CH2 (δH 3.37, m, H-15; 2.74,
m, H-16)] were observed. Rings C and D were readily
established from the HMBC correlations between the car-
bonyl at ring D and one aromatic proton and the two coupling
methylenes. The 13C chemical shifts of the carbons in rings
C and D (δc 130.6, C-8; 166.1, C-9; 131.6, C-11; 124.8,
C-12; 139.0, C-13; 156.8, C-14; 25.3, C-15; 37.0, C-16;
207.9, C-17) matched those of demethoxyviridin and its
analogues9 very well, which further confirmed these two
rings. The carbonyl in ring A (δc 192.5, C-3) had to be an
R,"-unsaturated ketone (δc 120.7, C-1; 150.5, C-2) since its
13C chemical shift was <195 ppm, and the olefinic proton
(δH 6.05, s, H-1) showed a strong HMBC correlation to that
carbonyl carbon. In the HMBC spectrum (Figure 1), the
methyl group (δH 1.54, s, H3-19) had correlations with the
protonated olefinic carbon at δc 120.7 (C-1), which indicated
that it must be at the "-position of the R,"-unsaturated ketone,
one aromatic carbon (δc 166.1, C-9), and two quaternary
carbons (δc 49.0, C-10; 82.5, C-5), one of which was
oxygenated. Although no HMBC correlations in CD3OD
between the third methylene and any carbon was observed,
rings A and B were deduced to be six- and five-membered
rings, respectively, with the oxygenated quaternary carbon
connected to the methylene (δc 44.5, C-4) at ring A and
carbonyl (δc 204.2, C-7) at ring B. To check this, both HSQC
and HMBC spectra of compound 1 were collected in C6D5N,
and correlations between the methylene at ring A and C-2,
C-3, C-5, C-7, and C-10 were observed. In the ROESY
spectrum of 1 in C6D5N, H3-19 showed correlation to 5-OH
(Figure 2), indicating a cis relationship between these two
functional groups. Hence, the structure of 1 was determined
as shown.
Compound 210 had a molecular formula of C18H16O4. The
only difference between 1 and 2 was the substituent at C-5.
In the HMBC spectrum of 2, the methyl group had
correlations to the protonated olefinic carbon, one aromatic
carbon and the quaternary carbon, and the tertiary carbon,
indicating a methine at the 5 position. No ROESY cross-
peak between H3-19 and 5-H was observed. Hence, the
structure of 2 was determined as shown.
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16 Hz, d (H-4b), 3.57 s (-OMe), 6.12 s (H-1), 7.76 d, J ) 8.0 Hz (H-11),
8.12 d, J ) 8.0 Hz (H-12), 8.92 s (5-OH); 1H NMR (600 MHz, CD3OD)
d 1.54 s (H3-19), 2.74 m (H2-16 and H-4a), 2.94 m (H-4b), 3.37 m (H2-
15), 3.56 s (-OMe), 6.05 s (H-1), 7.78 d, J ) 8.0 Hz (H-11), 8.01 d, J )
8.0 Hz (H-12); 13C NMR (150 MHz, CD3OD) d 25.3 (C-15), 25.8 (C-19),
37.0 (C-16), 44.5 (C-4), 49.0 (C-10), 55.8 (OMe), 82.5 (C-5), 120.7 (C-1),
124.8 (C-12), 130.6 (C-8), 131.6 (C-11), 139.0 (C-13), 150.5 (C-2), 156.8
(C-14), 166.1 (C-9), 192.5 (C-3), 204.2 (C-7), 207.9 (C-17); HRMS m/z
295.0969 ([M - H2O + H], calcd for C18H15O4, 295.0970).
(9) Giner, J.-L.; Kehbein, K. A.; Cook, J. A.; Smith, M. C.; Vlahos,
C. J.; Badwey, J. A. Bioorg. Med. Chem. 2006, 16, 2518–2521.
(10) Asterogynin B (2): colorless powder; [R]26D +46 (c, 0.03 MeOH);
UV (MeOH) λmax (log e) 235, 312 nm; 1H NMR (600 MHz, CD3OD) d
1.84 s (H3-19), 2.14 and 3.29 m (H2-4), 3.31 and 3.40 m (H2-15), 3.45 s
(-OMe), 5.91 s (H-2), 7.80 d, J ) 7.8 Hz (H-11), 8.03 d, J ) 7.8 Hz
(H-12); 13C NMR (150 MHz, CD3OD) d 24.5 (C-19), 25.4 (C-15), 36.4
(C-16), 38.9 (C-4), 45.6 (C-10), 55.2 (OMe), 53.3 (C-5), 123.3 (C-1), 124.0
(C-12), 130.8 (C-8), 132.6 (C-11), 138.6 (C-13), 149.8 (C-2), 156.0 (C-
14), 168.1 (C-9), 192.4 (C-3), 207.8 (C-17); HRMS m/z 297.1123 (calcd
for C18H17O4, 297.1127).
Figure 1. Key HMBC (arrows) and COSY (dashed curves)
correlation of (1).
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Because of their overall structure and association with
viridin (4) and viridiol (3), asterogynins A (1) and B (2) are
likely sterol derivatives with a tetracyclic (6-5-6-5)
carbocyclic ring system, which differs from the tetracyclic
(6-6-6-5) of 3, 4, and other steroids. Only a few
B-norsteroids (5 is typical)11 with more complex structures
have been previously reported from other sources. The
asterogynins A (1) and B (2) are quite different in having
no remnants of the typical steroid side chain. They also lack
the furan ring of 3 and 4. Viridin (4) is a modified steroid,12
and it is therefore likely that asterogynins A (1) and B (2)
are also derived from the steroidal pathway. Whether they
are further elaborations of viridin/viridiol through oxidative
removal of the furan ring or arise from a separate pathway
is not clear.
All four compounds were tested against PfHsp86, but only
compound 3 was active with an EC50 value of 5.5 ( 1.2
µg/mL. Further biological evaluations of compounds 1 and
2 are now being conducted and will be reported in due
course.
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Figure 2. Key ROESY correlation of 1.
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